 
  
 
TPL-000052_v10  Macitentan / ACT -064992 
Pulmonary arterial hy pertension 
Protocol AC- 055-403 
REPAIR : Right v Entricular remodeling  
in Pulmonary ArterI al hypeRtension 
A prospective,  multicenter, single -arm, open-label, P hase 4 study to evaluate the 
effects of macitentan on Right vE ntricular remodeling in Pulmonary A rterIal 
hype Rtension assessed by [CONTACT_892720]:  [ADDRESS_1250320] Number: 2014-004066-20 
Status and version: Final Version 6  
Date: 8 November 2016 
Actelion document number 
(Doc No.):  D-16.[ADDRESS_1250321]. It is understood that this informat ion will not be disclosed to others without written 
authorization from Actelion Pharmaceuticals Ltd, except to the extent necessary to obtain informed consent 
from those persons to whom the study treatment may be administered.  
  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 2/[ADDRESS_1250322] DETAILS 
SPO NSOR  
 ACTELION Pharmaceuticals Ltd  
Gewerbestrasse 16  
CH-4123 Allschwil 
Switzerland  
Clinical Trial Physician  
 Maziar Assadi -Gehr / Global Medical Affairs 
Physician  
 
Fax 
E-mail 
MEDICAL HOTLINE  
Toll phone number:  
  
Site-specific toll telephone numbers and toll -free numbers for the Medical Hotline can be 
found in the Investigator Site File. 
 
 
ACTELION CONTRIBUTORS TO THE PROTOCOL 
Clinical Trial Scientist   Clinical Scientist  
 
Clinical Trial Statistician  Nicolas Martin , Expert Statistician  
 
Drug Safety Physician   Senior Clinical Drug Safety 
Physician  
 
COORDINATING INVESTIGATOR 
[CONTACT_5627] / T itle Address  
Nazzareno Galiè, MD  Istituto di Cardiologia, Universita` di Bologna  
via Massarenti,  
, Italy    
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 3/[ADDRESS_1250323] RESEARCH ORGANIZATIONS INFORMATION 
CENTRAL LABORATORY  
 Covance Central Laboratory Services SA  
 
Switzerland  
CENTRAL IMAGE REPOSITORY  
(Cardiac MRI, RHC curves, 
PET -MR, Echo) World Care Clinical  (WCC) 
 
[LOCATION_003] 
IMAGE ANA LYSIS CENTER -
cardiac MRI  
 VUMC 
The Netherlands  
CENTRAL ASSESSMENT -PET -
MR 
 MGH [LOCATION_005] General Hospi[INVESTIGATOR_892698] -Echo 
 World Care Clinical  (WCC) 
 
[LOCATION_003] 
CRO  (MONITORING)  
 TFS 
S
weden 
Chiltern International  
 [LOCATION_006] 
HOME  PHLEBOTOMY  SERVICE  Global Care Clinical Trials Ltd  
[LOCATION_003] 
BIOSTATISTICS  Datametrix  
 
 Switzerland  
A list of site -specific contact [CONTACT_892721].  
 
  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 4/[ADDRESS_1250324] 2014- 004066- 20 
Doc No. D-16.554  
 
SIGNATURE [CONTACT_892802] / number  
Macitentan / ACT -064992 
Indication 
Pulmonary arterial hy pertension 
Protocol number, study acronym, study title  
AC-055-403, REPAIR , A prospective, multicenter, single -arm, open -label, Phase 4 study 
to evaluate the effects of macitentan on Right v Entricular remodeling in Pulmonary 
ArterIal hypeRtension assessed by [CONTACT_54753]  
I approve the design of this study. 
 
 
 
  
 
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 5/[ADDRESS_1250325] 2014- 004066- 20 
Doc No. D-16.554  
 
INVESTIGATOR SIGNATURE [CONTACT_892803] / number  
Macitentan / ACT -064992 
Indication 
Pulmonary arterial hy pertension 
Protocol num ber, study  acronym, study title 
AC-055-403, REPAIR , A prospective, multicenter, single -arm, open -label, Phase 4 study 
to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary 
ArterIal hypeRtension assessed by [CONTACT_892722] 
I agree to the terms and conditions relating to this study as defined in this protocol, the 
electronic Case Report Form ( CRF), and any other protocol -related documents. I fully 
understand that any changes instituted by [CONTACT_093](s) without previ ous agreement 
with the sponsor would constitute a protocol  deviation, including any ancillary studies or 
procedures performed on study patients (other than those procedures necessary for the 
wellbeing of the patients). 
I agree to conduct this study in acco rdance with the Declaration of Helsinki principles, 
International Council for  Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, 
and applicable regulations and laws. I will obtain approval by [CONTACT_892723] (IRB/IEC) prior to study start and signed 
informed consent from all patient s included in this study. If an amendment to the protocol 
is necessary, I will obtain approval by [CONTACT_2717]/IEC and ensure approval by [CONTACT_3527] (if applicable) have been obtained before the implementation of changes 
described in the amendment. I will allow direct access to source documents and study 
facilities to sponsor representative(s), particularly monitor(s) and auditor(s), and agree to 
inspection by [CONTACT_30962] a uthorities  or IRB/IEC representative. I will ensure that the 
study treatment (s) supplied by [CONTACT_892724]. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact [CONTACT_721027]. 
 Country  Site 
number  Town  Date   Signature  
[CONTACT_180550]        
[INVESTIGATOR_892699]:   Metabolism sub -study 
 Biopsy sub-study 
 Echo sub-study 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 6/[ADDRESS_1250326] ..........................................................................35  
1.2.2  Macitentan  ........................................................................................35  
[IP_ADDRESS]  Nonclinical results  ...................................................................36  
[IP_ADDRESS]  Phase 1 results  .........................................................................36  
[IP_ADDRESS]  Phase 2 results  .........................................................................36  
[IP_ADDRESS]  Phase 3 efficacy results  ...........................................................37  
[IP_ADDRESS]  Summary of potential risks and risk management ..................37  
1.3 Purpose and rationale of the study ................................................................39  
1.3.1  Purpose of the study ..........................................................................39  
1.3.2  Rationale  ...........................................................................................39  
[IP_ADDRESS]  Importance of the right ventricle in PAH  ................................39  
[IP_ADDRESS]  Pulmonary vascular resistance  ................................................40  
[IP_ADDRESS]  Cardiac magnetic resonance imaging  ......................................40  
[IP_ADDRESS]  Ventriculo -arterial coupling  ....................................................40  
[IP_ADDRESS]  Up-front combination therapy .................................................41  
[IP_ADDRESS]  Overall benefit -risk ratio .........................................................41  
2 STUDY OBJECTIVES  ...............................................................................................41  
2.1 Primary objective  ..........................................................................................41  
2.2 Secondary objective ......................................................................................41  
2.3 Exploratory objectives ..................................................................................41  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 7/[ADDRESS_1250327] 2014- 004066- 20 
Doc No. D-16.554  
 
2.4 Sub-studies rationale  and objectives  .............................................................42  
2.4.1  Metabolism sub -study (in selected US sites only)  ............................42  
[IP_ADDRESS]  Rationale  ..................................................................................42  
[IP_ADDRESS]  Objectives  ................................................................................42  
2.4.2  Biopsy sub-study ...............................................................................42  
[IP_ADDRESS]  Rationale for taking biopsies  ...................................................42  
[IP_ADDRESS]  Rationale f or mRNA transcript analysis  .................................42  
[IP_ADDRESS]  Objectives  ................................................................................43  
2.4.3  Echo sub-study ..................................................................................43  
[IP_ADDRESS]  Rationale  ..................................................................................43  
[IP_ADDRESS]  Objective  .................................................................................[ADDRESS_1250328]  .................................46  
4 PATIENT POPULATION ..........................................................................................47  
4.1 Patient population description ......................................................................47  
4.2 Rationale for the selection of the study population ......................................47  
4.3 Inclusion criteria  ...........................................................................................47  
4.4 Exclusion criteria  ..........................................................................................48  
4.5 Reliable contraception for women of childbearing potential .......................50  
4.5.1  Definition of woman of childbearing potential .................................50  
4.5.2  Europe and Asia ................................................................................50  
4.5.3  North America and Australia  ............................................................51  
4.6 Patient population in sub-studies ..................................................................51  
4.6.1  Metabolism sub -study .......................................................................51  
4.6.2  Biopsy sub-study ...............................................................................52  
4.6.3  Echo sub-study ..................................................................................52  
5 TREATMENTS  ..........................................................................................................52  
5.1 Study treatment  .............................................................................................52  
5.1.1  Investigational treatment: description and rationale  .........................52  
5.1.2  Study treatment administration  .........................................................52  
5.1.3  Treatment assignment  .......................................................................52  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 8/[ADDRESS_1250329] 2014- 004066- 20 
Doc No. D-16.554  
 
5.1.4  Patient identification  .........................................................................52  
5.1.5  Blinding ............................................................................................53  
5.1.6  Study treatment supply .....................................................................53  
[IP_ADDRESS]  Study treatment packaging and labeling  .................................53  
[IP_ADDRESS]  Study treatment storage and distribution .................................53  
[IP_ADDRESS]  Study treatment dispensing .....................................................53  
[IP_ADDRESS]  Study treatment return and destruction ...................................54  
5.1.7  Compliance with study treatment  .....................................................54  
5.1.8  Study treatment interruptions  ............................................................54  
5.1.9  Premature discontinuation of study treatment  ..................................54  
5.1.10  Study-specific criteria for interruption / premature 
discontinuation of study treatment ....................................................55  
[IP_ADDRESS]  Pregnancy  ................................................................................55  
[IP_ADDRESS]  Liver aminotransferases abnormalities  ....................................56  
[IP_ADDRESS]  Hemoglobin abnormalities  ......................................................57  
[IP_ADDRESS]  Start of an ERA / strong CYP3A4 inducer or inhibitor / 
investigational drug  .................................................................58  
5.2 Previous and concomitant therapy ................................................................58  
5.2.1  Definitions  ........................................................................................58  
5.2.2  Reporting of previous/concomitant therapy in the CRF ...................58  
5.2.3  Allowed concomitant therapy ...........................................................59  
[IP_ADDRESS]  Until Week 26 RHC ................................................................59  
[IP_ADDRESS]  After Week 26 RHC  ................................................................59  
5.2.4  Forbidden concomitant therapy ........................................................59  
5.2.5  Rescue therapy before Week 26 RHC  ..............................................60  
6 STUDY ENDPOINTS  ................................................................................................60  
6.1 Efficacy endpoints ........................................................................................60  
6.1.1  Primary efficacy endpoints  ...............................................................60  
6.1.2  Secondary efficacy endpoints ...........................................................61  
6.1.3  Exploratory efficacy endpoints .........................................................61  
6.2 Safety endpoints  ...........................................................................................63  
6.3 Exploratory endpoints in sub-studies ...........................................................63  
6.3.1  Metabolism sub -study .......................................................................63  
6.3.2  Biopsy sub-study ...............................................................................64  
6.3.3  Echo sub-study ..................................................................................64  
7 STUDY ASSESSMENTS  ...........................................................................................65  
7.1 Screening/baseline assessments  ....................................................................66  
7.1.1  Eligibility criteria  ..............................................................................66  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 9/[ADDRESS_1250330] .............................................................................66  
7.1.7  WHO Functional Class .....................................................................67  
7.1.8  Cardiac MRI  .....................................................................................67  
7.1.9  Right heart catheterization  ................................................................68  
7.1.10  Pressure-volume relationship  ............................................................68  
7.1.11  Blood tests .........................................................................................69  
7.1.12  Sub-studies ........................................................................................69  
[IP_ADDRESS]  Metabolism sub -study .............................................................69  
[IP_ADDRESS]  Biopsy sub-study .....................................................................69  
[IP_ADDRESS]  Echo sub-study ........................................................................[ADDRESS_1250331] .............................................................................72  
7.2.2  WHO Functional Class .....................................................................72  
7.2.3  Cardiac MRI  .....................................................................................72  
7.2.4  Hemodynamics  .................................................................................72  
7.2.5  Pressure-volume relationship  ............................................................72  
7.2.6  Laboratory tests  .................................................................................72  
7.3 Safety assessments  ........................................................................................73  
7.3.1  Adverse events  ..................................................................................73  
7.3.2  Vital signs  .........................................................................................73  
7.3.3  Weight ...............................................................................................73  
7.3.4  Physical examination  ........................................................................73  
7.3.5  Laboratory assessments  ....................................................................73  
[IP_ADDRESS]  Type of laboratory ...................................................................73  
[IP_ADDRESS]  Laboratory tests  .......................................................................75  
[IP_ADDRESS]  Potential additional laboratory tests  ........................................76  
7.4 Exploratory assessments in sub-studies ........................................................76  
7.4.1  Metabolism sub -study .......................................................................77  
7.4.2  Biopsy sub-study ...............................................................................77  
7.4.3  Echo sub-study ..................................................................................77  
8 SCHEDULE OF VISITS  ............................................................................................77  
8.1 Screening period  ...........................................................................................77  
8.2 Treatment period  ...........................................................................................78  
8.2.1  Treatment Initiation Visit ..................................................................78  
8.2.2  Rescue Therapy Initiation Visit ........................................................79  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 10/[ADDRESS_1250332] 2014- 004066- 20 
Doc No. D-16.554  
 
8.2.3  Week 26 visit ....................................................................................79  
8.2.4  Unscheduled visits ............................................................................80  
8.2.5  Premature End of Treatment visit  .....................................................81  
[IP_ADDRESS]  Patients discontinuing the study ..............................................81  
[IP_ADDRESS]  Patients agreeing to limited participation  ................................[ADDRESS_1250333] -STUDY TREATMENT/MEDICAL 
CARE ..........................................................................................................................83  
9.1 Study completion  ..........................................................................................83  
9.2 Premature withdrawal from study  ................................................................83  
9.3 Premature ter mination or suspension of the study ........................................84  
9.4 Medical care of patients after study completion/withdrawal from study  .....85  
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS  ...........................85  
10.1  Adverse events  ..............................................................................................85  
10.1.1  Definitions of adverse events ............................................................85  
10.1.2  Intensity of adverse events  ................................................................86  
10.1.3  Relationship to study treatment ........................................................86  
10.1.4  Adverse events associated with study design or protocol 
mandated procedures ........................................................................86  
10.1.5  Reporting of adverse events ..............................................................87  
10.1.6  Follow-up of adverse events .............................................................87  
10.2  Serious adverse events  ..................................................................................87  
10.2.1  Definitions of serious adverse events ...............................................87  
[IP_ADDRESS]  Serious adverse events  .............................................................87  
[IP_ADDRESS]  Serious adverse events associated with the study desig n 
or protocol mandated procedures ............................................88  
10.2.2  Reporting of serious adverse events .................................................88  
[IP_ADDRESS]  During screening period ..........................................................88  
[IP_ADDRESS]  During treatment period  ..........................................................88  
[IP_ADDRESS]  During follow -up period ..........................................................88  
10.2.3  Follow-up of serious adverse events .................................................88  
10.2.4  After the 30 -day follow-up period ....................................................88  
10.2.5  Reporting procedures ........................................................................88  
10.3  Pregnancy  .....................................................................................................89  
10.3.1  Reporting of pregnancy ....................................................................89  
10.3.2  Follow-up of pregnancy ....................................................................90  
10.4  Study safety monitoring  ................................................................................90  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 11/[ADDRESS_1250334] 2014- 004066- 20 
Doc No. D-16.554  
 
11 STATISTICAL METHODS  .......................................................................................90  
11.1  Analysis Sets  .................................................................................................90  
11.1.1  Screened Patients Set  ........................................................................90  
11.1.2  Safety Set  ..........................................................................................90  
11.1.3  Full Analysis Set ...............................................................................90  
11.1.4  Per Protocol Set  ................................................................................91  
11.1.5  Other analysis sets  ............................................................................91  
11.1.6  Usage of the analysis sets  .................................................................91  
11.2  Variables  .......................................................................................................91  
11.2.1  Primary efficacy variables  ................................................................91  
11.2.2  Secondary efficacy variables  ............................................................92  
11.2.3  Exploratory efficacy variables  ..........................................................92  
[IP_ADDRESS]  Hemodynamic variables and pressure-volume variables  ........92  
[IP_ADDRESS]  Variables related to maintenance of treatment effect  ..............92  
[IP_ADDRESS]  Variables related to the left ventricle  ......................................92  
[IP_ADDRESS]  Potential variables for disease monitoring ..............................93  
[IP_ADDRESS]  Clinical endpoint .....................................................................93  
11.2.4  Safety variables  .................................................................................93  
11.2.5  Other variables  ..................................................................................94  
11.3  Description of statistical analyses  .................................................................94  
11.3.1  Overall testing strategy  .....................................................................94  
11.3.2  Analysis of the primary efficacy variables  .......................................94  
[IP_ADDRESS]  Hypotheses and statistical model ............................................94  
[IP_ADDRESS]  Handling of missing data  .........................................................94  
[IP_ADDRESS]  Main analysis  ...........................................................................95  
[IP_ADDRESS]  Supportive/sensitivity analyses ...............................................96  
[IP_ADDRESS]  Subgroup analyses ...................................................................96  
11.3.3  Analysis of the secondary efficacy variables  ....................................97  
11.3.4  Analysis of the exploratory efficacy variables  .................................97  
11.3.5  Analysis of safety variables  ..............................................................98  
[IP_ADDRESS]  Adverse events  ........................................................................98  
[IP_ADDRESS]  Laboratory parameters  .............................................................98  
[IP_ADDRESS]  Vital sign s and body weight ....................................................[ADDRESS_1250335] ...........................................................................................100  
11.4.3  Statistical analysis  ...........................................................................101  
11.5  Sample size  .................................................................................................101  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 12/[ADDRESS_1250336] 2014- 004066- 20 
Doc No. D-16.554  
 
12 DATA HANDLING  ..................................................................................................102  
12.1  Data collection  ............................................................................................102  
12.2  Maintenance of data confidentiality  ...........................................................103  
12.3  Database management and quality control  .................................................103  
13 PROCEDURES AND GOOD CLINICAL PRACTICE  ...........................................104  
13.1  Ethics and Good Clinical Practice  ..............................................................104  
13.2  Independent Ethics Committee / Institutional Review Board  ....................104  
13.3  Informed consent ........................................................................................104  
13.4  Compensation to patients and investigators ...............................................105  
13.5  Protocol adherence/compliance  ..................................................................105  
13.6  Protocol amendments .................................................................................106  
13.7  Essential documents and retention of documents .......................................106  
13.8  Monitoring ..................................................................................................107  
13.9  Investigator site file  ....................................................................................108  
13.10  Audit ...........................................................................................................108  
13.11  Inspections ..................................................................................................109  
13.12  Reporting of study results and publication .................................................109  
14 REFERENCES  ..........................................................................................................111  
 
  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 13/[ADDRESS_1250337] OF TABLES 
 
Table 1  Visit and assessment schedule  ......................................................................32  
Table 2  New data published in 2015/2016 ...............................................................100  
Table 3  Efficacy boundaries for RVSV endpoint at interim/final analyses .............102  
Table 4  Efficacy boundaries for PVR endpoint at interim/final analyses ................[ADDRESS_1250338] OF APPENDICES 
 Appendix 1
 Actelion guidelines for RHC  .......................................................................117  
Appendix 2  Actelion guidelines for 6MWT  ...................................................................119  
Appendix 3  Borg dyspnea index .....................................................................................122  
Appendix 4  WHO Functional Classification of pulmonary hypertension ......................123  
Appendix 5  Study drug storage  ......................................................................................124  
Appendix 6  Central laboratory ........................................................................................125  
Appendix 7  Eligibility questionnaire  ..............................................................................126  
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 14/[ADDRESS_1250339] Disc  
CFR  Code of Federal Regulations (US)  
CI  Confidence interval  
CIR  Central Image Repository  
CL  Confidence limit  
CO  Cardiac output  
CRF  Case Report Form  
CRO  Contract Research Organization  
CV  Coefficients of Variation  
CYP  Cytochrome P450  
CYP3A4  Cytochrome P450 isozyme 3A4  
DLCO  Diffusing capacity of the lung for carbon monoxide  
dPAP  Diastolic pulmonary arterial pressure  
dSAP  Diastolic systemic arterial pressure  
ECG  Electrocardiogram  
eCRF  electronic Case Report Form  
EOS  End of Study  
EOT  End of Treatment  
ERA  Endothelin receptor antagonist  
ET-1  Endothelin -1 
ETA  Endothelin A receptor  
ETB  Endothelin B receptor  
FAS  Full Analysis Set  
FC  Functional Class  
FDG  Fluorodeoxyglucose  
FEV1  Forced expi[INVESTIGATOR_3741] 1 second  
FVC  Forced vital capacity  
GCP  Good Clinical Practice  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 15/[ADDRESS_1250340]  
HIV  Human immunodeficiency virus  
HR  Heart rate  
i.v.  Intravenous  
IAC  Image Analysis Center  
IB  Investigator’s Brochure  
ICF  Informed Consent Form  
ICH  International Council for  Harmonisation  
ICMJE  Internationa l Committee of Journal Editors  
IEC  Independent Ethics Committee  
ILSDRB  Independent Liver Safety Data Review Board  
INR  International Normalized Ratio  
IPF  Idiopathic pulmonary fibrosis  
IRB  Institutional Review Board  
IRT  Interactive Response Technology  
ISF  Investigative Site File  
IUD  Intrauterine device  
IUS  Intrauterine system  
LDH  Lactate dehydrogenase  
LFT  Liver function test 
LLN  Lower limit of the normal range  
LV  Left Ventricular 
LVEDP  Left Ventricular End Diastolic Pressure  
LVEDV  Left Ventricular End Diastolic Volume 
LVEF  Left Ventricular Ejection Fraction 
LVESV  Left Ventricular End Systolic Volume 
LVSV  Left Ventricular  Stroke Volume 
MedDRA   Medical Dictionary for Regulatory Activities  
mPAP  Mean pulmonary arterial pressure  
MR  Magnetic resonance  
mRAP  Mean right atrial pressure  
MRI  Magnetic resonance imaging  
mRNA  Messenger RNA  
NT-proBNP  N-terminal pro -brain natriuretic peptide  
PAH  Pulmonary arterial hypertension  
PAP  Pulmonary arterial pressure  
PBMC  Peripheral blood mononuclear cell  
PCWP  Pulmonary capi[INVESTIGATOR_47469]  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 16/[ADDRESS_1250341]  Upper limit of the normal range  
VEGF  Vascular Endothelial Growth Factor  
WHO  World Health Organization  
WU  Woods Units  
 
 
  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 17/[ADDRESS_1250342] 2014- 004066- 20 
Doc No. D-16.554  
 
PROTOCOL SYNOPSIS AC-055-403 
TITLE  A prospective, multicenter, single -arm, open -label, Phase 4 
study to evaluate the effects of macitentan on Right vEntricular 
remodeling in Pulmonary ArterIal hypeRtension assessed by 
[CONTACT_54753] . 
ACRONYM  REPAIR: Right v Entricular remodeling in Pulmonary ArterIal 
hype Rtension 
OBJECTIVES  Primary objective  
To evaluate the effect of macitentan  on right ventricular and 
hemodynamic  properties in patients with symptomatic 
pulmonary arterial hypertension  (PAH). 
Secondary objective  
To evaluate the safety and tolerability of macitentan in patients 
with symptomatic PAH. 
Exploratory objectives 
To investigate the effect of macitentan on disease-related 
circulating biomarkers in patients with symptomatic PAH. 
To explore a potential association between change in right 
ventricular properties and clinical outcome  in patients with 
symptomatic PAH. 
To investigate the effect of macitentan on ventriculo -arterial 
coupling in patients with symptomatic PAH. 
To evaluate the effect of macitentan on left ventricular  (LV) 
properties in patients with symptomatic PAH.  
DESIGN  Prospective, multicenter, single -arm, open -label, Phase 4 study. 
PERIODS  Screening:  from informed consent signature  [CONTACT_892804], may last up to 28 days. 
Treatment period : from first dose intake (Day 1) to End of 
Treatment ( EOT) at Week 52  ± [ADDRESS_1250343] 30 days and ends 
with the End of Study (EOS) Visit 30 to 37 days after EOT.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 18/[ADDRESS_1250344] visit. 
SITE(S)  
/ COUNTRY(IES)   Approximately [ADDRESS_1250345] S / GROUPS  100 patients enrolled in one group.  
MAIN INCLUSION 
CRITERIA  1. Signed informed consent prior to any study -mandated 
procedure. 
2. Symptomatic PAH . 
3. World Health Organization (WHO) Functional Class (FC) 
I to III. 
4. PAH etiology belonging to one of the followi ng groups 
according to Nice classification:  
1.1 Idiopathic PAH 
1.2 Heritable PAH  
1.3 Drug- and toxin-induced PAH 
1.4.1 PAH associated with  connective tissue disease 
1.4.4 PAH associated with congenital heart diseases: 
only simple  (atrial septal defect, ventricular septal 
defect, patent ductus arteriosus) congenital system ic to 
pulmonary shunts at least [ADDRESS_1250346] surgical repair.  
5. Hemodynamic diagnosis of PAH confirmed by [CONTACT_314475] (RHC) performed between Day −28 and Day 
1 (inclusion RHC; RHC data obtained at study site within 
this time frame,  prior to obtaining signed informed cons ent, 
are acceptable)  showing: 
• Mean pulmonary arterial pressure  (mPAP) 
≥ 25 mmHg and 
− Pulmonary capi[INVESTIGATOR_47469] ( PCWP) 
or left ventricular end diastolic pressure  
(LVEDP) ≤ 12 mmHg and pulmonary 
vascular resistance ( PVR) ≥ 4 Woods Units 
(WU) (320 dyn.sec.cm-5) or 
− 12 mmHg ≤ PCWP or LVEDP ≤ 15 mmHg 
and PVR ≥ 6 WU (480 dyn.sec.cm-5). 
6. 6-minute walk distance (6MWD) ≥ [ADDRESS_1250347] 1 month prior to the inclusion 
RHC. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 19/[ADDRESS_1250348] 2014- 004066- 20 
Doc No. D-16.554  
 
8. For patients treated with phosphodiesterase type -5 (PDE-5) 
inhibitors, treatment dose must have been stable at least 
3 months prior to the inclusion RHC (initiation o f PDE-[ADDRESS_1250349] been performed ). 
9. For patients treated with beta blocker s, treatment dose must 
have been  stable at least 1 month prior to the inclusion 
RHC. 
10. Men or w omen ≥ 18 and < 75 years. For patients aged ≥ 65 
and < 75 years, an eligibility form will be submitted to a 
Steering Committee member who will reserve th e right to 
exclude the patient.  
11. Women of childbearing potential [ see Section 4.5.1] must:  
a. Have a negative serum pregnancy test during 
screening and a negative urine pregnancy test on Day 1, and  
b. Agree to use reliable methods of contraception [ see 
Section 4.5] from screening up to 30 days after study 
treatment discontinuation, and 
c. Agree to perfor m monthly pregnancy tests up to 
30 days after study treatment discontinuation . 
MAIN EXCLUSION 
CRITERIA  1. Body weight < 40 kg . 
2. Body mass index  (BMI) > 35kg/m2. For patients with 
30kg/m2 < BMI < 35kg/m2, an eligibility form will be 
submitted to a Steering Committee member who will 
reserve the right to exclude the patient . 
3. Pregnancy, breastfeeding , or intention to become pregnant 
during the study. 
4. Recently started (< 8 weeks prior to informed consent 
signature) or planned cardio-p ulmonary rehabilitation 
program. 
5. Known concomitant life -threatening disease with a life  
expectancy < [ADDRESS_1250350] protocol or treatment 
compliance. 
7. Hospi[INVESTIGATOR_631522]  (except for diagnosis of PAH)  
within 3 months prior to informed consent signature. 
8. Left atrial volume indexed for body surface area  (BSA) 
≥ 43mL/m2 by [CONTACT_892725] . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 20/[ADDRESS_1250351] 2014- 004066- 20 
Doc No. D-16.554  
 
9. Moderate to severe left -heart valvular disease . 
10. History of pulmonary embolism or deep vein thrombosis. 
11. Presence of one or more of the following signs of relevant 
lung disease at any time up to screening:  
− Diffusing capacity of the lung for carbon monoxide 
(DLCO) < 40% of predicted (eligible only if no or 
mild interstitial lung disease on computed 
tomography). 
− Forced vital capacity (FVC) < 60% of predicted.  
− Forced expi[INVESTIGATOR_31737] (FEV 1) 
< 60% of predicted. 
12. Moderate to severe restrictive lung disease (i.e., total lung 
capacity < 60% of predicted value) at any time prior to 
enrollment. 
13. Historical evidence of significant coronary artery disease 
established by: 
− History of myocardial infarction  or 
− More than 50% stenosis in a coronary artery (by 
[CONTACT_892726]) 
or 
− Elevation of the  ST segment on electrocardiogram  
or 
− History of c oronary artery by[CONTACT_892727] 
− Stable angina. 
14. Known uncontrolled diabetes mellitus  (in the opi[INVESTIGATOR_1070]) . 
15. Severe renal insufficiency  (calculated creatinine clearance 
< 30 mL/min ). 
16. Cancer. 
17. Systolic blood pressure < 90 mmHg. 
18. Severe hepatic impairment (with or without cirrho sis) 
according to National Cancer Institute organ dysfunction 
working group criteria, defined as total bilirubin > 3 × upper 
limit of the normal range  (ULN) accompanied by [CONTACT_892728] ( AST) elevation > ULN at 
screening. 
19. Hemoglobin < 100g/L. 
20. Serum AST and/or alanine aminotransferase (ALT)  
> 3 × ULN. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 21/[ADDRESS_1250352]  based on medical 
history. 
23. Prior use of endothelin receptor antagonists  (ERAs), 
stimulators of soluble guanylate cyclase or prosta cyclin or 
prostacyclin analogs . 
24. Treatment with strong inducers of cytochrome P450 
isozyme 3A4 ( CYP3A4) within 4 weeks prior to study 
treatment initiation  (e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], 
rifabutin, phenytoin and St. John’ s Wort). 
25. Treatment with strong inhibitors of CYP3A4 within 4 weeks 
prior to study treatment initiation (e.g., ketoconazole , 
itraconazole, voriconazole, clarithromycin, telithromycin,  
nefazodone, ritonavir, and saquinavir). 
26. Treatment with another investigational drug (planned, or 
taken within the 3 months prior to study treatment 
initiation). 
27. Hypersensitivity to any ERA or any excipi[INVESTIGATOR_892700]  (lactose, magnesium stearate, 
microcrystalline cellulose, povidone, sodium starch 
glycolate, polyvinyl alcohol, polysorbate, titanium dioxide, 
talc, xanthan gum, and lecithin soya). 
28. Claustrophobia. 
29. MRI-incompatible p ermanent cardiac pacemaker, automatic 
internal cardioverter . 
30. Metallic implant (e.g., defibrillator, neurostimulator , hearing 
aid, permanent use of infusion device). 
31. Atrial fibrillation, multiple premature ventricular or atrial 
contractions , or any other condition that would interfere 
with proper cardiac gating during MRI. 
32. For patients enrolling in the metabolism sub- study only:  
glucose intolerance.  
33. For pa tients enrolling in the biopsy sub- study only:  PAH 
etiology belonging to Nice classification 1.4.4: PAH 
associated with congenital heart diseases  or 1.4.1: PAH 
associated with connective tissue disease . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 22/[ADDRESS_1250353] 2014- 004066- 20 
Doc No. D-16.554  
 
STUDY TREATMENTS  Investigational treatment  
Open-label macitentan 10  mg once daily , oral. 
Comparator and/or placebo 
Not applicable . 
CONCOMITANT 
THERAPY  Allowed concomitant therapy  until Week 26 RHC  
• Therapi[INVESTIGATOR_892701]. 
• Oral loop diuretics if  used at a stable dose for 1 week prior 
to Week 26 R HC. 
• Use of rescue therapy  (see below) only in case of disease 
progression. 
• A PDE-[ADDRESS_1250354] 
14 days after study treatment initiation.  
Allowed concomitant therapy after Week 26 RHC 
Treatment initiation and dose changes for: 
• Loop diuretics . 
• PDE-5 inhibitors. 
• Prostanoid analogs by [CONTACT_250112]. 
• Stimulators of soluble guanylate cyclase . 
• Any other PAH -specific therapy that may obtain marketing 
authorization during study conduct. 
Forbidden concomitant therapy  
ERAs other than study drug, investigational drug other than 
study drug, s trong CYP3A4 inhibitor s (e.g., ketoconazole , 
itraconazole, voriconazole, clarithromycin, telithromycin,  
nefazodone, ritonavir, and saquinavir ) and strong inducers of 
CYP3A4 (e.g., carbamazepi[INVESTIGATOR_050],  rifampi[INVESTIGATOR_2513], rifabutin, phenytoin 
and St. John’ s Wort). 
Initiation of one of these forbidden medications will lead to 
premature discontinuation of study treatment.  
Rescue therapy  before Week 26 RHC  
The following t reatment changes are allowed before Week 26 
RHC only in case of disease progression : 
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 23/[ADDRESS_1250355] 2014- 004066- 20 
Doc No. D-16.554  
 
• Initiation of:  
− Intravenous (i.v.) loop diuretics  
− PDE-5 inhibitors 
− Prostanoid analogs by [CONTACT_250112] 
− Stimulators of soluble guanylate cyclase  
− Any other PAH -specific therapy that may obtain 
marketing authorization during study conduct. 
• Up-titration of PDE -5 inhibitors. 
Disease progression is defined as: 
• Decrease in 6MWD by [CONTACT_726] 15% associated with 
worsening in WHO FC, or 
• Need for subcutaneous ( s.c.) or i.v. prostanoid therapy, or  
• Hospi[INVESTIGATOR_631522] (investigator ’s assessment) . 
After Week 26 RHC, treatment chang es are allowed.  
ENDPOINTS  Primary efficacy endpoint s 
The study has two primary efficacy  endpoints: 
- Change from baseline to Week 26 in Right Ventricular 
(RV) Stroke Volume (RVSV) assessed by [CONTACT_892729]. 
- Ratio of Week 26 to baseline PVR  assessed by [CONTACT_321333]. 
Secondary efficacy endpoints  
Change from baseline to Week 26 in: 
- RV End Diastolic Volume (RVEDV)  
- RV End Systolic Volume (RVESV)  
- RV Ejection Fraction (RVEF)  
- RV mass 
- 6MWD 
- WHO FC  
Exploratory endpoints 
Change from baseline to Week 26 in : 
- mPAP 
- Mean right atrial pressure 
- Cardiac index  
- Arterial elastance  
- RV end-systolic elastance  
- RV maximum isovolumic pressure  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 24/[ADDRESS_1250356] 2014- 004066- 20 
Doc No. D-16.554  
 
Change from baseline to Week 52 in:  
- RVSV determined by [CONTACT_892730]  
- RVEDV 
- RVESV 
- RVEF 
- RV mass 
- 6MWD 
- WHO FC  
Change from baseline to Week 26 and Week 52 in: 
- Left Ventricular  Stroke Volume (LVSV) determined by 
[CONTACT_892731]  
- LV End Diastolic Volume (LVEDV)  
- LV End Systolic Volume (LVESV) 
- LV Ejection Fraction (LVEF)  
- LV mass 
- RVEDV/LVEDV  
- RVESV/LVESV  
- N-terminal pro -brain natriuretic peptide  (NT-proBNP) 
- Uric acid 
- Red cell distribution width  
- Activin A  
- Cystatin C  
- Follistatin  
- Galectin-3 
- Growth Differentiation Factor ( GDF)-15 
- Cardiac troponin T 
- Lactate dehydrogenase ( LDH) 
- Osteoprotegerin 
- Tumor Necrosis Factor ( TNF) alpha 
Time to first clinical worsening event defined as:  
- Decrease in 6MWD by > 15% from baseline associated 
with worsening in WHO FC, or  
- Initiation of s.c. or i.v. prostanoid therapy, or  
- Hospi[INVESTIGATOR_631522] (investigator’ s assessm ent), or 
- Death 
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 25/[ADDRESS_1250357] 2014- 004066- 20 
Doc No. D-16.554  
 
Safety endpoints  
- Treatment -emergent adverse events ( AEs) up to 30 days 
after EOT. 
- Treatment -emergent serious adverse events ( SAEs) up 
to [ADDRESS_1250358] (ALT and/or AST) 
abnormality ( ≥ 3; ≥ 3 and < 5 × UL N; ≥ 5 and 
< 8 × ULN ; ≥ 8 × ULN) up to EOT . 
- Occurrence of hemoglobin abnormality ( ≤ 80 g/L; 
> 80 and ≤  100 g/L) up to EOT . 
- Occurrence of ALT and/or AST  abnormality ≥ 3 × ULN  
associated with bilirubin ≥ 2 × ULN.  
ASSESSMENTS Refer to the schedule of assessment s in Table 1. 
STATISTICAL 
METHODOLOGY   • Analysis sets  
The Full Analysis Set (FAS) includes all patients who received 
at least one dose of study drug and who had a baseline as well as a post -baseline measurement for both pr
imary endpoints 
(RVSV and PVR).  
The Modified FAS comprises all patients from the FAS who 
had a post -baseline measurement taken between 16 and 
30 weeks of treatment.  
The Safety Set (SS) includes all patients who received at least 
one dose of study drug. 
• Primary efficacy endpoint s 
The study has two primary efficacy  endpoints: 
• Change from baseline to Week 26 in RVSV assessed by 
[CONTACT_892732].  
• Ratio of Week 26 to baseline PVR  assessed by [CONTACT_321333] . 
• Null and alternative hypotheses  
The null hypothesis is: 
The mean change from baseline in RVSV is less than or equal 
to zero AND the geometric mean ratio of Week 26 to baseline 
PVR is greater than or equal to one. 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 26/[ADDRESS_1250359] 2014- 004066- 20 
Doc No. D-16.554  
 
The alternative hypothesis is:  
The mean change from baseline in  RVSV is greater than zero  
OR the geometric mean ratio of Week 26 to baseline PVR is  
less than one. 
• Type- I and - II errors and power  
The overall type I error (α) of 0.025 (one- sided) will be split 
between the endpoints: change from baseline in RVSV will be 
tested at α = 0.02 and ratio to baseline  PVR will be tested at 
α = 0.005.  
Per endpoint the type II error is set to 0.10 and the power to 
90%. 
• Primary efficacy  analysis 
The primary efficacy analyses (interim and final)  will be 
performed  on the Modified FAS. Change from baseline in 
RVSV will be analyzed using an Analysis of Covariance 
(ANCOVA) with a factor for other PAH-specific therapy (none, 
background or initiated at baseline ) and a covariate for baseline 
RVSV. The mean change from ba seline and its 96% confidence 
interval (CI) will be estimated based on the model. 
The ratio of Week 26 to baseline  PVR will be log transformed 
(base e) and analyzed using an ANCOVA with a factor for other PAH-specific therapy (none, background or initiated at 
baseline) and a covariate for baseline log PVR. The mean 
change from baseline (on log scale) and its 99% 
CI will be 
estimated based on the model. The Geometric Mean Ratio (versu
s baseline) and its 99% CI will be obtained by 
[CONTACT_151698]. 
If a patient  discontinues treatment prematurely before Week [ADDRESS_1250360] 16 weeks of  study treatment.  
The null hypothesis will be tested at interim and final analysis , 
if study continues, and may be rejected based on pre -defined 
boundaries. 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 27/[ADDRESS_1250361] 2014- 004066- 20 
Doc No. D-16.554  
 
• Secondary analyses  
Secondary efficacy variables will be analyzed for the Modified 
FAS only at final analysis at α = 0.025 (one -sided) using 95% 
CIs. No correction for multiple testing will be applied for these analyses. 
Association between (change from baseline to Week 26 in) 
cardiac MRI variables and time to first clin ical worsening event 
will be explored using Cox models. 
• Safety endpoints  
Safety data will be summarized using descriptive statistics. 
Safety analyses will be performed on the SS. 
• Interim analysis 
An interim analysis will be conducted when [ADDRESS_1250362] be met. 
• Sample size calculation  
For MRI-based RVSV, no individual patient data are available 
at Actelion. Individual RVSV was approximated in the 
hemodynamic sub -study of SERAPHIN (AC -055-302) 
combining the cardiac index obtained from the RHC with BSA and heart rate from vital signs measurements. The change from 
baseline in approximate RVSV was around 9 mL, in line with literature suggesting that a differe nce of 8–
12 mL is clinically 
relevant [Van Wolferen 2011] . Assuming a standard deviation 
of 18–22 mL, also based on the hemodynamic sub- study of 
SERAPHIN, the sample size for 90% power is 30 –93 evaluable 
patients for final analysis (α = 0.02, one -sided). T he number of 
patients and efficacy boundaries for the interim analysis are described in  Table 3. 
For PVR, an integrated analysis of two bosentan studies, BENEFIT (AC -052-366) and EARLY (AC -052-
364), and the 
hemodynamic sub -study of SERAPHIN suggested that the 
mean change from baseline is expected to be around −0.24 on log scale (95% CI: −0.29, −0.19) and that the within group standard deviation is  
around 0.41 on log scale (90% CI: 0.39, 
0.43). Under these assumptions, 30–84 evaluable patients are 
needed for final analysis for 90% power (α = 0.005, one -sided). 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 28/[ADDRESS_1250363] (ILSDRB, an 
external expert committee of hepatologists) provides ongoing  
assessment and advice regarding serious hepatic adverse events  
of special interest (HAESI)  that require further evaluation 
during the study as per ILSDRB charter . 
SUB- STUDIES  Three sub -studies are planned and described under the same 
protocol. 
The sub-studies will be conducted in selected centers. In these 
centers, all patients eligible for the main study will be offered to 
participate in the sub -study(ies). 
Metabolism sub -study, in the US only  
Patients: From 10 to 30 patients eligible for the main study and 
not matching the additional exclusion criterion  number 32: 
glucose intolerance. 
Objective s: To assess the effect of macitentan on  cardiac and 
arterial metabolism in patients with symptomatic PAH by 
[CONTACT_340662]  (PET)-Magnetic Resonance 
(MR) imaging . 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 29/[ADDRESS_1250364] 2014- 004066- 20 
Doc No. D-16.554  
 
Exploratory endpoints :  
Change from baseline to Week 26 and to Week 52 in : 
- RV 18F-fluorodeoxyglucose (FDG) uptake 
- Aortic 18F-FDG uptake 
- Right common carotid  18F-FDG uptake  
- Left common carotid  18F-FDG uptake  
Biopsy sub- study  
Patients: From 10 to 20 patients eligible for the main study  and 
not matching the additional exclusion criterion number 33: PAH 
etiology belonging to Nice classification 1.4.4: PAH associated 
with congenital heart diseases  or 1.4.1: PAH associated with 
connective tissue disease . 
Objective s: To assess the histologic al and biochemical effects 
of macitentan on the endomyocardium of the interventricular 
septum in patients with symptomatic PAH. 
To assess the biochemical effects of macitentan on peripheral 
blood mononuclear cells (PBMC) in patients with symptomatic 
PAH. 
Exploratory endpoints :  
Change from baseline to Week 26 in : 
- Qualitative assessment of endomyocardium function 
markers in biopsies 
- Relative q uantitative assessment of endomyocardium 
function markers in biopsies 
- Number of capi[INVESTIGATOR_892702] 
- Mean cardiomyocyte volume 
- Qualitative assessment of cardiomyocytes  
- mRNA transcript analysis  
- PBMC mRNA transcript analysis  
Echo  sub-study  
Patients: From 40 to 50 patients eligible for the main study.  
Objective : To assess the effect of macitentan on  right and left 
ventricular function by  [CONTACT_892733]. 
Exploratory endpoints :  
Change from baseline to Week  26 and Week 52 in: 
- LV eccentricity index at end -diastole 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 30/[ADDRESS_1250365] 2014- 004066- 20 
Doc No. D-16.554  
 
- LV eccentricity index at end -systole 
- Minimum diameter of the inferior vena cava (at 
inspi[INVESTIGATOR_1516]) 
- Maximum diameter of the inferior vena cava (at 
end-expi[INVESTIGATOR_1516]) 
- Tricuspid annular plane systolic excursion (TAPSE) 
- Pericardial effusion size scored from [ADDRESS_1250366] 
Doppler 
- Total RV Systolic Time (duration of tricuspid insufficiency 
jet) 
- Doppler RV index  (RV myocardial performance index) , by 
[CONTACT_892734] 
- Tricuspid peak  jet velocity  
- RV systolic  pressure (estimated by [CONTACT_892735]) 
- Early diastolic velocity of the jet o f pulmonary valve 
regurgitation  
- End-diastolic velocity of the jet o f pulmonary valve 
regurgitation  
- Cardiac output determined from LV outflow tract 
- Mitral E-wave velocity  
- Mitral A-wave velocity  
- Mitral annulus peak early diastolic velocity E’ 
- E/A ratio 
- E/E’ ratio  
- 2-dimensional (2D) RV dimension end- diastole 
- Tricuspid peak annular velocity s ’ 
- RV end diastolic area  
- RV end systolic area  
- RV fractional area change 
- RVSV determined from  pulmonary valve Doppler and 
pulmonary annulus dimension 
- Tricuspid peak E, peak A, deceleration time 
- Tricuspid peak diastolic annular velocities e’, a’ 
- LVEDV determined from 2D measurements  
- LVESV determined from 2D measurements  
- Mitral deceleration time  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 31/[ADDRESS_1250367] tissue Doppler velocit y a’ 
- 2D Global L ongitudinal RV strain  
- 2D circumferential RV strain  
- Time to peak RV strain  
- RVSV 
- RVEDV 
- RVESV 
- RVEF 
- RV mass 
- LVSV 
- LVEDV 
- LVESV 
- LVEF 
- LV mass 
- RVEDV/LVEDV  
- RVESV/LVESV  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 32/[ADDRESS_1250368] 2014- 004066- 20 
Doc No. D-16.554  
 
Table 1 Visit and assessment schedule  
PERIODS  SCREENING  TREATMENT   FOLLOW -UP 
Duration  Up to 28 days  52 weeks  Up to 37 days 
VISITS name  [CONTACT_892805] (if 
before Week 26 RHC)  Week 26 visit  Premature EOT visit 
(if after Week 26 
RHC) EOT visit1 Unscheduled 
visit EOS visit 
(phone) 
Time  Day −28 to 
Day 1 Day 1 
 Prior to initiation  of 
rescue therapy  Prem. EOT: latest 7 days 
after decision to end 
study treatment  Week 26 
(± 14 days) Latest 7 days after 
decision to end study 
treatment  Week 52 
(± 7 days)  30 to 37 days 
after EOT  
Informed consent  X         
Eligibility criteria  X         
Demographic & baseline 
characteristics  X         
Medical history  X         
Weight  X  X X X X X X [ADDRESS_1250369] 6 months  Recommended monthly    
Pregnancy test7,8   X Monthly X  X 
PET -MR scan X 9  X 4,9 X 4,9 X 9 X 9 X 9   
Biopsy  X 9  X 3,4,9 X 3,4,9 X 9     
Echo  X 9  X 4,9 X 4,9 X 9 X 9 X 9   
Study drug dispensing/return   X  X X X X   
AEs and SAEs  X X X X X X X X X 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 33/[ADDRESS_1250370]; AE, adverse event; EOS, end of study; EOT, end of treatment;  MRI, magnetic resonance imaging;  PET-MR, positron emission tomography - magnetic resonance;  Prem., 
premature; RHC, right heart catheterization ; RTI, rescue therapy  initiation; SAE, serious AE; WHO FC, World Health Organization functional  class. 1. Not performed for patients who had a premature 
EOT previously ; 2. Cardiac MRI  and RHC  must be performed within 21  days of each other ; 3. If visit is before Week 16, decision to conduct the exam based on clinical judgment; 4.  Done once only 
and replaces Week 26 exam; 5.Stored samples will be destroyed [ADDRESS_1250371] patient ’s last visit; 6.If visit is before Week 48, decision to conduct the exam base d on clinical judgment; 7 . For 
women of childbearing potential only; 8. Pregnancy tests will be done using the monthly blood draws where applicable, and with urine pregnancy tests otherwise; 9 . For patients in the respective sub -
study only; 10 . Assessed if clinically indicated; 11. RHC data obtained at study site between Day −28 and Day 1, prior to obtaining signed informed consent , are acceptable . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 34/[ADDRESS_1250372] serious chronic disorder of the pulmonary circulation is pulmonary arterial 
hypertension (PAH), a syndrome of diverse etiology and pathogenesis characterized by a 
progressive increase in pulmonary arterial pressure (PAP) and in pulmonary vascular resistance (PVR) potentially leading to right heart failure and death  [Benza 2010, 
Kylhammar 2014, Oudiz 2013] . 
PAH is associated with structural changes in both pulmonary vasculature and right ventricle. The changes in vascular structure involve three combined elements: vasoconstriction, vascular -wall remodeling, and thrombosis in situ  [Humbert 2004] . The 
changes in the right ventricle mainly consist of hypertrophy, dilation, altered contractility 
and septal bowing  [Rich 2012, Franco 2012, Vonk-Noordegraaf 2011] . Collectively these 
changes of the right ventricle are termed remodeling.  
PAH is hemodynamically defined as a resting mean pulmonary arterial pressure (mPAP) 
greater than 25 mmHg with normal pulmonary capi[INVESTIGATOR_359222] (< 15 mmHg)  and a PVR greater than 3 Woods Units ( WU) [Hoeper 2013] . 
The updated clinical classification of pulmonary hypertension ( PH; Nice 2013)  
[Simonneau 2013] classifies the numerous conditions that are known to lead or be 
associated with the development of PAH into [ADDRESS_1250373] of all, similar therapeutic approach. PAH may occur in the absence of a demonstrable cause (idiopathic), in a familial setting  (heritable) , as the result of the use of drugs and toxins, or it can be 
associated with a connective tissue disease, HIV infection, portal hypertension, 
congenital heart disease, or schistosomiasis.  
1.1.[ADDRESS_1250374] led to the development of new therapi[INVESTIGATOR_359223] (prostacyclin pathway , 
endothelin pathway , and nitric oxide pathway)  [Galiè 2013] that are believed to play 
important pathogenic roles. 
Several agents are currently approved for the treatment of PAH in the [LOCATION_002] , 
Europe, and Australia . Intravenous (i.v.) prostacyclin (epoprostenol), prostanoid analogs , 
i.e., treprostinil (i .v., subcutaneous [s.c.], inhaled  and oral), and iloprost (i.v. and inhaled ), 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 35/[ADDRESS_1250375] s (ERAs; bosentan and macitentan ), a selective ERA 
(ambrisentan), phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil and tadalafil ), and 
more recently, a stimulator of soluble guanylate cyclase ( riociguat). 
Vasodilators, such as calcium channel blockers, are effective only in a minority of 
patients who have an acute response to vasodilator testing [ Rich 1992, Sitbon 2005].  
Despi[INVESTIGATOR_359225], PAH remains a serious life- threatening condition 
[Galiè 2013, Benza 2010 ], and new compounds continue to be explored. 
1.[ADDRESS_1250376]  
Endothelin- 1 (ET-1), a [ADDRESS_1250377] potent vasoconstrictors 
and mitogens for smooth muscle, and contributes to increased vascular tone and proliferation in pulmonary vasculopathy [ Galiè 2004 ]. 
There are two distinct receptors for ET -1, endothelin receptor A (ETA) and endothelin 
receptor B (ETB). Each receptor has  unique binding location and affinity  for the 
endothelin peptide  [Benigni 1995, Massaki 1998] . ETA receptors are expressed on 
pulmonary vascular smooth muscle cells, whereas ETB receptors are present both on pulmonary vascular cells and on smooth muscle cells. 
When activated, ETA receptor s located in pulmonary vascular smooth m uscle cells 
mediate a potent vasoconstrictive response and ETB receptors on endothelial cells 
mediate vasodilatation via increased production of nitric oxide and prostacyclin  
[Hirata 1993, de Nucci 1988] . ET-1 is also known to be a potent mitogen, with the ability 
to induce cell proliferation in vascular smooth muscle cells. It has been shown that both 
the ETA and ETB mediate the mitogenic a ction of ET -1 [Clarke 1989, Chua 1992, 
Davie 2002, Sugawara 1996].  
Laboratory and clinical investigations have shown that ET -1 is overexpressed in several 
forms of pulmonary vascular disease. ET -1 is likely a major player in the vasodilator and 
vasoconstri ctor imbalance, as well as in the abnormal pulmonary vascular remodeling 
present in the development and progression of PH of various etiologies  [Stewart 1991, 
Giaid 1993] . 
1.2.2 Macitentan  
Macitentan is approved for the treatment of PAH  in the US, EU, Australia, Canada, 
Japan, Switzerland, New Zealand, Mexico, Israel, Kuwait, South Korea, Argentina, Chile, Singapore, Taiwan, Turkey, Russia, Columbia, Morocco, and Hong Kong. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 36/[ADDRESS_1250378] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Nonclinical results  
Macitentan is an orally active, non- peptide, potent dual ETA and ETB receptor 
antagonist. Macitentan showed  dose dependent efficacy in nonclinical models of 
hypertension and PH . In nonclinical safety studies, no effects on normal physiological 
functions or ECG variables, including cardiac repolarization, were observed, with the 
exception of a decrease in arteri al blood pressure observed in a cardiovascular study in 
dogs. Macitentan has no genotoxic and no carcinogenic potential. In the pi[INVESTIGATOR_22735] 26- week 
and 39-week toxicity studies, the exposures in animals found at the no-observed- adverse-
effect levels were above the anticipated clinical exposures and provided a margin of 
safety for studies in humans. Reproductive toxicity studies showed that macitentan is 
teratogenic without affecting male or female fertility. Teratogenicity is considered to be an ERA class effect.  
More detailed information on macitentan can be found in the Investigator’ s Brochure (IB) 
[Macitentan  IB]. 
[IP_ADDRESS] Phase 1 results  
During the Phase 1 program, more than 200 healthy subjects and about 30 patients (with 
renal and hepatic impairment) were treated with macitentan. Macitentan was well tolerated in all studies. The most frequently repor ted adverse event (AE) was headache.  
More detailed information on macitenta n can be found in the IB [ Macitentan  IB]. 
[IP_ADDRESS] Phase 2 results  
Phase 2 studies were conducted in patients with mild- to-moderate essential hypertension, 
and in patients with idiopathic pulmonary fibrosis  (IPF). In both indications, m acitentan 
was well tolerated across all dose levels, ranging from 0.3 mg to 10 mg. 
A Phase 2 dose -finding study [Macitentan  IB] was conducted in patients with 
mild-to-moderate essential hypertension. In this study, treatment with the 10 mg dose of 
macitentan was associated with a statistically significant reduction (versus  placebo) from 
baseline to Week [ADDRESS_1250379] 
one serious adverse event (SAE) were evenly distributed across active treatment groups. There were no deaths.  
In a Phase 2 study in patients with IPF [Raghu 2013] , the primary endpoint (change in 
forced vital capacity [FVC]) was not met, but it was shown that macitentan treatment with 10 mg dose was well tolerated. Overall, the safety profile was similar in the 
macitentan 10 mg and placebo groups. The i ncidence of treatment -emergent AEs was 
similar in both groups. 
More detailed information on macitentan can be found in the IB [ Macitentan  IB]. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 37/[ADDRESS_1250380] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Phase 3 efficacy results 
Effectiveness was established in a long -term study in PAH patients with predominantly 
WHO Functional C lass (FC) II-III symptoms treated for an average of 2 years  
[Pulido 2013] . Patients had idiopathic or heritable PAH (57%), PAH caused by 
[CONTACT_269393] (31%), and PAH caused by [CONTACT_892736] (8%)  and were treated with macitentan monotherapy or in combinat ion 
with PDE-5 inhibitors or inhaled prostanoids. 
The trial demonstrated that macitentan 10 mg reduces the risk of morbidity / mortality in 
patients with symptomatic PAH , with a hazard ratio versus placebo of 0.547, 97.5%  
confidence limits ( CLs) 0.392–0.762, p < 0.0001. This represents a risk reduction of 
45%. 
The placebo -corrected mean change in 6 -minute walk distance (6MWD) from baseline to 
Month 6 showed an increase of 22.0 m (97.5% CLs 3.2, 40.8) with macitentan 10 mg 
versus placebo.  
A hemodynamic s ub-study showed a reduction of PVR from baseline to Month 6 of 
36.5%, CLs 21.7–49.2) with macitentan 10 mg.  
More detailed information on macitentan can be found in the IB [ Macitentan  IB]. 
[IP_ADDRESS] Summary of potential risks and risk management 
Nonclinical studies with macitentan did not identify important risks of likely relevance to 
humans except for teratogenicity, a class effect of ERAs. The protocol , therefore, 
includes stringent requirements for pregnancy testing and reliable methods of 
contraception for female patients of childbearing potential.  
In the [ADDRESS_1250381] 
elevations was observed across macitentan treatment groups and placebo. The proportions of patients with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevations > 3 × upper limit of the normal range (ULN) were 
similar across the treatment groups, but a higher perc entage of patients treated with 
macitentan 10 mg had ALT > 3 × ULN compared to placebo. However, there were no 
patients in the studies who met the Hy ’s Law criteria (i.e., ALT/AST > 3 × ULN and total 
bilirubin > 2 × ULN), and who had no associated increase  in alkaline phosphatase in the 
absence of alternative explanations which were possibly or likely the cause of the elevations. Patients with serum AST and/or ALT > 3 × ULN are excluded from the study, 
and monthly liver tests are mandatory during the first 6 months and recommended 
thereafter. The protocol also includes clear instructions regarding re -tests and criteria for 
treatment discontinuation in the case of clinically relevant elevations of aminotransferases.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 38/[ADDRESS_1250382] 2014- 004066- 20 
Doc No. D-16.554  
 
Treatment with ERAs has been associated with increased incidence of edema, anemia 
and/or decreased hemoglobin [Abman 2009, O’Callaghan 2011] . Treatment with 
macitentan  was associated with a dose- related reduction in hemoglobin levels, which was 
established within the first 3 months of treatment. Decreased hemoglobin levels tended to show recovery towards baseline after discontinuation of treatment. Higher incidences of anemia AEs were reported in a dose -related fashion in the patients treated with 
macitentan in comparison to those treated with placebo. Anemia required transfusion in some patients treated with macitentan. Patients with hemoglobin < 100 g/L are excluded 
from the study. Monthly hemoglobin tests are mandatory during the first 6 months and 
recommended thereafter. The protocol also includes clear instructions regarding re -tests 
and criteria for treatment discontinuation in the case of clinically relevant anemia. 
The incidences of edema AEs were similar in the macitentan and placebo groups, 
although subgroup analyses indicated fluctuations in the incidence of edema, with no clear pattern according to treatment (macitentan v ersus placebo) or macitentan dose. 
Edema SAEs were uncommon with macitentan treatment and only 3 patients (2 on 
placebo and 1 on macitentan 10 mg) discontinued treatment due to an edema AE. Overall, there is no indication that edema represents a significant safety concern with macitentan therapy  in PAH. 
Due to the vasodilatory effects of macitentan, effects on blood pressure might occur. In patients with normal blood pressure prior to initiation of macitentan treatment , there was 
a slightly higher incidence of AEs denoting hypotension, relative to placebo on macitentan. However, hypotension SAEs were reported less frequently on macitentan than on placebo, and only one macitentan- treated patient discontinued due to this AE. 
Hypotension AEs were predominantly reported for female patients and there was no indication of an increased incidence in other potentially vulnerable subgroups, such as the elderly, or patients with renal function impairment at baseline. Patients with systolic blood pressure < 90 mmHg are excluded from the study. 
Reductions from baseline in leukocyte and platelet counts may be observed with macitentan. In the AC -055-302 / SERAPHIN study, macitentan was associated with 
modest and non-dose- dependent decreases in mean leukocyte count from baseline to End 
of Treatment (EOT). A small p roportion of PAH patients, in both placebo and macitentan 
groups, showed markedly reduced platelet counts, with or without bleeding complications, at some time during the study. Resolution during continued treatment with macitentan was observed, as well as  absence of recurrence after treatment re- initiation, 
findings that make a specific, causal relationship to macitentan unlikely.  
In the AC -055-302 / SERAPHIN study, menstrual disorder AEs (mainly menorrhagia, 
metrorrhagia, and dysfunctional bleed) and ovar ian cysts were reported at a low 
incidence overall, but more frequently on macitentan than placebo, in females of 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 39/[ADDRESS_1250383] infections but also 
bronchitis was seen with macitentan v ersus placebo. It is likely that many such events 
may represent symptoms of congestion due to local vasodilatation (e.g., rhinitis), rather than actual infection. F or the clinically more relevant lower respi[INVESTIGATOR_6014], 
specially pneumonia, there was no relevant difference between macitentan and placebo. In addition, there was a higher incidence of urinary tract infections and gastroenteritis in the patients who received macitentan treatment compared to those who received placebo. 
However, given that there was no imbalance in the incidence of these events that were reported as SAEs or that led to discontinuation of treatment, coupled with the fact that there was no increase in the reporting rate over time, these AEs were considered to be of 
limited clinical relevance.  
Given the extensive and long -term controlled data available with macitentan in PAH and 
the careful follow -up of patients mandated by [CONTACT_760], the benefit/risk assessment 
supports the use of macitentan in the current study. 
1.3 Purpose and rationale of the study 
1.3.1 Purpose of the study  
The purpose of the study is to further extend the knowledge of macitentan by [CONTACT_892737], and specifically on the right ventricle. 
1.3.2 Rationale 
[IP_ADDRESS] Importance of t he right ventricle in PAH  
The pathophysiologic mechanisms of PAH are initiated by [CONTACT_892738]. The right ventricle  responds by  [CONTACT_892739] . 
Progressively, this increased contractility is no longer sufficient  to maintain an 
appropriate blood supply, the right ventricle hypertrophies , which translates into a thicker 
myocardium. D ilation is then achieved to increase the blood volume in the right ventricle. 
Gradually, the right ventricle  becomes more spherical so that the septum between right 
and left ventricle s flattens. Right ventric ular remodeling compensates for a variable 
period of time but ultimately may no longer suffice, leading to  right heart failure and 
death. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 40/[ADDRESS_1250384] 2014- 004066- 20 
Doc No. D-16.554  
 
Although PAH is a disease of the pulmonary vasculature, the geometry and function of 
the right ventricle are tightly linked  with survival  [Van Wolferen  2007, Yamada 2012, 
Swift 2014, Raymond 2002, Van de Veerdonk 2011].  In fact, the primary cause of death  
in PAH is right ventricular failure. The  function of the  right ventricle is , therefore, of 
critical importance in this condition. 
While the safety and efficacy of macitentan  have been studied in PAH clinical trials, its 
effects on the right ventricle are yet to be determined.  
The capacity of the right ventricle to undergo reverse remodel ing has been described in 
PAH patients who underwent lung transplant  [Kasimir 2004] , and in patients with PAH 
treated with  single [Wilkins 2005, Galiè 2003, Van Wolferen 2006, Hinderliter 1997, 
Roeleveld  2004, Blalock 2010]  or combined PAH -targeted therapi[INVESTIGATOR_014] [Peacock 2014].  
It therefore seems reasonable to hyp othesize that macitentan reverses right ventricular 
remodeling. 
[IP_ADDRESS] Pulmonary vascular resistance  
PAH is characterized by [CONTACT_892740], quantified by [CONTACT_566678]. PVR represents the resistance against which the rig ht 
ventricle needs to pump. In PAH, a decrease in PVR is therefore beneficial for the right ventricle. 
PVR is determined by [CONTACT_137910] (RHC). Since this procedure is indispensable for the diagnosis of PAH  and to evaluate treatment response [Galiè 2013], 
sites treating PAH patients are well experienced with RHC. The study will be run in sites specialized in PAH.  RHC procedures in patients with PH in experienced centers are 
reported to be associated with low morbidity and mortality rates [Hoeper 2006]  and 
deemed acceptable in this study.  
[IP_ADDRESS] Cardiac magnetic resonance imaging  
Cardiac magnetic resonance imaging (cardiac MRI) is a safe imaging technique as it is 
non-invasive and does not use ionizing radiations. Images of slic es in any plane can be 
obtained with very g ood spatial and temporal resolution. This translates into a low 
variability of inter -study and inter -rater cardiac MRI assessments which allows a reduced 
sample size for clinical trials compared to other imaging tools [Addetia 2014].  
Cardiac MRI is , therefore, the method of choice to study the evolution of the right 
ventricle under treatment.  
[IP_ADDRESS] Ventriculo -arterial coupling  
Beyond the measurement of volumes, a more comprehensive understanding of the 
balance between right ventricle and the arterial system can be achieved by [CONTACT_163297] 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 41/[ADDRESS_1250385] 2014- 004066- 20 
Doc No. D-16.554  
 
ventriculo- arterial coupling, which is quantified by [CONTACT_892741]-systolic 
elastance to arterial elastance [Foëx 1994] . Ventricular end -systolic elastance represents  
the intrinsic , load-independent contractility of the ventricle.  Likewise, arterial  elastance 
represents the load from the pulmonary vascula ture that the right ventricle  faces. 
Elastances are determined from the relationship between volume and pressure in the 
ventricle. While volume can be measured by [CONTACT_566757]  [Trip 2013] , the determination 
of pressure requ ires RHC [Sunagawa 1980, Takeuchi 1991, Kuehne 2004, 
Brimioulle  2003]. Determination of ventriculo -arterial coupling does not require any 
additional procedure for the patient beside cardiac MRI and RHC, which are part of the 
study. 
[IP_ADDRESS] Up-front combination therapy 
Based on recent  data [Galiè 2014], targeting mo re than one disease pathway from initial 
diagnosis may be beneficial . 
Thus, combination of a PDE -5 inhibitor and an ERA in a  treatment -naïve patient is 
allowed. 
[IP_ADDRESS] Overall benefit -risk ratio  
Given the data available with macitentan in PAH, the careful follow -up of patients 
mandated by [CONTACT_892742], the benefit/risk assessment supports the conduct of the current study. 
[ADDRESS_1250386]  of macitentan  on LV properties  in patients with symptomatic PAH. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 42/[ADDRESS_1250387] 2014- 004066- 20 
Doc No. D-16.554  
 
2.4 Sub-studies rationale and objectives 
2.4.1 Metabolism sub -study  (in selected US sites only)  
[IP_ADDRESS] Rationale 
In PAH, right ventricle  hypertrophy causes a greater oxygen requirement. This induces an 
adaptation of the metabolic pathway s by a shift from fatty acid  to glucose consumption 
[Archer 2013] . Glucose consumption can be assessed by [CONTACT_340662] 
(PET) [Bokhari 2011] . 
[IP_ADDRESS] Objectives 
To assess the effect of macitentan on cardiac and arterial metabolism in patients with 
symptomatic PAH by [CONTACT_10052] -MR imaging. 
2.4.2 Biopsy sub- study  
[IP_ADDRESS] Rationale for taking biops ies 
Right ventric ular remodeling is associated with tissue changes such as fibrosis, capi[INVESTIGATOR_892703] -cellular level, for example changes in 
cardiomyocyte size and mitochondrial morphology. In addition, there are expression 
changes in the messenger RNA  (mRNA) encoding receptor and enzyme proteins and 
expression changes in functionally important proteins. 
Biopsies may bring complementary information  that could not be obtained by [CONTACT_132067]. There are inherent risks to biopsies  of the endomyocardium of the interventricular 
septum, such as perforation of the septum. Risks are further mitigated  here by [CONTACT_892743]- study. Therefore, the risks are deemed 
acceptable.  
[IP_ADDRESS] Rationale for mRNA transcript analysis  
The functioning of cells is governed by [CONTACT_892744], receptors or hormones. 
mRNA transcript analysis allows the identification of proteins synthetized in cells.  
In this study, mRNA transcript analysis is performed both in endomyocardial cells and in peripheral blood mononuclear cel ls (PBMC) in order to compare proteins and expressed 
mRNA in PBMC  with those expressed in the endomyocardial cells and to test the 
hypothesis that the expression pattern of t he peripheral circulating PBMC may reflect 
changes observed in the endomyocardium and thus serve as a surrogate for the heart tissue sam ple in the assessment of targets influenced by [CONTACT_892745].  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 43/[ADDRESS_1250388] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Objectives 
To assess the histological and biochemical effects of macitentan on the endomyocardium 
of the interventricular septum in patients with symptomatic PAH. 
To assess the biochemical effects of macitentan on PBMC in patients with symptomatic 
PAH. 
2.4.3 Echo  sub-study  
[IP_ADDRESS] Rationale 
Three-dimensional (3D), 2-dimensional (2D), M- mode and Doppler  echocardiography  
allow to assess the geometry and function of the right and left ventricles, thereby [CONTACT_892746]. [IP_ADDRESS] Objective  
To assess the effect of macitentan on right and left ventricular function by 
[CONTACT_892747]. 
3 OVERALL STUDY DESIGN AND PLAN  
3.1 Study design  
This is a prospective, multi -center, single-arm, open -label, Phase 4 study to evaluate the 
effects of macitentan on right ventric ular remodeling in PAH assessed by [CONTACT_892748] . 
One hundred patients will be enrolled in approximately 50 sites in approximately 
12 countries in Asia, Australia, Europe, and North America. Enrollment  will be 
competitive across participating sites.  
The study consists of the following time points and periods: 
Screening commences from signature [CONTACT_42956] (ICF) and ends 
with study treatment initiation  (up to 28 days after informed consent signature ). 
Baseline:  baseline values are those from the inclusion RHC and those collected du ring 
screening or at Treatment I nitiation Visit (Day 1) before initiation of study treatment.  
Treatment Period  starts with the 1st dose of study  drug (Day 1 of study) and ends with 
EOT on the day of the last dose of study drug  which is at premature discontinuation of 
study drug or Week 52 ± [ADDRESS_1250389] be organized as soon as possible and no later than 7 days after the 
decision to end study treatment. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 44/[ADDRESS_1250390] dose of study drug and 
ends 30 to 37 days after EOT , with End of Study ( EOS) Visit. For patients who withdraw 
their consent, the investigator will seek agreement to conduct the safety follow-up. 
EOS for a patient  is the end of safety follow -up, or date of death, or date of consent 
withdrawal, or date of last contact [CONTACT_892749] -up. 
Sub- studies  
As part of this protocol, thre e sub-studies will be conducted in selected centers. In these 
centers, all patients eligible for the main study will be offered to participate in the 
sub-study (ies). 
1. Metabolism sub-study (selected US sites only) . 
2. Biopsy sub-study. 
3. Echo sub-study. 
Study Duration  
For an individual patient, treatment duration will be up to [ADDRESS_1250391] patient ’s last visit.   
An interim analysis will be conducted when [ADDRESS_1250392] available assessment data 
for both primary endpoints. If the interim analysis concludes that the study is positive on both primary endpoints, enrollment may stop. Otherwise, the study will continue until 100 patients are enrolled. The decision to stop or continue the study will be taken jointly 
by [CONTACT_892750] , considering statistical analysis results as well 
as clinical expertise. 
The overall study design is depi[INVESTIGATOR_6517] 1. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 45/[ADDRESS_1250393] 2014- 004066- 20 
Doc No. D-16.554  
 
Figure 1 Study design  
 
 
 
   ICF, informed consent form (signature); EOT, end of treatment ; EOS, end of study . 
3.2 Study design rationale 
Cardiac MRI  allows the assessment  of right ventricular geometry and function, with a 
low between -study [Grothues 2003, Bradlow 2010]  and between -observer 
[Bradlow 2010]  variability. It is , therefore, the method of choice  for assessi ng right 
ventricular remodeling.  
Non-controlled, open- label trials are classically used in imaging studies that assess 
cardiac changes in PAH  [Wilkins 2005, Van Wolferen 2006, Hinderliter 1997, 
Roeleveld  2004, Blalock 2010, Peacock 2014].  
Open-label trials have a potential for bias. Bias in the assessment of the primary endpoint 
is reduced by [CONTACT_892751].  
Objectivity of cardiac MRI images assessment is ensured by [CONTACT_892752], i.e., before 
or during treatment.  Since PAH is a progressive disease,  a reverse remodeling is not 
expected to be observed unless it is induced by a treatment.  Therefore, patients may be 
used as their own control, i.e., a patient’s post-baseline value s may be compared to the 
corresponding baseline values. 
To ensure that the effects observed on the right ventricle are due to the newly introduced treatment , eligibility criteria are designed to select for : 
• Treatment -naïve patients, who may initiate macitentan alone or combined with a  
PDE-5 inhibitor;  
• And patients on a stable dose of PDE-[ADDRESS_1250394] a relatively low  proportion of patients 
ICF 
 EOS 
 EOT Visit 
52 weeks ± 7 days  
Treatment Initiation 
Visit  - Day 1 
Screening 
Up to 28 days 
Treatment 
52 weeks ± 7 days  
Follow -up 
30 days 
Week 26 Visit  
26 weeks ± 14 days  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 46/[ADDRESS_1250395] at 
26 weeks is maintained at 52 week s. 
3.3 Site personnel and their roles 
• The site physician will conduct physical examinations.  
• The site physician or nurse will administer the 6-minute walk test (6MWT). 
• Study-mandated RHCs will be performed by  [CONTACT_892753].  
• Cardiac MRI will be  performed by  [CONTACT_892754]. 
In the corresponding sub-studies: 
• PET-MR scan will be  done by [CONTACT_892755]. 
• The biopsy will be  done by [CONTACT_892756]. 
• Echo will be done by a specialist designated by [CONTACT_779] . 
3.[ADDRESS_1250396] been 
appointed by [CONTACT_892757] a dedicated charter : 
• Cardiac MRI results : (analyzed by [CONTACT_892758]  [IAC]). 
• Pressure-volume relationships (analyzed by [CONTACT_476994]) . 
• Variables that are specific to the metabolism sub -study. 
• Echo results. 
3.4.[ADDRESS_1250397] (ILSDRB, an external  expert 
committee of hepatologists) provides ongoing  assessment and advice regarding serious 
hepatic adverse events of special interes t (HAESI) that require further evaluation during 
the study (as per ILS DRB charter). 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 47/[ADDRESS_1250398] 2014- 004066- 20 
Doc No. D-16.554  
 
4 PATIENT POPULATION 
4.1 Patient population description 
Adult and elderly patients will be enrolled  with idiopathic PAH, heritable PAH, 
drug- and toxin- induced PAH , PAH associated with connective tissue disease or PAH 
associated with congenital heart diseases  under certain conditions [ see Section 4.3]. 
It is planned to enroll [ADDRESS_1250399] very similar characteristics , 
although patients with  PAH associated with connective tissue disease suffer from diverse 
comorbidities and their prognosis is worse [Benza 2010, Fisher 2006] . In systemic 
sclerosis, right ventric ular function is more depressed [Hassoun 2009, Tedford 2013, 
Fisher 2006]  with a lower contractility [Overbeek 2008] . The prevalence of pericardial 
effusion is also higher  [Fisher 2006].  Despi[INVESTIGATOR_892704], recent data using cardiac MRI  have shown a significant 
treatment effect of combination therapy in a sub- population of patients with PAH 
associated with connective tissue disease without significant restrictive or obstructive 
lung disease [ Hassoun 2015] .  
Furthermore,  previous PAH  treatments are limited to PDE-[ADDRESS_1250400] of the newly added  treatment.  The absence of clinically relevant 
interaction between macitentan and the PDE -5 inhibitor sildenafil and its metabolite 
(N-desmethyl -sildenafil)  has been shown [ Macitentan  IB]. 
The study population is, therefore, expected to be relatively homogeneous and suitable to 
achieve the study objectives.  
4.[ADDRESS_1250401] be fulfilled . It is not 
permitted to waive any of the criteria for any patient: 
1. Signed informed consent prior to any study-mandated procedure. 
2. Symptomatic PAH . 
3. WHO FC I to III . 
4. PAH etiology belonging to one of the following groups according to Nice 
classification: 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 48/[ADDRESS_1250402] 2014- 004066- 20 
Doc No. D-16.554  
 
1.3 Drug- and toxin-induced PAH 
1.4.1 PAH associated with connective tissue disease 1.4.4 PAH associated with congenital heart diseases: only simple  (atrial septal  
defect, ventricular septal defect, patent ductus arterio sus) congenital systemic to 
pulmonary shunts at least [ADDRESS_1250403] surgical repair.  
5. Hemodynamic diagnosis of PAH confirmed by [CONTACT_892759] −28 
and Day 1 (inclusion RHC; RHC data obtained at study site within this time frame, 
prior to obtaining signed informed cons ent, are acceptable)  showing: 
• mPAP ≥ 25 mmHg and 
o Pulmonary capi[INVESTIGATOR_47469]  (PCWP) or left ventricular end 
diastolic pressure  (LVEDP) ≤ 12 mmHg and PVR ≥ 4WU 
(320 dyn.sec.cm
-5) or 
o 12 mmHg ≤ P C W P  o r  L V E D P  ≤  1 5  m m H g  a n d  P V R  ≥6 WU 
(480 dyn.sec.cm-5). 
6. 6MWD ≥ [ADDRESS_1250404] 3 months prior to the inclusion RHC (initiation of PDE -[ADDRESS_1250405] been performed ). 
9. For patients tre ated with beta blocker s, treatment dose must have been stable at least 
1 month prior to the inclusion RHC . 
10. Men or w omen ≥ 18 and < 75 years. For patients aged ≥ 65 and < 75 years, an 
eligibility form [Appendix 7 ] will be submitted to a Steering Committee member who 
will reserve the right to exclude the patient.  
11. Women of childbearing potential [ see Section  4.5.1] must: 
a. Have a negative serum pregnancy test at screening and a negative urine 
pregnancy test on Day 1, and 
b. Agree to use reliable methods of contraception [ see Section 4.5] from 
screening up to [ADDRESS_1250406] not fulfill any of the following  exclusion criteria. It is not permitted to 
waive any of the criteria for any patient : 
1. Body weight < 40 kg. 
2. Body mass index  (BMI) > 35kg/m2. For patients with 30kg/m2 < BMI < 35kg/m2, an 
eligibility form will be submitted to a Steering Committee member who will reserve the right to exclude the patient [ Appendix 7 ]. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 49/[ADDRESS_1250407] 2014- 004066- 20 
Doc No. D-16.554  
 
3. Pregnancy, breastfeeding , or intention to become pregnant during the study. 
4. Recently started (< 8 weeks prior to informed consent signature) or planned 
cardio-pulmonar y rehabilitation program. 
5. Known concomitant life- threatening disease with a life  expectancy < [ADDRESS_1250408] protocol or treatment compliance . 
7. Hospi[INVESTIGATOR_631522] (except for diagnosis of PAH) within 3 months prior to 
informed consent signature. 
8. Left atrial volume indexed for body surface area  (BSA) ≥ 43mL/m2 by 
[CONTACT_892725] . 
9. Moderate to severe left -heart valvular disease. 
10. History of pulmonary embolism or deep vein thrombosis. 
11. Presence of one or more of the following signs of relevant lung disease at any time up 
to screening:  
− Diffusing capacity of the lung for carbon monoxide (DL CO) < 40% of predicted 
(eligible only if no or mild interstitial lung disease on computed tomography). 
− FVC < 60% of predicted. 
− Forced expi[INVESTIGATOR_31737] (FEV 1) < 60% of predicted. 
12. Moderate to severe restrictive lung disease  (i.e., total lung capacity  < 60% of 
predicted value) at any time prior  to enrollment. 
13. Historical evidence of significant coronary artery disease established by: 
− History of myocardial infarction or 
− More than 50% stenosis in a coronary artery (by [CONTACT_892760]) or  
− Elevation of the ST  segment on electrocardiogram  or 
− History of c oronary artery by[CONTACT_892727] 
− Stable angina. 
14. Known uncontrolled diabetes mellitus  (in the opi[INVESTIGATOR_871]). 
15. Severe renal insufficiency  (calculated creatinine clearance < 30 mL/min) . 
16. Cancer. 
17. Systolic blood pressure < 90 mmHg. 
18. Severe hepatic impairment (with or without cirrho sis) according to National Cancer 
Institute organ dysfunction working group criteria, defined as total bilirubin 
> 3 × ULN accompanied by [CONTACT_892761] > ULN at screening 
19. Hemoglobin < 100 g/L. 
20. Serum AST and/or ALT > 3 × ULN . 
21. Need for dialysis . 
22. Responders to acute vasoreactivity test  based on medical history. 
23. Prior use of ERAs, stimulators of soluble guanylate cyclase or prostacyclin or 
prostacyclin  analogs. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 50/[ADDRESS_1250409] 2014- 004066- 20 
Doc No. D-16.554  
 
24. Treatment with strong inducers of cytochrome P450 isozyme 3A4 ( CYP3A4) within 
4 weeks prior to study treatment initiation (e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], rifabutin, 
phenytoin and St. John’ s Wort). 
25. Treatment with strong inhibitors of CYP3A4 within 4 weeks prior to study treatment 
initiation (e.g., ketoconazole , itraconazole, voriconazole , clarithromycin, 
telithromycin,  nefazodone, ritonavir, and saquinavir). 
26. Treatment with another investigational drug (planned, or taken within the 3 months 
prior to study treatment initiation ). 
27. Hypersensitivity to any ERA or any excipi[INVESTIGATOR_892705]  
(lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch 
glycolate, polyvinyl alcohol, polysorbate, titanium dioxide, talc, xanthan gum, and lecithin soya) . 
28. Claustrophobia. 
29. MRI-incompatible p ermanent cardiac pacemaker, automatic internal cardioverter . 
30. Metallic implant (e.g., defibrillator, neurostimulator , hearing aid, permanent use of 
infusion device). 
31. Atrial fibrillation, multiple premature ventricular or atrial contractions, or any other condition that would interfere with proper cardiac gating during MRI. 
32. For patients enrolling in the metabolism sub-study only: glucose intolerance.  
33. For patients enrolling in the biopsy sub- study only: PAH etiology belonging to 
Nice classification 1.4.4: PAH associated with congenital heart diseases  or 1.4.1: 
PAH associated with connective tissue disease.  
4.[ADDRESS_1250410] one of the following criteria:  
• Previous bilateral salpi[INVESTIGATOR_8936] -oophorectomy or hysterectomy. 
• Premature ovarian failure confirmed by a specialist.  
• Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis. 
• Post-menopausal, defined as 12 consecutive months with no menses without an 
alternative medical cause
 (ICH M3 definition). 
4.5.[ADDRESS_1250411] one of the following methods is regarded as reliable contraception: 
1. Oral, implantable, transdermal, or injectable hormonal contr aceptives or intrauterine 
devices (IUD), or 
2. True abstinence from intercourse with a male partner  only when this is in line with 
the preferred lifestyle of the patient, or  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 51/[ADDRESS_1250412] 2014- 004066- 20 
Doc No. D-16.554  
 
3. Permanent female sterilization ( tubal occlusion/ ligation at least 6 weeks prior to 
screening), or 
4. Sterilization of the male partner , with documented post -vasectomy confirmation of  
the absence of sperm in the ejaculate.  
Rhythm methods , use of a condom by [CONTACT_180487] , use of a female condom or 
diaphragm alone are not considered acceptable methods o f contraception for this study. 
4.5.3 North America and Australia  
The use of one of the following options is regarded as reliable contraception: 
Option [ADDRESS_1250413]:   One m ethod from 
this list:   One method from 
this list:   One method from 
this list:  
Standard IUD  Estrogen and   Diaphragm with   Partner’s vasectomy  
(Copper T380A IUD)  
Intrauterine system   progesterone oral 
contraceptives ( “the   spermicide  
Cervical cap with   PLUS one method 
from this list:  
(LNg 20IUS:   pi[INVESTIGATOR_4382]”)  spermicide   Male condom  
progesterone IUS)  
Progesterone implant   Estrogen and 
progesterone   PLUS one method 
from this list:   Diaphragm with 
spermicide  
Tubal sterilization   transdermal patch   Male condom  Cervical cap with  
  Vaginal ring     spermicide  
  Progesterone injection     Estrogen and 
progesterone oral  PLUS one method  
  from this list:     contraceptives ( “the 
pi[INVESTIGATOR_4382]”) Male condom  
  Diaphragm with 
spermicide  
Cervical cap with     Estrogen and 
progesterone 
transdermal patch   
spermicide  Vaginal ring  
      Progesterone injection 
IUD, intrauterine device; IUS, intrauterine system.  
4.6 Patient population in sub-studies 
4.6.1 Metabolism sub -study  
Between 10 and 30 patients enrolled in the main study will also  be enrolled in the 
metabolism sub -study. For this sub- study, patients with glucose intolerance are excluded 
because the tracer used for PET -MR imaging is a glucose analog, contra- indicated in 
these patients.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 52/[ADDRESS_1250414] 2014- 004066- 20 
Doc No. D-16.554  
 
4.6.2 Biopsy sub- study  
Between 10 and 20 patients enroll ed in the main study will also be enrolled in the biopsy 
sub-study. For this sub- study, patients with PAH etiology belongi ng to Nice classification 
1.4.4 (PAH associated with congenital heart diseases ) or 1.4.1 (PAH associated with 
connective tissue disease) are excluded because their endomyocardium presents 
differences from the endo myocardium in the other etiologies enrolled in the study. 
4.6.3 Echo  sub-study  
Between 40 and 50 patients enrolled in the main study will also  be enroll ed in the Echo 
sub-study. 
5 TREATMENTS 
5.1 Study treatment  
5.1.1 Investigational treatment : description and rationale  
The study treatment  is macitentan [ADDRESS_1250415] labeling . The efficac y and safety of 
macitentan 10  mg in patients with PAH were demonstrated in the AC -055-302 / 
SERAPHIN study [Pulido 2013] . The risk of a morbidity/mortality event was reduced by 
45% with macitentan  10 mg compared to placebo  (p < 0.0001), and the treatment was 
well tolerated.  Further details can be found in Section [IP_ADDRESS] and in the IB 
[Macitentan  IB]. 
5.1.[ADDRESS_1250416] take it as soon 
as possible that day and take the next dose at the next  scheduled time.  The patient sh ould 
not take two doses at the same time if a dose has been missed.  
Study assessments will be performed at trough [see Section 7]. 
5.1.3 Treatment assignment  
All patients will receive open -label macitentan 10  mg once daily. 
5.1.4 Patient identification  
When screening a patient , the investigator/delegate contacts the Interactive Response 
Technology (IRT) s ystem which assigns a patient number  to the patien t. The patient 
number consists of 4 digits identifying the site and 3 digits identifying the patient, 
e.g., 1234567. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 53/[ADDRESS_1250417] 2014- 004066- 20 
Doc No. D-16.554  
 
After having confirmed a patient ’s eligibility, and prior to study treatment initiation, the 
investigator/delegate contacts the IRT system which assigns a treatment kit number  to the 
patient.  
5.1.5 Blinding  
Not applicable. 
5.1.6 Study treatment  supply  
Manufacture, labeling, packaging and supply of study treatments will be  conducted 
according  to Good Manufacturing Practice  (GMP), Good Clinical Practice ( GCP) and 
any local or national regulatory  requirements . 
All treatment  supplies are to be used only in accordance with this protocol, and not for 
any other purpose. 
[IP_ADDRESS] Study treatment  packaging and labeling  
[IP_ADDRESS].1 Study treatment  packaging 
Study treatment is provided as tablets and supplied in childproof bottles containing 
36 tablets each (1  month supply) . At Treatment Initiation Visit and Week 26 visit, 
six bottles will be provided to the patients. 
[IP_ADDRESS].[ADDRESS_1250418] (if applicable), or designee must remove the tear -off 
part and attach it to the Investigational Medicinal Product Label Dispensing Log. [IP_ADDRESS] Study treatment  storage and distribution  
Treatment  supplies must be kept in an appropriate, secure area and stored according to 
the conditions specified on the medication  labels. Detailed instructions regarding the 
handling and storage of study treatment are provided in Appendix 5. [IP_ADDRESS] Study treatment dispensing  
Patients will receive sufficient study treatment to cover the period up to the next 
scheduled visit. Patients are asked to return all used, partially used  and unused study 
bottles at each visit. The protocol -mandated study drug dispensing/return procedures may 
not be altered without prior written approval from Actelion.  An accurate record of the 
date and amount of study treatment  dispensed to each patient must be avail able for 
inspection at any time.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 54/[ADDRESS_1250419] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Study treatment  return and destruction  
On an ongoing basis and/or on termination  of the study, the monitor will collec t used and 
unused patient kits, which will be sent to the warehouse, where Actelion or a deputy will 
check treatment  reconciliation . In certain circumstances, used and unused treatment  
containers may be destroyed at the site once treatment  accountability is finalized  and has 
been checked by [CONTACT_806218], and written permission for destruction has been 
obtained from Actelion. 
5.1.[ADDRESS_1250420] be performed by [CONTACT_892762], in order to ensure that the patient is 
compliant with study requirements. Study treatment accountability is recorded in the 
Case Report Form (CRF ) and checked by [CONTACT_892763].  
Compliance is based on study treatment accountability . 
Compliance =(number  of tablets  provided  to patient  − number  of tablets  returned )
Total  number  of Tablets  that  should  have been  taken  during  the period )×100  
Compliance with study treatment intake < 80% or > 120% will be considered a  deviation 
from the protocol. 
5.1.8 Study treatment interruptions  
Study treatment may be temporarily interrupted in response to an AE, a diagnostic or 
therapeutic procedure, a laboratory abnormality, or for administrative reasons. 
Study-specific criteria for interruption of study treatment are des cribed in Section  5.1.10. 
If study treatment intake is interrupted by [CONTACT_633312], he/she must 
immediately inform the investigator.  
Interruptions of study treatment must be kept as short as possible, and must be recorded 
in the CRF . An interruption for more than 4 consecutive weeks  will lead to permanent 
treatment discontinuation.  
5.1.9 Premature discontinuation of study treatment  
The decisi on to prematurely discontinue study treatment may be made by [CONTACT_102], the 
investigator , or Actelio n. 
A patient has the right to prematurely dis continue study treatment at any time by 
[CONTACT_892764] . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 55/[ADDRESS_1250421] discontinue study treatment for a given patient if, on balance, 
he/she believes that continued administration would be contrary to the best interests of 
the patient . 
Premature discontinuation of study treatment may also result from a decision by [CONTACT_180494], e.g., in case of  premature termination or suspe nsion of the study 
[see Section  9.3]. 
Study treatment may be discontinued in response to an AE, lack of efficacy (including 
disease progression, treatment failure, worsening of patient condition), a protocol deviation ( e.g., non- compliance with study requirements, such as non- compliance with 
study treatment intake or visit attendance), or if the patient is lost to follow -up. 
study-specific criteria f or discontinuation of study treatment are described in 
Section 5.1.10. 
The main reason and whether discontinuation of study treatment is the decision of the 
patient, the investigator , or Actelion must be documented in the CRF . 
A patient who prematurely discontinues study treatment is NOT considered as withdrawn 
from the study and will be followed up until 30 to 37 days after EOT, provided that the 
patient’s consent for this limited participation in the study has not been withdrawn. 
Patients prematurely discontinuing study treatment will be asked to return for a 
Premature EOT Visit within [ADDRESS_1250422] to follow- up are also considered as withdrawn from the study. 
Withdrawal from the study and follow-up medical care of patients withdrawn from the 
study is described in Section s 9.2 and 9.4,  respectively . 
5.1.10 Study -specific criteria for interruption / premature discontinuation of study 
treatment  
[IP_ADDRESS] Pregnancy 
If a female patient becomes pregnant while on study drug, study drug must be 
discontinued immediately, and a Pregnancy Form must be completed [ see Section  10.3]. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 56/[ADDRESS_1250423] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Liver aminotransferases abnormalities 
Interruption of study drug 
Study drug must be interrupted in the following cases: 
• Aminotransferases (i.e., ALT and/or AS T) ≥ 3 and ≤ 8 × ULN without associated 
clinical symptoms of liver injury and without associated increase in total bilirubin 
≥ 2 ×ULN . 
In such a case, a re -test of aminotransferases (ALT and AST), total and direct bilirubin, 
and alkaline phosphatase must be performed within one week. If AST and/or ALT 
elevation is confirmed, monitoring of  aminotransferases, total and d irect bilirubin, and 
alkaline phosphatase levels  must be continued weekly until values return to pre -treatment 
levels or within normal ranges. If the aminotransferase values return to pre -treatment 
levels or within normal ranges, reintroduction of study tr eatment can be considered.  
Interruptions must be for less than 4 consecutive weeks; longer interruptions must lead to 
permanent discontinuation of study drug.  
Reintroduction of study treatment after treatment interruption should only be considered 
if the potential benefits of treatment with macitentan outweigh the potential risks and when liver aminotransferase values are within pre- treatment levels or within normal 
ranges. The advice of a hepatologist is recommended.  
Liver aminotransferase levels must the n be checked within 3 days after reintroduction, 
then again after a further 2 weeks and thereafter according to the protocol [Section [IP_ADDRESS]]. 
Permanent discontinuation of study drug 
Study drug must be stopped and its reintroduction is not to be considered in the following cases: 
• Aminotransferases > 8 × ULN . 
• Aminotransferases ≥ 3 × ULN and associated clinical symptoms o f liver injury, 
e.g., nausea, vomiting, fever, abdominal pain, jaundice, anorexia, dark urine, itching, unusual lethargy or fatigue, flu like syndrome (arthralgia, myalgia, fever). 
• Aminotransferases ≥ 3 × ULN and ass ociated increase in total bilirubin ≥ 2 ×ULN. 
In such cases, aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must be monitored weekly after study drug discontinuation until values return to pre-treatment levels or within normal ranges.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 57/[ADDRESS_1250424] 2014- 004066- 20 
Doc No. D-16.554  
 
Other diagnoses (e.g., viral hepatitis, mononucleosis, toxoplasmosis, cytomegalovirus) 
and/or etiologies (e.g., acetaminophen -related liver toxicity) must be considered and 
ruled out by [CONTACT_180495]. 
All liver aminotransferas es abnormalities leading to study drug interruption or 
discontinuation must be recorded as AEs [ see Section  10]. 
An ILSDRB (an external expert committee of hepatolo gists) provides ongoing 
assessment and advice regarding serious HAESI that require further evaluation during the 
study (as per ILSDRB charter) .  
[IP_ADDRESS] Hemoglobin abnormalities 
In case of hemoglobin decrease from baseline1 of > 20 g/L, a retest must be performed 
within 10 days, with additional laboratory evaluations that may include, but are not 
limited to, any of the following:  
• Red blood cell cellular indices (mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration). 
• Peripheral blood smear. 
• Reticulocyte count . 
• Iron status (iron level, serum ferritin, total iron binding capacity, transferrin 
saturation). 
• Lactate dehydrogenase. 
• Indirect bilirubin. 
Study drug should be temporarily interrupted if clinically mandated based on the investigator ’s judgment, or in any of the following situations: 
• A decrease in hemoglobin to < 80 g/L (< 4.9 mmol/L).  
• A decrease in hemoglobin from baseline
1 of > 50 g/L.  
• The need for transfusion.  
Reintroduction of study medication may be considered if hemoglobin recovery, defined as a return of hemoglobin above the lower limit of the normal range (LLN)  or if it returns 
to a value close to that at baseline.  
Interruption of study medica tion must not last lon ger than 4 consecutive weeks; longer 
interruptions must lead to permanent discontinuation of study drug. 
                                                 
1 Baseline hemoglobin: last value obtained prior to first intake of study treatment.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 58/[ADDRESS_1250425] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Start of an ERA / strong CYP3A4 inducer or inhibitor  / investigational drug  
Study drug must be permanently discontinued if another ERA and/or a strong CYP3A4 
inducer and/or a strong CYP3A 4 inhibitor and/or another investigational  drug is started 
during treatment period. 
5.[ADDRESS_1250426] are those susceptible to influence PAH 
disease, namely PAH -specific therapi[INVESTIGATOR_892706]. These therapi[INVESTIGATOR_892707] [see Section 4.3]. Initiation of these therapi[INVESTIGATOR_892708]-titration of PDE -5 inhibitors before Week 26 is allowed only in case of disease 
progression [ see Section 5.2.5], except for patients naïve to PAH treatment who are 
allowed to initiate and titrate a PDE -5 inhibitor within 2 weeks of study drug initiation 
[see Section  [IP_ADDRESS]]. 
5.2.2 Reporting of previous/concomitant therapy  in the CRF  
The use of a ll study-concomitant therapy (including contraceptives and traditional  and 
alternative medicines, i.e., plant -, animal-, or mineral -based medicines ) will be recorded 
in the CRF . 
Previous therapy must be recorded in the CRF if discontinued less than 3 months prior to 
study treatment initiation . 
For all therapy, t he generic name, start/end dates of administration (as well as whether it 
was ongoing at study treatment initiation and/or EOS), route, dose, and indication will be 
recorded in the CRF. 
For the following therapi[INVESTIGATOR_014], treatment dose and every dose change must be recorded in 
the CRF: 
• Loop diuretics . 
• PDE-5 inhibitors. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 59/[ADDRESS_1250427] 2014- 004066- 20 
Doc No. D-16.554  
 
• Prostanoid analogs by [CONTACT_250112]. 
• Stimulators of soluble guanylate cyclase . 
• Beta-blockers. 
• Any other PAH -specific therapy that may obtain marketing authorization during 
study conduct. 
5.2.3 Allowed concomitant therapy  
[IP_ADDRESS] Until Week 26 RHC 
The following therapi[INVESTIGATOR_892709] 26 RHC: 
• Therapi[INVESTIGATOR_892701] [see Sections 4.3 and 4.4] . 
• Oral loop diuretics if used at a stable dose for 1  week prior to Week 26 RHC. 
• Use of rescue therapy [see Section 5.2.5] only in case of disease progression. 
• A PDE-[ADDRESS_1250428] 14 days after study treatment initiation.  
[IP_ADDRESS] After Week 26 RHC  
After Week 26 RHC, t reatment initiation and dose changes are allowed for:  
• Loop diuretics . 
• PDE-5 inhibitors. 
• Prostanoid analogs by [CONTACT_250112]. 
• Stimulators of soluble guanylate cyclase . 
• Any other PAH -specific therapy that may obtain marketing authorization during 
study conduct. 
5.2.[ADDRESS_1250429] as study drug are forbidden: 
• ERAs other than study drug. 
Therapi[INVESTIGATOR_892710]:  
• Investigational drug other than study drug. 
Therapi[INVESTIGATOR_892711]- and over-dose 
[Macitentan  IB, section 1.7.2]: 
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, 
clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir). 
• Strong inducers of CYP3A4 (e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], rifabutin, phenytoin 
and St. John’ s Wort). 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 60/[ADDRESS_1250430] 2014- 004066- 20 
Doc No. D-16.554  
 
Initiation of one of these prohibited medications will lead to premature discontinuation of 
study treatment.  
Disease-specific treatments are forbidden, except in specific situations , since they  would 
interfere with efficacy evaluation  [Section 5.2.5]. 
5.2.5 Rescue therapy  before Week 26 RHC  
The following t reatment changes are allowed before Week 26 RHC only in case of 
disease progression : 
• Initiation of:  
− i.v. loop diuretics . 
− PDE-5 inhibitors. 
− Prostanoid analogs by [CONTACT_250112]. 
− Stimulators of soluble guanylate cyclase . 
− Any other PAH- specific therapy that may obtain marketing authorization during 
study conduct. 
• Up-titration of PDE -5 inhibitors. 
Use of these treatments does not require study treatment discontinuation. 
Disease progression is defined as: 
• Decrease in 6MWD by [CONTACT_726] 15% associated with worsening in WHO FC, or  
• Need for s.c. or i.v. prostanoid therapy, or  
• Hospi[INVESTIGATOR_631522] (investigator’ s assessment) . 
Disease progression must be recorded as an AE in the CRF. Decreases in 6MW D > 15% 
from baseline in conjunction with worsening WHO FC that occur between scheduled 
visits and do not result in a rescue therapy initiation ( RTI) visit must be recorded in the 
electronic CRF ( eCRF) using an unscheduled visit form. 
After Week 26 RHC, treatment changes are al lowed. 
6 STUDY ENDPOINTS 
6.1 Efficacy endpoints 
6.1.1 Primary efficacy endpoint s 
The study has two primary efficacy endpoints: 
• Change from baseline to Week 26 in Right Ventricular (RV) Stroke Volume (RVSV) 
assessed by [CONTACT_892732]. 
• Ratio of Week 26 to baseline PVR  assessed by [CONTACT_321333] . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 61/[ADDRESS_1250431] outcome [Van Wolferen  2007]. RVSV 
quantifies blood flow independently of heart rate  (HR). An increase in RVSV would 
reflect a favorable, reverse remodeling of the right ventricle and is expect ed to reduce 
PAH symptoms through a better oxygenation. 
A decrease in PVR appears as the primary direct effect expected from a  PAH therapy.  
Furthermore it is an objective measure ment of disease progression. 
The primary endpoint is defined at [ADDRESS_1250432] of characteristics of the right ventricle, and of widely accepted tools to 
assess PAH progression : 
Change from baseline to Week 26 in: 
• RV End Diastolic Volume (RVEDV)  
• RV End Systolic Volume (RVESV)  
• RV Ejection Fraction (RVEF)  
• RV mass 
• 6MWD 
• WHO FC  
MRI variables will be assessed  by [CONTACT_476994] . 
6.1.3 Exploratory efficacy endpoints  
The following endpoints are usual tools to monitor disease progression or treatment 
response and will be assessed: 
Change from baseline to Week 26 in : 
• mPAP 
• Mean right atrial pressure (mRAP) 
• Cardiac index  
• Arterial elastance  
• RV end-systolic elastance  
• RV maximum isovolumic pressure  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 62/[ADDRESS_1250433] at 
26 weeks is maintained at 52 weeks. Primary and secondary endpoints are repeated at 
52 weeks except for variables assessed by [CONTACT_892765] 
52 weeks. 
Change from baseline to Week 52 in : 
• RVSV determined by [CONTACT_892732] 
• RVEDV 
• RVESV 
• RVEF 
• RV mass 
• 6MWD 
• WHO FC  
Variables pertaining to the left ventricle will also be assessed, at 26 weeks and 52 weeks.  
Change from baseline to Week 26 and Week 52 in : 
• Stroke Volume determined by [CONTACT_892731]  
• LV End Diastolic Volume (LVEDV)  
• LV End Systolic Volume (LVESV) 
• LV Ejection Fraction (LVEF)  
• LV mass 
• RVEDV/LVEDV  
• RVESV/LVESV  
MRI variables and variables determined from pressure -volume relationship will be 
assessed by [CONTACT_476994].  
The following exploratory endpoints aim to investigate potential simple methods for 
disease monitoring, as opposed to RHC, MRI or echocardiography: 
Change from baseline to Week 26 and Week 52 in : 
• N-terminal pro -brain natriuretic peptide  (NT-proBNP) 
• Uric acid 
• Red cell distribution width  
• Activin A  
• Cystatin C  
• Follistatin  
• Galectin-3 
• Growth Differentiation Factor ( GDF)-15 
• Cardiac troponin T 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 63/[ADDRESS_1250434] 2014- 004066- 20 
Doc No. D-16.554  
 
• Lactate dehydrogenase ( LDH) 
• Osteoprotegerin 
• Tumor Necrosis Factor ( TNF) alpha 
These variables will be assessed by [CONTACT_2237].  
The following endpoint is designed to investigate patient outcome.  
• Time to first clinical worsening event defined as:  
− Decrease in 6MWD by > 15% from baseline associated with  worsening in WHO 
FC, or 
− Initiation of s.c. or i.v. prostanoid therapy, or  
− Hospi[INVESTIGATOR_631522] (investigator ’s assessment) , or 
− Death. 
6.2 Safety endpoints  
• Treatment -emergent AEs up to 30 days after EOT . 
• Treatment -emergent SAEs up to 30 days after EOT. 
• AEs leading to premature discontinuation of study drug. 
• Treatment -emergent marked laboratory abnormalities up to 30 days after EOT . 
• Occurrence of liver function test ( [LFT] ALT and/or AST) abnormality ( ≥ 3; ≥ 3 and 
< 5 × ULN; ≥ 5 and < 8 × ULN; ≥ 8 × ULN) up to EOT . 
• Occurrence of hemoglobin abnormality (≤ 80 g/L; > 80 and ≤ 100 g/L) up to EOT . 
• Occurrence of ALT and/or AST abnormality ≥ 3 × U LN associated with bilirubin 
≥ 2 × ULN.  
6.3 Exploratory endpoints  in sub-studies 
6.3.1 Metabolism  sub-study  
Exploratory endpoints: 
• Change from baseline to Week 26 and to Week 52 in : 
- RV 18F-fluorodeoxyglucose (FDG) uptake 
- Aortic 18F-FDG uptake  
- Right common carotid 18F-FDG uptake  
- Left common carotid 18F-FDG uptake 
All variables that are specific to the metabolism sub-study will be centrally assessed  
according to a charter . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 64/[ADDRESS_1250435] 2014- 004066- 20 
Doc No. D-16.554  
 
6.3.2 Biopsy sub -study  
Exploratory endpoints:  
• Change from baseline to Week 26 in: 
- Qualitative assessment of endomyocardium function markers in biopsies 
- Relative q uantitative assessment of endomyocardium function markers in biopsies 
- Number of capi[INVESTIGATOR_892702] 
- Mean cardiomyocyte volume 
- Qualitative assessment of cardiomyocytes  
- Endomyocardium cells mRNA transcript analysis  
- PBMC mRNA transcript analysis  
Biopsy and blood samples will be analyzed by [CONTACT_2237].  
6.3.3 Echo  sub-study  
Exploratory endpoints:  
• Change from baseline to Week 26  and Week 52 in: 
- LV eccentricity index at end -diastole 
- LV eccentricity index at end -systole 
- Minimum diameter of the inferior vena cava  (at inspi[INVESTIGATOR_51520]) 
- Maximum diameter of the inferior vena cava (at end-expi[INVESTIGATOR_1516]) 
- Tricuspid annular plane systolic excursion (TAPSE) 
- Pericardial effusion size scored from [ADDRESS_1250436] Doppler 
- Total RV Systolic Time (duration of tricuspid insufficiency jet)  
- Doppler RV index  (RV myocardial performance index) , by [CONTACT_892766] 
- Tricuspid peak jet velocity  
- RV systolic pressure (estimated by t ricuspid valve Doppler) 
- Early diastolic velocity of the jet o f pulmonary valve regurgitation 
- End-diastolic velocity of the jet o f pulmonary valve regurgitation 
- Cardiac output determined from LV outflow tract 
- Mitral E-wave velocity  
- Mitral A-wave velocity  
- Mitral annulus peak early diastolic velocity E’ 
- E/A ratio 
- E/E’ ratio  
- 2D RV dimension end- diastole 
- Tricuspid peak annular velocity s ’ 
- RV end diastolic area  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 65/[ADDRESS_1250437] 2014- 004066- 20 
Doc No. D-16.554  
 
- RV end systolic area  
- RV fractional area change 
- RVSV determined from  pulmonary valve Doppler and pulmonary annulus 
dimension 
- Tricuspid peak E, peak A, deceleration time 
- Tricuspid peak diastolic annular velocities e’, a’ 
- LVEDV determined from 2D measurements  
- LVESV determined from 2D measurements  
- Mitral deceleration time  
- Mitral annular plane tissue Doppler velocity a’ 
- 2D Global L ongitudinal RV strain  
- 2D circumferential RV strain  
- Time to peak RV strain  
- RVSV 
- RVEDV 
- RVESV 
- RVEF 
- RV mass 
- Left Ventricular  Stroke Volume ( LVSV) 
- LVEDV 
- LVESV 
- LVEF 
- LV mass 
- RVEDV/LVEDV  
- RVESV/LVESV  
In this study protocol, Echo refers to 3D, 2D, M -mode and Doppler echocardiography . 
All Echo results will be centrally assessed  according to a charter . 
[ADDRESS_1250438] been 
made. 
All study assessments are performed by a qualified study staff member: medical, nursing , 
or specialist technical staff, and are recorded in the CRF, unless otherw ise specified.  
Study assessments performed during unscheduled visit s (RTI, premature EOT , other 
unscheduled visit ) will also be recorded in the CRF. 
If the principal investigator [INVESTIGATOR_180454]/assessment for a patient, 
e.g., RHC, MRI, blood sampling, etc., to an external facility, he/she must inform Actelion 
to whom these tasks are delegated. The set -up and oversight will be agreed upon with 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 66/[ADDRESS_1250439] patient: 
• Temperature measurement devices for study medication  storage area and freezer . 
7.1 Screening/ baseline assessments 
7.1.1 Eligibility criteria  
Eligibility criteria will be collected in the CRF.  
7.1.2 Demographic and baseline characteristics  
The following baseline variables will be collected  in the CRF during the screening period 
for all screened patients: 
• Age, gender, height, weight. 
• Race if allowed by [CONTACT_427] . 
• PAH etiology , age at PAH diagnosis. 
7.1.3 Medical history  
The patient ’s relevant medical history up to start of study (i.e., informed consent  
signature) must be recorded in the CRF and should include, but is not limited to: 
− Complications or symptoms associated  with PAH  (e.g., peripheral edema or right 
heart failure)  
− Any chronic conditions (e.g., diabetes, hypertension, angina pectoris) 
− Acute conditions present at screening or which occur red in the past with sequelae  
− Any serious condition in the past resolved without sequelae (e.g., acute peritonitis) 
7.1.4 Medications  
Previous [ see Section 5.2.2] and concomitant medications must be recorded  in the CRF . 
Each treatment taken by [CONTACT_892767] a corresponding symptom or 
condition in medical history (except prophylactic treatments).  
7.1.5 Birth control methods  
For women of childbearing potential [ see Section 4.3], birth control methods must be 
recorded in the CRF.  
7.1.[ADDRESS_1250440] which measures the distance covered over a 
6-minute walk [ATS Statement 2002] . The Borg dyspnea index is evaluated after each 
6MWT. It rates dyspnea on a scale from ‘0’ to ‘10’ [ Appendix 3 ]. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 67/[ADDRESS_1250441] execution of these tests ‘Actelion guidelines for 6MWT ’ 
[Appendix 2]  must be followed. For patients who have never performed a 6MWT 
previously, a training test will be requested before the qualifying test for inclusion. 
7.1.7 WHO Functional Class 
WHO FC [Appendix 4]  is a classification which reflects disease severity based on 
symptoms.  
7.1.8 Cardiac MRI  
Images will be taken in accordance with  the Cardiac MRI image acquisition protocol  
and uploaded to the Central Image Repository (CIR) through a dedicated web application 
or sent to the CIR by [CONTACT_30367]  (on a CD).  A quality check will be performed as soon as the 
data sets are received.  
The actual assessments  will be done on data sets blinded to the patient identity and to the 
date of image acquisition, and only after a patient ’s study completion or withdrawal . An 
exception to this rule will be made for patients analyzed for the interim analysis and who 
have not yet completed the study or withdrawn. For these patients, available images will 
be analyzed at the time of interim analysis.  
All sets of images for each patient will be assessed at the same time by [CONTACT_109426], 
in order to ensure rigorously consistent assessment. Thus, patients analyzed  for the 
interim analysis and who have not yet completed the study or withdrawn will be analyzed twice if new images become available:  
• Available images will be analyzed at interim analysis, and the results used for the 
interim analysis . 
• All images will be analyzed at final analysis, and the results used for the final 
analysis. 
The IAC will assess the following variables according to a dedicated charter and the 
results will be sent to Actelion : 
• RVSV determined from pulmonary artery  flow 
• RVEDV 
• RVESV 
• RVEF 
• RV mass 
• LVSV determined from aortic flow  
• LVEDV 
• LVESV 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 68/[ADDRESS_1250442] 2014- 004066- 20 
Doc No. D-16.554  
 
• LVEF 
• LV mass 
• RVEDV/LVEDV  
• RVESV/LVESV  
7.1.9 Right heart catheterization  
The Actelion guidelines for RHC [Appendix 1] , including formulas, will be followed.  
Digitally sampled right ventricle  pressure curve  and pulmonary artery pressure curve , 
simultaneous with ECG sampling , must be recorded . The record must cover at least 
[ADDRESS_1250443] through a dedicated web application, 
and blinded to the patient identity as well as to the date of acquisition.  
Where electronic recording of pressure curves is not possible at a site, alternative 
solutions will be determined on a case by [CONTACT_892768].  
The following variables will be determined locally and entered in the CRF: 
• PVR 
• mPAP 
• Systolic pulmonary artery pressure (sPAP) 
• Diastolic pulmonary artery pressure (dPAP) 
• PCWP or LVEDP  
• mRAP 
• Cardiac output (C O) 
• HR during RHC 
• Systolic systemic artery pressure (sSAP)  
• Diastolic systemic artery pressure (dSAP)  
• The date of RHC will be entered in the CRF 
7.1.10 Pressure- volume relationship  
The IAC will assess pressure- volume relationship based on cardiac MRI results  and RHC 
pressure curves.  
The IAC will assess the following variables according to a dedicated charter and the 
results will be sent to Actelion : 
• Arterial elastance  
• RV end-systolic elastance  
• RV maximum isovolumic pressure  
The methods used to determine these variables will be  described in  a charter. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 69/[ADDRESS_1250444] 2014- 004066- 20 
Doc No. D-16.554  
 
7.1.11 Blood tests  
Blood samples will be taken and analyzed by a central lab. These analyses are listed in 
Section [IP_ADDRESS]. The results will be transferred to Actelion.  
7.1.12 Sub- studies  
[IP_ADDRESS] Metabolism sub-study 
18F-FDG PET -MR scan will be performed according to the  guidelines detailed in  the 
PET -MR image acquisition protocol . The 18F-FDG PET -MR scan of the sub- study will 
be combined with the cardiac MRI of the main study. 
Complete results will be blinded to the patient identity and to the date of image 
acquisition  prior to the assessment . The following variables will be centrally assessed  
according to a dedicated charter  and the results will be sent to Actelion : 
• RV 18F-FDG uptake 
• Aortic 18F-FDG uptake  
• Right common carotid 18F-FDG uptake  
• Left common carotid 18F-FDG uptake 
During the course of the PET -MR procedure, a  blood sample will be taken  (see PET -MR 
image acquisition  protocol ) and sent to the central laboratory which will assess the 
following variables and transfer the results to Actelion: 
• Glucose 
• Insulin 
• Free fatty acid  
[IP_ADDRESS] Biopsy sub-study 
During each RHC, a maximum of [ADDRESS_1250445] additional blood samples taken at the 
same time points. Samples will be sent to the central lab oratory which will coordinate the 
assessment of the following variables and transfer the results to Actelion: 
Biopsies  
• Immunochemistry: qualitative description of the samples after staining for:  
− Fibrosis 
− VEGF B 
− PCNA 
− Cleaved caspase 3  
− LC3B2 
− Caveolin 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 70/[ADDRESS_1250446] 2014- 004066- 20 
Doc No. D-16.554  
 
− E NOS 
− NOX-2  
• Relative quantitative assessment of  selected proteins  in biopsies, determined by 
[CONTACT_892769]2 
• Determination by [CONTACT_178774]/light microscopy of: 
− Number of capi[INVESTIGATOR_892702] 
− Mean cardiomyocyte volume 
− Description of cardiomyocytes and mitochondria 
• Endomyocardium cells mRNA transcript analysis  
Blood 
• PBMC mRNA transcript analysis  
[IP_ADDRESS] Echo sub-study 
Echo (i.e., 3D, 2D, M -mode and Doppler echocardiography ) will be performed according 
to the guidelines detailed in the Echo image acquisition  protocol . Complete results will 
be blinded to the patient identity and to the date of image acquisition. The following 
variables will be centrally assessed according to a dedicated charter and the results will 
be sent to Actelion : 
• LV eccentricity index at  end-diastole 
• LV eccentricity index at end -systole 
• Minimum diameter of the inferior vena cava (at inspi[INVESTIGATOR_1516])  
• Maximum diameter of the inferior vena cava (at end -expi[INVESTIGATOR_1516]) 
• Tricuspid annular plane systolic excursion (TAPSE) 
• Pericardial effusion size scored from 0 to 4 
• Right ventricle acceleration time, by [CONTACT_892734] 
• Right ventricle ejection time, by [CONTACT_892734] 
• Total RV Systolic Time (duration of tricuspid insufficiency jet)  
• Doppler RV index  (RV myocar dial performance index ), by [CONTACT_892770] 
• Tricuspid peak jet velocity  
• RV systolic pressure (estimated by [CONTACT_892771]) 
• Early diastolic velocity of the jet of pulmonary valve regurgitation  
• End-diastolic velocity of the jet of pulmonary valve regurgitation  
                                                 
2 Akt - phosphor, AMPK alpha - phospho, Caspase -1, Caspase 3 - cleaved, Caveolin -1, c-Kit, CREB, CREB - phospho, 
Dihydropyrimidine dehydrogenase, DPYD, Erk1/2 - phospho, FAK1 - phospho, FAK1 - phospho, GDF-15, IGF1R, 
KLF-5, mTOR, mTOR - phospho, NF -kappaB p65, Nrf2, p53, PARP, PARP - cleaved, PCNA, PTEN, Raptor, 
STAT 3, STAT 3 - phospho, Superoxide dismutase (Cu/Zn) . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 71/[ADDRESS_1250447] 2014- 004066- 20 
Doc No. D-16.554  
 
• Cardiac output determined from LV outflow tract 
• Mitral E-wave velocity  
• Mitral A-wave velocity  
• Mitral annulus peak early diastolic velocity E ’ 
• E/A ratio 
• E/E’ ratio  
• 2D RV dimension end- diastole 
• Tricuspid peak annular velo city s’ 
• RV end diastolic area  
• RV end systolic area  
• RV fractional area change 
• RVSV determined from pulmonary valve Doppler and pulmonary annulus dimension 
• Tricuspid peak E, peak A, deceleration time 
• Tricuspid peak diastolic annular velocities e’, a’ 
• LVEDV d etermined from 2D measurements  
• LVESV determined from 2D measurements  
• Mitral deceleration time  
• Mitral annular plane tissue Doppler velocity a’ 
• 2D Global Longitudinal RV strain  
• 2D circumferential RV strain  
• Time to peak RV strain  
• RVSV 
• RVEDV 
• RVESV 
• RVEF 
• RV mass 
• LVSV 
• LVEDV 
• LVESV 
• LVEF 
• LV mass 
• RVEDV/LVEDV  
• RVESV/LVESV  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 72/[ADDRESS_1250448]  
The 6MWT will be evaluated as described in  Section 7.1.6 during screening, at Week 26 
and at Week 52. 6MWT will also be performed at RTI visit or premature EOT visit 
where applicable. 6MWT may be performed at other unscheduled visits if clinically 
indicated.  
7.2.2 WHO Functional Class 
WHO FC will be assessed as described in  Section 7.1.7 during screening, at Week 26 and 
at Week 52. WHO FC will also be assessed at RTI visit or premature EOT visit where 
applicable.  WHO FC may be assessed at other unscheduled visits if clinically indicated.  
7.2.3 Cardiac MRI  
Cardiac MRI will be perfor med as described in  Section 7.1.8 during screening, at 
Week 26, and at Week  52. 
In case of rescue therapy initiation or p remature end of treatment  (where applicable), 
cardiac MRI will be conducted depending on the  visit date [Table 1] and will replace the 
Week 26 or Week 52 cardiac MRI. 
7.2.4 Hemodynamics  
RHC will be performed as described in  Section 7.1.9 during screening and at Week 26. 
In case of rescue therapy initiation or premature end of treatment before Week  26 (where 
applicable), RHC will be conducted depending on the visit date [ Table 1] and will replace 
the Week 26 RHC. 7.2.5 Pressure- volume relationship  
Pressure-volume relationship will be assessed as described in  Section 7.1.10 based on 
cardiac MRI and RHC assessments performed during screening and at Week 26. 
In case of rescue therapy initiation or premature end of treatment before Week  26 (where 
applicable), press ure-volume relationship will be assessed at the corresponding time 
point, provided RHC and cardiac MRI results are available for this time point.  
7.2.6 Laboratory tes ts 
Exploratory e fficacy laboratory assessments [Section [IP_ADDRESS]] will be done on blood 
samples collected  during screening, at Week 26 and at Week 52. They will also be 
assessed at RTI visit or premature EOT visit where applicable.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 73/[ADDRESS_1250449] 2014- 004066- 20 
Doc No. D-16.554  
 
7.3 Safety assessments 
7.3.1 Adverse events  
The definitions, reporting and follow -up of AEs, SAEs , and pregnancies  are described in 
Section 10. 
7.3.2 Vital signs  
Vital signs will be assessed during screening, at Treatment Initiation Visit, at Week 26 , 
and at EOT. They will also be assessed at RTI visit or premature EOT visit where 
applicable.  Vital signs may be assessed at other unscheduled visits if clinically indicated.  
Systolic and diastolic blood pressure and HR will be measured non- invasively in the 
supi[INVESTIGATOR_892712]. 
7.3.3 Weight  
Body weight (in underwear ) will be measured during screening , at Week 26 and at 
Week 52. Weight will also be measured at RTI visit or premature EOT visit where 
applicable.  Weight may be assessed at other unscheduled visits if clinically indicated. 
Weight will be  used in the calculation of BMI and of hemodynamic indices . 
7.3.4 Physical examination 
Physical examination (i.e., inspection, percussion, palpation and auscultation)  will be 
performed during screening, at Treatment Initiation Visit, at Week [ADDRESS_1250450] be specified on the corresponding CRF 
page, describing the sign s related to the abnormality (e. g., systolic murmur) and not the 
diagnosis (e.g., mitral valve insufficiency). Clinically relevant findings (other than those 
related to PAH that were present at the time of  informed consent  signature ) must be 
recorded on the Medical Hist ory CRF page. Physical exam ination findings made after 
study start, that meet the definition  of an AE [Section 10.1.1] must be recorded by [CONTACT_892772]. 
7.3.5 Laboratory assessments 
[IP_ADDRESS] Type of laboratory 
A central laboratory ( Covance; see central laboratory manual for contact [CONTACT_8972]) will be 
used for all protocol -mandated laboratory tests, including re-tests due to laboratory 
abnormalities and laboratory tests performed at unscheduled visits. Central laboratory 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 74/[ADDRESS_1250451] 2014- 004066- 20 
Doc No. D-16.554  
 
data will be automatically transferred from the central laboratory database to Actelion ’s 
clinical database.  
During screening, patient eligibility may be determined using local laboratory tests as 
long as the central laboratory kit is used in parallel.  
Under specific circumstances (e.g., if the patient lives distant from the site and cannot 
return every month), laboratory samples may be collected at a laboratory close to where the patient  lives (satellite laboratory) , and sent to the central laboratory for analysis. In 
such a case, the satellite laboratory must be pr ovided with the central laboratory sampling 
kits. Shipment of the samples will be organized by [CONTACT_208240]. If this process 
is implemented , the satellite laboratory must be identified prior to enrollme nt of the 
patient in the study. The supervision of the satellite laboratory remains under the 
responsibility of the principal investigator.  
In exceptional cases (e.g., patient is hospi[INVESTIGATOR_42868] a different hospi[INVESTIGATOR_180456] a medical emergency , missing laboratory values ) the local laboratory results 
(with the corresponding normal ranges) will be entered into  the clinical database via 
dedicated CRF pages. If applicable, the investigator/delegate will provide Actelion with 
the name, professional degree , and curriculum vitae  of the director of the satellite 
laboratory, a copy of the laboratory ’s certification, and the normal ranges for each 
laboratory test that is evaluated in the study. These laboratory references must be updated whenever necessary.  
In case a central laborat ory sample is lost or cannot be analyzed  for any reason, the 
investigator will collect an additional sample as soon as possible for repeat analysis, unless a local laboratory sample was collected within the same time -window and these 
test results are available.  
Central laboratory reports will be sent to the investigator. In case of specific (pre -defined) 
laboratory abnormalities, the central laboratory will alert Actelion and the concerned site. Alert flags that will trigger such notifications are displayed  in Appendix 6.  
All laboratory reports must be signed and dated by [CONTACT_892773] 3 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values are considered clinically relevant or not. Clinically relevant laborat ory findings that are 
known at the time of informed consent signat ure must be recorded on the medical history 
page of the CRF. Any clinically relevant laboratory abnormalities detected after informed 
consent signature [CONTACT_180554] [see Section  10], and 
must be followed until the value returns to within the normal range or is stable, or until 
the change is no longer clinically relevant. Further laboratory analyses must be performed 
as indicated and according to the judgment of the investigator. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 75/[ADDRESS_1250452] 2014- 004066- 20 
Doc No. D-16.554  
 
Details about the collection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual. 
[IP_ADDRESS] Laboratory tests  
Complete laboratory tests (hematology, clinical chemistry, coagulation tests, pregnancy 
test, and exploratory efficacy) will be performed during screening, at Week [ADDRESS_1250453] results will not be entered in the CRF.  
Hematology  
• Hemoglobin, hematocrit 
• Erythrocyte count (reticulocyte count)  
• Leukocyte count with differential counts 
• Platelet count  
Clinical chemistry  
• LFT: Aminotransferases (AST/ALT), alkaline phosphatase, total and direct bilirubin, 
LDH 
• Creatinine, urea 
• Uric acid 
• Glucose 
• Cholesterol, triglycerides  
• Sodium, potassium, chloride, calcium 
• Protein, albumin 
Coagulation tests  
• Prothrombin time and/or International Normalized Ratio (INR)  
• Activated partial thromboplastin time (aPTT)  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 76/[ADDRESS_1250454]  for women of childbearing potential 
Serum pregnancy tests will be performed at each blood draw ( during screening , at 
Week 26 Visit, at EO T, at RTI visit or premature EOT visit where applicable) and if 
pregnancy is suspected during the study. 
Urine pregnancy test s will be performed at Treatment Initiation Visit and at EOS .  
Monthly pregnancy tests will be performed using the monthly blood draws where  
applicable, and with urine pregnancy tests otherwise. Urine pregnancy test kits will be provided by [CONTACT_892774]  (CRO). 
Pregnancy reporting requirements are described in  Section 10.3. 
Efficacy / Exploratory 
• NT-proBNP 
• Uric acid 
• Red cell distribution width  
• Activin A  
• Cystatin C  
• Follistatin  
• Galectin-3 
• GDF-15 
• Cardiac troponin T 
• LDH 
• Osteoprotegerin 
• TNF alpha  
• Potential additional laboratory tests [see Section  [IP_ADDRESS]]. 
[IP_ADDRESS] Potential additional laboratory tests  
The list of biomarkers in this protocol may be expanded with additional circulating 
biomarkers reflecting cardiac remodeling or function based on available scientific evidence. No genetic testing will be performed. The samples will be stored at the central laboratory until one year after the last patient ’s last visit and destroyed after that date.  
7.4 Exploratory assessments in sub-studies 
These assessments are carried out only in patients enrolling in the respective sub -study. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 77/[ADDRESS_1250455] 2014- 004066- 20 
Doc No. D-16.554  
 
7.4.1 Metabolism sub -study  
18F-FDG PET -MR scan will be performed as described in  Section [IP_ADDRESS] during 
screening, at Week 26 and at Week 52.  
In case of rescue therapy initiation or premature end of treatment (where applicable), 
18F-FDG PET -MR scan will be conducted depending on the visit date [Table 1] and will 
replace the Week 26 or Week 52 18F-FDG PET -MR scan. 
7.4.2 Biopsy sub- study  
Biopsies will be taken during the RHC procedure  as described in  Section [IP_ADDRESS] and an 
additional blood sample will be taken. Biopsy and blood draw will be conducted during 
screening and  at Week 26. If a RHC is performed at RT I or premature EOT, biops ies and 
an additional blood sample will be taken at that time and will replace the Week 26 
biopsy. 
7.4.3 Echo  sub-study  
Echo will be performed as described in  Section [IP_ADDRESS] during screening, at Week 26 
and at Week 52. 
In case of rescue therapy initiation or premature end of treatment (where applicable), 
Echo will be conducted and will replace the Week [ADDRESS_1250456] be documented in the hospi[INVESTIGATOR_3853]. It is permitted to re-screen patient s once, if the reason for non -eligibility was transient 
(e.g., abnormal lab oratory test, insufficient wash-out period of a forbidden medication, 
etc.), provided that documented authorization has been received from Actelion. All 
screening assessments must then be repeated at the time of re- screening . 
For a tabulated summary of all visits and assessments described in the following sections 
see Table 1. 
8.[ADDRESS_1250457] be performed within 28 days prior to 
Treatment I nitiation Visit (Day 1). It is the responsibility of the investigator to obtain 
written informed consent from each patient participating  in the study after adequate 
explanation of the objectives , methods and potential hazards of the study. 
The ICF must be signed and dated by [CONTACT_892775]. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 78/[ADDRESS_1250458] 2014- 004066- 20 
Doc No. D-16.554  
 
The screening period includes [ see Table 1]: 
• Eligibility criteria check  
• Recording of demographic and baseline characteristics  
• Recording of medical history 
• Weight 
• Recording of previous and concomitant medications  
• Recording of birth control methods for women of childbearing potential 
• Physical examination  and vital signs  
• 6MWT 
• WHO FC  
• Cardiac MRI  
• RHC (provided that the above mentioned criteria are compatible with study eligibility 
criteria) 
• Blood tests 
• Recording of AEs and SAEs 
Cardiac MRI and RHC must be conducted within 21 days of each other . 
For patients enrolling in the corresponding sub-study only , the following 
assessments/procedures must also be conducted  during the screening period: 
• PET-MR scan with injection of 18F-FDG (combined with cardiac MRI) 
• Endomyo cardium biopsy and additional blood sample 
• Echo 
8.[ADDRESS_1250459] screening assessment, 
provided that all assessments are done before study drug intake.  
Treatment I nitiation Visit includes: 
• Recording of concomitant medications 
• Recording of birth control methods for women of childbearing potential 
• Physical examination  and vital signs  
• Urine pregnancy test  for women of childbearing potential 
• First intake of study drug 
• Recording of AEs  and SAEs 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 79/[ADDRESS_1250460] 2014- 004066- 20 
Doc No. D-16.554  
 
8.2.2 Rescue Therapy Initiation Visit  
In case of disease progression that requires initiation of rescue therapy before Week 26 
RHC, a site visit is organized and the follow ing assessments are to be performed  before 
the actual  rescue therapy initiation : 
• Weight 
• Recording of concomitant medications 
• Recording of birth control methods for women of childbearing potential 
• Physical examination  and vital signs  
• 6MWT 
• WHO FC  
• Cardiac MRI  
− Before Week 16: decision to conduct the exam based on clinical judgment 
− Between Week 16 and Week 2 6 RHC: must be performed and replaces Week 26 
cardiac MRI  
• RHC 
− Before Week 16: decision to conduct the exam based on clinical judgment 
− Between Week 16 and Week 26 RHC: must be performed and replaces Week 26 
RHC 
• Blood tests 
• Recording of AEs and SAEs 
Cardiac MRI and RHC must be conducted  within 21 days of each other . 
For patients in the corresponding sub- study only, the following assessments/procedures 
are also conducted:  
• PET-MR scan with injection of 18F-FDG (combined with cardiac MRI) , replaces 
Week 26 18F-FDG PET-MR scan 
• Endomyo cardium biopsy  and additional blood sample  if a RHC is performed . This 
replaces Week 26 biopsy and blood sample 
• Echo, replaces Week 26 Echo 
For patients with multiple opportunities to undergo cardiac MRI, RHC, PET -MR scan, 
biopsy and E cho in replacement of Week 26 ( e.g., several RTI before Week 2 6 RHC or 
RTI and EOT before Week 26 RHC ), these exams are done once only.  
8.2.3 Week  26 visit  
At Week 26 (± 14 days), the following assessments will be performed: 
• Weight 
• Recording of concomitant medications 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 80/[ADDRESS_1250461] 2014- 004066- 20 
Doc No. D-16.554  
 
• Recording of birth control methods for women of childbearing potential  
• Physical examination  and vital signs  
• 6MWT 
• WHO FC  
• Cardiac MRI 
• RHC 
• Blood tests  
• Recording of AEs and SAEs  
Cardiac MRI  and RHC must be conducted within 21 days of each other . 
For patients in the corresponding sub-study only: 
• PET-MR scan with  injection of 18F-FDG (combined with cardiac MRI) 
• Endomyo cardium biopsy and additional blood sample 
• Echo 
8.2.4 Unscheduled visits  
Unscheduled visits may be performed at any time during the study. Depending on the 
reason for the unscheduled visit (e.g., loss of efficacy, AE, etc.), appropriate assessments 
may be performed based on the judgment  of the investigator  and must be recorded in the 
CRF. After an unscheduled visit, the regular scheduled study visits must continue according to the planned visit and assessment schedule. 
Assessments performed may include:  
• Weight if clinically in dicated 
• Recording of concomitant medications 
• Recording of birth control methods for women of childbearing potential  
• Physical examination  and vital signs if clinically indicated  
• 6MWT if clinically indicated  
• WHO FC  if clinically indicated  
• Recording of AEs and SAEs 
Decreases in 6MW D > 15% from baseline in conjunction with worsening WHO FC that 
occur between scheduled visits and do not result in an RTI visit must be recorded in the 
eCRF using an unscheduled visit form. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 81/[ADDRESS_1250462] 2014- 004066- 20 
Doc No. D-16.554  
 
8.2.5 Premature E nd of T reatment visit  
[IP_ADDRESS] Patients discontinuing the study  
The reason for premature discontinuation from the study and the person making the 
decision will be collected [see Section 9.2]. The investigator must seek and document 
agreement to conduct the safety follow-up. 
For patients enrolled in a sub -study, the investigator must clarify whether the patient 
wants to discontinue the sub-study only, or both the main study and the  sub-study. 
[IP_ADDRESS] Patients agreeing to limited participation 
For patients permanently discontinuing study treatment who accept to continue study 
assessments [see Section 9.2], the premature EOT  visit takes place at the latest 7 days 
after the decision to end study treatment and includes:  
• Reason for premature discontinuation and person taking the decision 
• Weight 
• Recording  of concomitant medications  
• Recording of birth control methods for women of childbearing potential 
• Physical examination  and vital signs  
• 6MWT 
• WHO FC  
• Cardiac MRI  
− Before Week 16: decision to conduct the exam based on clinical judgment 
− Between Week 16 and Week  26 RHC: must be performed and replaces Week 26 
cardiac MRI  
− Between Week 2 6 RHC and Week 48: decision to conduct the exam based on 
clinical judgment  
− After Week 48: must be performed and replaces Week 52 cardiac MRI  
• RHC 
− Before Week 16: decision to conduct the exam based on clinical judgment 
− Between Week 16 and Week 2 6 RHC: must be performed and replaces Week 26 
RHC 
• Blood tests 
• Recording of AEs and SAEs  
Cardiac MRI  and RHC must be conducted within 21 days of each other . 
For patients in the corresponding sub- study only, the following assessments/procedures 
are also conducted : 
• PET-MR scan with injection of 18F-FDG (combined with cardiac MRI) 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 82/[ADDRESS_1250463] 2014- 004066- 20 
Doc No. D-16.554  
 
− Before Week 26 RHC: must be performed and replaces Week 26  18F-FDG 
PET-MR scan  
− Between Week 26 RHC and Week 48: must be performe d and replaces Week 52 
18F-FDG PET-MR scan 
• Endomyo cardium biopsy  and additional blood sample  if a RHC is performed. This 
replaces Week 26 biopsy and blood sample 
• Echo 
− Before Week 26 RHC: must be performed and replaces Week 26 Echo 
− Between Week 26 RHC and Week 48: must be performed and replaces Week 52 
Echo 
For patients with multiple opportunities to undergo cardiac MRI, RHC, PET -MR scan, 
biopsy and E cho in replacement of Week 26 (e.g.,  several RT I before Week 2 6 RHC or 
RTI and EOT before Week 26 RHC ), these exams are done once only.  
Premature EOT visit is followed by [CONTACT_180796] -up, 30 to 37 days after study 
treatment discontinuation.  
8.2.6 End o f Treatment visit  
At Week 52 (± 7 days), the following assessments will be repeated:  
• Weight 
• Recording of concomitant medications 
• Recording of birth control methods for women of childbearing potential 
• Physical examination  and vital signs  
• 6MWT 
• WHO FC  
• Cardiac MRI  
• Blood tests 
• Recording of AEs and SAEs  
For patients in the corresponding sub-study only: 
• PET-MR scan with 18F-FDG (combined with cardiac MRI)  
• Echo 
8.[ADDRESS_1250464] been sought for patients who withdrew their 
consent. The visit can be done via telephone, and includes: 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 83/[ADDRESS_1250465] 2014- 004066- 20 
Doc No. D-16.554  
 
• Recording of concomitant medications. 
• Urine pregnancy test  for women of childbearing potential. 
• Recording of birth control methods for women of childbearing potential. 
• Recording of AEs and SAEs . 
[ADDRESS_1250466]- STUDY TREATMENT/MEDICAL 
CARE 
9.[ADDRESS_1250467] patient ’s last visit.  
9.2 Premature withdrawal from study  
Patients may voluntarily withdraw from the study for any reason at any time. Patients are 
considered withdrawn if: 
• They state an intention to withdraw  further participation in  all components of the 
study. 
• They die. 
• They are lost to follow-up for any other reason (see below) . 
• The investigator believe s that continued participation in the study would be contrary 
to the best interests of the patient. 
• Actelion makes this decision for any reason, including premature termination or 
suspension of the study [ see Section  9.3]. 
Patients are considered as lost to follow -up if all r easonable attempts  by [CONTACT_892776]. The site must take preventive measures to avoid a 
patient being lost to follow -up (e.g., document different ways of contact [CONTACT_892777], home address, e -mail address,  person to be contact[CONTACT_892778] ). If the patient cannot be reached , the site must make a 
reasonable effort to contact [CONTACT_102], document all attempts  and enter the los s of 
follow-up information into the CRF. The following methods must be used: at least three 
telephone calls must be placed to the last available telephone number and one registered 
letter must be sent  by [CONTACT_215253]. Additional methods may be 
acceptable if they are compliant with local rules/regulations (e.g. , site staff visit to the 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 84/[ADDRESS_1250468] 2014- 004066- 20 
Doc No. D-16.554  
 
patient’s home), respecting the patient ’s right to privacy. If the patient is still unreachable 
after all contact [CONTACT_42927] , he/she will be considered to be lost to follow-up.  
If premature withdrawal occurs for any reason, the reason for premature withdrawal from 
the study, along with who made the decision ( patient, investigator , or Actelion)  must be 
recorded in the CRF. 
If for any reason (except death or loss -to-follow-up) a patient is withdrawn from the 
study, the investigator must make efforts to conduct a last visit to assess the safety and 
well-being of the patient, collect unused study drug  and discuss follow -up medical care. 
The investigator  must provide follow -up medical care for  all patients who are 
prematurely withdrawn from the study, or must refer them  for appropriate ongoing care , 
as described in Section 9.4. 
9.3 Premature termination or suspension of the study 
Actelion reserves the right to terminate the study at any time globally or locally. Investigators can terminate the participation of their site in the study at any time.  
If a study is prematurely suspended or terminated, Actelion will promptly inform the investigators, the Institutional Review Boards or Independent Ethics Committee s 
(IRBs/IECs ) and Health Authorities, as appropriate, and provide the reasons for the 
suspension or termination.  
If the study is suspended or prematurely terminated for any reason, the investigator in 
agreement with Actelion must promptly inform all enrolled patients, and ensure their 
appropriate treatment and follow -up, as described in Section 9.2 for patients prematurely 
withdrawn from the study . The investigator may be informed of additional procedures to 
be followed in order to ensure that adequate consideration is given to the protection of the patients’ interests . 
In addition, if the investigator suspends or terminates a study without prior ag reement 
from Actelion, the investigator must promptly inform Actelion and the IRB/IEC, and 
provide both with a detailed written explanation of the termination or suspension. 
If the IRB/IEC suspends or terminates its approval/favorable opi[INVESTIGATOR_1101] a study, t he 
investigator must promptly notify Actelion and provide a detailed written explanation of 
the termination or suspension. 
Any suspension or premature termination of the study must be discussed with the 
Steering Committee . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 85/[ADDRESS_1250469] udy completion/ withdrawal from study 
After the patient’s study completion or premature withdrawal  from the study, whichever 
applies, the investigator/delegate will explain to patients what treatment(s)/medical care 
is necessary and available according to l ocal regulations. 
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
10.1 Adverse events  
10.1.1 Definitions of adverse events  
An AE is any ad verse change, i.e., any unfavorable and unintended sign, including an 
abnormal laboratory finding, symptom or disease that occurs in a patient during the 
course of the study, whether or not considered by [CONTACT_892779] . 
A treatment- emergent AE is any AE temporally associated with the use of study 
treatment  (from study treatment  initiation until EOS, which is 30 to 37 days after study 
treatment  discontinuation) whether or not considered by [CONTACT_42928]. 
AEs: 
• Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre- existing epi[INVESTIGATOR_892713] m edical 
condition. 
• Disease or medical condition detected or diagnosed during the course of the study  
even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at study start  that worsen 
following the start of the study.  
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they 
represent a clinically significant finding that was not present at study start or 
worsened during the course of the study. 
• Laboratory test abnormali ties if they represent a clinically significant finding, 
symptomatic or not, which was not present at  study start  or worsened during the 
course of the study or led to dose reduction, interruption or permanent discontinuation 
of study treatment .  
Overdose, misuse and abuse of the study treatment  must be reported as an AE and, in 
addition, study treatment  errors must  be documented in the study drug log of the CRF . 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 86/[ADDRESS_1250470] 2014- 004066- 20 
Doc No. D-16.554  
 
10.1.2 Intensity of adverse events  
The intensity of clinical AEs is graded on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the CRF .  
If the intensity of an AE worsens during study treatment  administration, only the worst 
intensity must be reported on the AE page. If the AE lessens in intensity, no change in the 
severity is required.  
The three categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the patient. It does not influence daily activities, and 
usually does not require intervention. 
 Moderate  
The event may make the patient uncomfortable. Performance of daily activities may be 
influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort, and usually interferes wit h daily activities. 
The patient may not be able to continue in the study, and treatment or intervention is 
usually needed. 
A mild, moderate, or severe AE may or may not be serious [ see Section  10.3.1]. These 
terms are used to describe the intensity of a specific event . Medical judgment must be 
used on a case- by-case basis.  
Seriousness, rather than severity assessment , determines the  regulatory reporting 
obligations. 
10.1.[ADDRESS_1250471] a reasonable possibility of a causal relationship to either the study design or to 
protocol-mandated procedures. Example s include discontinuation of a patient’s previous 
treatment during a washout period leading to exacerbation of underlying disease.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 87/[ADDRESS_1250472] be 
followed up until they are no longer considered clinically relevant . 
10.2 Serious adverse events 
10.2.1 Definitions of serious adverse events  
[IP_ADDRESS] Serious adverse events  
An SAE is defined by [CONTACT_892780] (ICH) guidelines as 
any AE fulfilling at least one of the following criteria: 
• Fatal. 
• Life-threatening: refers to an event in which the patient was at risk of death at the 
time of the event. It does not refer to a n event that hypothetically might have caused 
death had it been more severe.  
• Requiring inpatient hospi[INVESTIGATOR_059], or prolongation of existing hospi[INVESTIGATOR_059]. 
• Resulting in persistent or significant disability or incapacity . 
• Congenital anomaly or birth defe ct. 
• Medically significant : refers to i mportant medical events that may not immediately 
result in death, be life -threatening, or require hospi[INVESTIGATOR_42862], based upon appropriate medical judgment, the y may jeopardize the 
patient, and may require medical or surgical intervention to prevent one of the 
outcomes listed in the definitions above.  
The following reasons for hospi[INVESTIGATOR_180457] :  
• Hospi[INVESTIGATOR_180458], or social and/or convenience reasons. 
• Hospi[INVESTIGATOR_626745]-planned (i.e., planned prior to informed consent  signature ) 
surgery or  standard monitoring of a pre -existing disease or medical condition that did 
not worsen, e.g., hospi[INVESTIGATOR_892714] a patient with stable 
angina pectoris.  
• However, complications that occur during hospi[INVESTIGATOR_42866] (for 
example, if a complication prolongs hospi[INVESTIGATOR_059]). 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 88/[ADDRESS_1250473] 2014- 004066- 20 
Doc No. D-16.554  
 
[IP_ADDRESS] Serious adverse events associated with the study design or protocol mandated 
procedures  
An SAE is defined as related to study  design or protocol mandated procedures if it 
appears to have a reasonable possibility of a causal relationship  to either the study design 
or to protocol -mandated procedures.  Examples  include discontinuation of a patient’s 
previous treatment during a washout period leading to exacerbation of underlying 
disease, or a complication of an invasive procedure that is specifically required by [CONTACT_12695]. 
10.2.2 Reporting of serious adverse events  
[IP_ADDRESS] During screening period  
All SAEs that occur after informed consent signature [CONTACT_892806].  
These SAEs must be reported on an SAE form and on the AE pages  in the CRF.  
[IP_ADDRESS] During treatment period  
All SAEs , regardless of investigator- attributed causal relationship , must be reported. 
These SAEs must be reported on an SAE form  and on the AE pages in the CRF. 
[IP_ADDRESS] During follow-up period 
All SAEs  which occur up to [ADDRESS_1250474] be reported to the Actelion 
drug safety department within 24 h of the investigator ’s knowledge of the event, only if 
considered causally related to previous exposure to the study treatment  or study design or 
protocol-mandated procedures by [CONTACT_093].  10.2.[ADDRESS_1250475] be reported by [CONTACT_180512] 24 h of the investigator’s first knowledge of the event. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 89/[ADDRESS_1250476] be faxed or emailed to the Actelion drug safety department (contact 
[CONTACT_180514] ). The investigator must complete the SAE form in 
English, and  must assess the causal relationship of the event to study treatment . 
Follow-up information about a previously reported SAE must also be reported within 
[ADDRESS_1250477] the investigator to 
obtain further information.  
If the patient is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_42869], it is the investigator ’s 
responsibility to contact [CONTACT_42933][INVESTIGATOR_180459]. 
The reference safety document to assess expectedness of a suspect serious adverse 
reaction and reported by [CONTACT_892781], ECs/IRBs and investigators is 
the reference safety information section of the IB.  
The SAEs listed below are commonly seen with the underlying disease and are therefore 
expected to occur in this patient population. T hese SAEs must be reported on an SAE 
form and on the CRF. These SAEs do  not require systematic expedited reporting to 
Health Authorities, IRBs/IECs , and investigators. 
The following events that are expected to occur in patients with PH or PAH will be 
considered as ‘disease-related’ and ‘expected’ for regulatory reporting purposes in this 
population: signs and symptoms of PAH/PH, worsening/exacerbation/progression including fatal outcome, and, in particular, abdominal pain, anorexia, chest pain, cyanosis, diaphoresis, dizziness, pre -syncope, dyspnea, orthopnea, fatigue, hemoptysis, 
heart failure, hypoxia, palpi[INVESTIGATOR_814], syncope, collapse, systemic arterial hypotension, and tachycardia.  
10.[ADDRESS_1250478] be reported within 24 h of the investigator ’s knowledge of the event.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 90/[ADDRESS_1250479] be reported on the Actelion Pregnancy form, which is faxed or emailed 
to the Actelion drug safety department (see contact [CONTACT_892782]), and on an AE page or a pregnancy page in the CRF . 
10.3.[ADDRESS_1250480] be reported on an SAE form as described in  
Section 10.3.1. 
10.4 Study safety monitoring 
Clinical study safety information (AEs, SAEs, laboratory values, vital signs) is monitored 
and reviewed on a continuous basis by [CONTACT_892783] (in charge  of ensuring 
patients’ safety as well as data quality ) by [CONTACT_892784]. 
11 STATISTICAL METHODS 
All statistical analyses will be conducted by [CONTACT_208250].  
A Statistical Analysis Plan (SAP) will provide full details of the analyses, data displays, 
and algorithms to be used for data derivations. 
11.1 Analysis Sets 
11.1.1 Screened Patien ts Set 
This analysis set includes all patients who were screened  and received a patient  number. 
11.1.2 Safety S et 
The Safety S et (SS) includes all patients from the Screened Patients Set who received at 
least one dose of study drug. 
11.1.3 Full Analysis Set  
The Full Analysis Set (FAS) includes all patients from the SS who had a base line as well 
as a post-baseline measurement for both primary endpoints (RVSV and PVR).  
The Modified FAS comprises all patients included in the FAS who had a post -baseline 
measurement taken between 16 weeks and 30 weeks of treatment  for both primary 
endpoints. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 91/[ADDRESS_1250481] 2014- 004066- 20 
Doc No. D-16.554  
 
11.1.4 Per Protocol Set  
The Per Protocol Set (PPS) comprises all patients included in the Modified FAS without 
major protocol deviations that affect the main analysis of the primary efficacy variables. 
The reasons for excluding patien ts from the PPS will be fully defined and documented in 
the SAP. 
11.1.[ADDRESS_1250482] -baseline measurement taken between  16 weeks and 30 weeks of treatment  
for PVR. 
Specific analysis sets for the sub -studies will be defined in the SAP.  
11.1.6 Usage of the analysis sets 
The primary efficacy analysis will be performed on the Modified FAS . Secondary and 
exploratory efficacy analyses will be performed on the FAS.  
The PPS will be used for performing a sensitivity analysis on the primary endpoints. 
The specific RVSV and PVR Analysis Sets  will only be used if the intersection of the 
two sets (i.e., the Modified F AS) is markedly smaller than the union. Criteria will be 
specified in the SAP.  
Safety analyses will be performed on the SS. Patien t listings will be based on the 
Screened Patients  Set, unless otherwise specified.  
Patient disposition will be described for the Screened Patients Set. 
11.2 Variables  
11.2.1 Primary efficacy v ariables 
The two primary efficacy variables are:  
• Change from baseline to Week 26 in RVSV assessed by [CONTACT_892785].  
• Ratio of Week 26 to baseline PVR assessed by [CONTACT_321333].  
Change from baseline in RVSV (mL) is calculated as RVSV at Week 26 minus RVSV at 
baseline. A positive change from baseline corresponds to an improvement.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 92/[ADDRESS_1250483] 2014- 004066- 20 
Doc No. D-16.554  
 
PVR [dyn·s·cm-5] is calculated as  (mPAP − PCWP) / CO × 80 [refer to Appendix 1] . 
A ratio versus baseline < 1 corresponds to an improvement. 
11.2.2 Secondary efficacy variables  
Secondary efficacy variables are absolute changes from baseline to Week 26 in: 
• RVEDV (mL) 
• RVESV ( mL) 
• RVEF (%) 
• RV mass (g) 
• 6MWD (m) 
• WHO FC (I–IV) 
11.2.3 Exploratory efficacy variables 
[IP_ADDRESS] Hemodynamic variables  and pressure -volume variables  
These variables include c hanges from baseline to Week 26 in : 
• mPAP (mmHg) 
• mRAP (mmHg) 
• Cardiac index (L/min/m2) 
• Arterial elastance (mmHg/mL)  
• RV end-systolic elastance (mmHg/mL)  
• RV maximum isovolumic pressure (mmHg ) 
[IP_ADDRESS] Variables related to maintenance of treatment effect  
These variables  include changes from baseline to Week 52 for the primary and secondary 
efficacy variables (except those determined by [CONTACT_892786] 52): 
• RVSV determined by [CONTACT_892732] 
• RVEDV 
• RVESV 
• RVEF 
• RV mass 
• 6MWD 
• WHO FC  
[IP_ADDRESS] Variables related to the left ventricle  
These variables  include changes from baseline to Week 26 and Week 52 in: 
• LVSV determined by [CONTACT_892731] (mL) 
• LVEDV (mL) 
• LVESV (mL) 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 93/[ADDRESS_1250484] 2014- 004066- 20 
Doc No. D-16.554  
 
• LVEF (%) 
• LV mass (g) 
• RVEDV/LVEDV (1) 
• RVESV/LVESV (1) 
[IP_ADDRESS] Potential variables for disease monitoring 
These endpoints include c hanges from baseline to Week 26 and Week 52 in : 
• NT-proBNP 
• Uric acid 
• Red cell distribution width  
• Activin A  
• Cystatin C  
• Follistatin  
• Galectin-3 
• GDF-15 
• Cardiac troponin T 
• LDH 
• Osteoprotegerin 
• TNF alpha  
[IP_ADDRESS] Clinical endpoint 
The clinical endpoint is the time from the initiation of treatment to first clinical 
worsening defined as the first occurrence of : 
• Decrease in 6MWD by > 15% from baseline associated with  worsening in WHO FC , 
or 
• Initiation of s.c. or i.v. prostanoid therapy, or  
• Hospi[INVESTIGATOR_631522] (investigator ’s assessment) , or 
• Death 
11.2.4 Safety variables 
Safety variables include:  
• Treatment -emergent AEs up to 30 days after EOT  
• Treatment -emergent SAEs up to 30 days after EOT  
• AEs leading to prematur e discontinuation of study drug 
• Treatment -emergent marked laboratory abnormalities up to 30 days after EOT  
• Occurrence of LFT (ALT or AST) abnormalities  up to EOT , classified as:  
− ≥ 3 × ULN  
− ≥ 3 × ULN and < 5 × ULN  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 94/[ADDRESS_1250485] 2014- 004066- 20 
Doc No. D-16.554  
 
− ≥ 5 × ULN and < 8 × ULN  
− ≥ 8 × ULN  
• Occurrence of hemoglobin abnormalities up to EOT , classified as:  
− ≤ 80 g/L 
− > 80 g/L and ≤ 100 g/L 
• Occurrence of ALT and/or AST abnormality ≥ 3 × ULN associated with bilirubin  
≥ 2 × ULN  
11.2.5 Other variables 
Variables associated with the sub -studies will be described in the SAP. 
11.3 Description of statistical analyses 
11.3.1 Overall testing strategy  
The overall type I error is α = 0.025 (one -sided) and will be split between the two 
primary endpoints RVSV (α = 0.02) and PVR (α = 0.005). The justification for the 
unequal split is that PVR is a well- known endpoint (hence, the smaller part of the α), 
whereas RVSV is less well -known, i.e., more uncertainty of the estimate/variability  
(hence, the larger part of the α).  
Per endpoint the type  II error is set t o 0.10 and the power to  90%.  
An efficacy interim analy sis is introduced in protocol Version 6 and corresponding 
statistical considerations are provided in Section 11.4.3. 
11.3.2 Analysis of the p rimary efficacy variables 
[IP_ADDRESS] Hypotheses and statistical model 
The null hypothesis is: 
The mean change from baseline to Week 26 in RVSV is less than or equal to zero AND 
the geometric mean ratio of Week 26 to baseline PVR is greater than or equal to o ne. 
The alternative hypothesis is:  
The mean change from baseline in RVSV is greater than zero OR  the geometric mean 
ratio of Week 26 to baseline PVR is less than one. 
[IP_ADDRESS] Handling of missing data 
General. RVSV will be based on pulmonary artery flow. If, however, RVSV determined 
from pulmonary ar tery flow differs from RVSV determined from aortic flow by [CONTACT_26813] 20% (in either direction), then RVSV should be determined by [CONTACT_892787].  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 95/[ADDRESS_1250486] 2014- 004066- 20 
Doc No. D-16.554  
 
If PVR cannot be calculated due to missing PCWP but mPAP and CO are available for 
the same visit, one of the following methods will be applied:  
1. If PCWP is missing both at baseline and post -baseline, the study population median  
PCWP (baseline and post -baseline, respectively ) will be imputed (based on the 
Modified F AS). 
2. If PCWP is missing either at baselin e or post-baseline, the patient ’s available PCWP 
will be imputed.  
This imputation is based on the clinical assumption that macitentan does not affect 
PCWP. 
Baseline. Patients without a baseline RVSV or PVR measurement will be excluded from 
the analyses.  
Post-baseline. In patients without a Week [ADDRESS_1250487] -baseline 
measurement (presumably taken at treatment discontinuation or initiation of rescue therapy) will be carried forward, provided that this measurement was taken after at least 
16 weeks of treatment. Week 26 measurements taken after 30 weeks of treatment  will be 
excluded from the analyses.  
[IP_ADDRESS] Main analysis 
The primary  efficacy analysis will be performed on the Modified F AS for the interim and  
the final analysis .  
RVSV will be summarized by [CONTACT_7206] (baseline, Week 26) using descriptive statistics (n, mean, SD, median, Q1 and Q3). The change from baseline to Week 26 in RVSV will be summarized similarly.  
Change from baseline in RVSV will be analyzed using an Analysis of Covariance (ANCOVA) with a factor for other PAH-specific therapy (none, background or initiated 
at baseline) and a covariate for baseline RVSV. The mean change from baseline and its 
96% confidence i nterval (CI) will be estimated based on the model.  
PVR will be summarized by [CONTACT_892788] (CVs). The Week 26 versus baseline ratio in PVR 
will be summarized similarly.  
The ratio of Week 26 versus  baseline PVR will be log -transformed (base e) and analyzed 
using an ANCOVA with a factor for other PAH-specific therapy (none, background or 
initiated at baseline) and a covariate for baseline log PVR. The mean change from 
baseline (on log scale) and its 99% CI will be estimated bas ed on the model. The 
geometric mean ratio (v ersus baseline) and its 99% CI will be obtained by 
[CONTACT_151698]. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 96/[ADDRESS_1250488] that ratios versus baseline follow a 
normal distribution more closely after a log transformation. In addition, mean absolute 
changes from baseline on log scale can be translated into (geometric) mean ratios by 
[CONTACT_151698]. 
The null hypothesis will be tested at interim and final an alysis, if study continues, and 
may be rejected based on pre-defined boundaries defined in Section 11.4.3 . 
[IP_ADDRESS] Supportive/sensitivity analyses  
A sensitivity analysis w ill be performed on the FAS. In patients without a Week [ADDRESS_1250489], regardless of 
the time it was taken. Week 26 measurements performed  after 30 weeks of treatment  will 
be excluded from the ana lysis. 
Another sensitivity analysis will be performed on the PP S that will (at least) be restricted 
to completers, i.e., patients with Week [ADDRESS_1250490]-baseline RVSV or PVR. For those patients, the Week 26 RVSV or PVR 
measurement needs to  be imputed. Imputation rules will be specified in the SAP.  
Sensitivity ana lyses for RVSV and PVR may also be performed for the specific RVSV 
and PVR Analysis Set s, respectively, but only if deemed necessary as specified in the 
SAP. 
[IP_ADDRESS] Subgroup analyses 
Subgroup analyses for the primary endpoints will be performed only at final anal ysis for 
patients with v ersus without PAH -specific therapy at baseline using the ANCOVA 
models specified in Section  [IP_ADDRESS], but without the factor for PAH -specific therapy. In 
this analysis 95% CIs will be used. Subgroup analyses for RVSV and log PVR will also be performed for patients on 
WHO FC I– II versus III using the ANCOVA models specified in Section [IP_ADDRESS], In this 
analysis 95% CIs will be used. Additional subgroup analyses will be specified in the SAP. Exploratory analyses will be performed aimed at identifying prognostic factors for 
changes f rom baseline in RVSV and log PVR. This will be done using linear regression 
models. Candidate prognostic factors will be specified in the SAP. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 97/[ADDRESS_1250491] 2014- 004066- 20 
Doc No. D-16.554  
 
11.3.3 Analysis of the s econdary efficacy variables 
Secondary efficacy analyses will be performed only at final analysis  on the Modified 
FAS at α = 0.025 (one -sided) using 95% CIs. Supportive secondary efficacy analyses will 
also be performed on the FAS. No correction for multiple testing will be applied for these 
analyses. 
MRI-based secondary efficacy variables (changes fr om baseline to Week 26 in RVEDV, 
RVESV, RVEF, RV mass) will be summarized and analyzed as described for RVSV in 
Section [IP_ADDRESS]. 
The 6MWD  will be summarized by [CONTACT_2712] . Change from 
baseline to Week 26 will be summarized similarly. Change from baseline in 6MWD will 
be analyzed using an A NCOVA with a factor for other PAH-specific therapy (none, 
background or initiated at baseline ) and a covariate for baseline 6 MWD and WHO FC .  
WHO FC will be summarized by [CONTACT_892789]. Changes from 
baseline in WHO FC will be dichotomiz ed as worsening (i.e., change > 0) v ersus no 
change or improvement (i.e., change ≤ 0) . Worsening will be analyzed using a logistic 
regression model with a factor for background PAH- specific therapy  at baseline.  
NT-proBNP will be summarized by [CONTACT_892790].  The Week 26 v ersus baseline ratio will be summarized 
similarly. The ratio v ersus baseline in NT-proBNP will be log -transformed and analyzed 
using an ANCOVA with a factor for other PAH-specific therapy (none, background or 
initiated at baseline) and a covariate for baseline log NT-proBNP.  
11.3.4 Analysis of the exploratory efficacy variables  
Other efficacy variables will be summarized for the Modified FAS using descriptive 
statistics only. No statistical analyses will be performed.  
Hemodynamic variables [ Section [IP_ADDRESS]] will be summarized by [CONTACT_542697]. Week 52 variables [ Section [IP_ADDRESS]] will be summarized similarly 
to the corresponding Week 26 measurements.  
Pressure-volume variables  (changes from baseline to Week 26 in arterial elastance, RV 
end-systolic elastance, RV maximum isovolumic pressure)  will be summarized and 
analyzed as desc ribed for PVR  in Section [IP_ADDRESS],  but without the log-transformation. 
Variables related to the left ventricle [ Section [IP_ADDRESS]] will be summarized similarly as 
the corresponding right ventricular variables. The ratios RVEDV/LVEDV and RVESV/LVESV will be summarized using descriptive statistics as well as geometric 
means and CVs. Potential variables for disease monitoring [ Section [IP_ADDRESS]] will be 
summarized similarly as NT-proBNP. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 98/[ADDRESS_1250492] clinical worsening  [Section [IP_ADDRESS]] will be 
summarized using a Kaplan -Meier plot.  
Association between (change from baseline to Week 26  in) cardiac MRI variables and 
time to first clin ical worsening event will be explored using Cox models. 
11.3.5 Analysis of s afety  variables 
All safety analyses will be performed on the SS. All safety data will be listed, with flags 
for quantitative abnormalities.  
[IP_ADDRESS] Adverse events  
A treatment -emergent AE is any AE temporally associated with the use of a study drug 
from study drug initiation until [ADDRESS_1250493] once from baseline up to 30 days following study drug discontinuation will be 
tabulated by:  
• MedDRA system organ cl ass (SOC) and individual preferred term  (PT) within each 
SOC, in descending order of incidence. 
• Frequency of patients with events coded with the same PT, in descending order of 
incidence.   
Furthermore, treatment -emergent AEs and SAEs occurring up to 30 days after study drug 
discontinuation will be tabulated as described above by [CONTACT_11762].  
AEs leading to premature  discontinuation of study drug and death will also be 
summarized as described above.   
Listings will be provided for all reported AEs, including SAEs. In addition, separate 
listings will be provided for SAEs, for AEs leading to premature discontinuation of study 
drug, and for AEs leading to death. 
[IP_ADDRESS] Laboratory parameters 
Descriptive summary statistics by [CONTACT_892791] , from baseline  up to EOT plus [ADDRESS_1250494] fitting 
time-window for that assessment.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 99/[ADDRESS_1250495] 2014- 004066- 20 
Doc No. D-16.554  
 
Actelion internal guidelines will be used for the definitions of marked abnormalities  and 
for the standardization of numeric values obtained from different laboratories and/or 
using different normal ranges. Standard numeric laboratory  variables are transformed to 
standard units. All laboratory data transferred are taken into account regardless of whether they correspond to scheduled (per protocol) or unscheduled assessments.  
Marked laboratory abnormalities will be summarized for each laboratory parameter by 
[CONTACT_71505]. Absolute values and changes of laboratory parameter values 
during the course of the study from baseline up to EOT plus 30 days will be summarized using the usual location and scale summary statistics . 
Laboratory parameters include: 
• Hematology: hemoglobin, hematocrit, erythrocyte count  (reticulocyte count) , 
leukocyte count with differential counts, platelet count. 
• Blood chemistry: AST, ALT, alkaline phosphatase, total and direct bilirubin, LDH, 
creatinine, urea, uric acid, glucose, cholesterol, triglycerides, sodium, potassium, 
chloride, calcium, protein, albumin. 
• Coagulation tests: prothrombin time, INR, aPTT. 
The number and percentage of patients with LFT abnormalities  [classified as in 
Section 11.2.4] up to 30 days after study drug discontinuation will be tabulated. 
The number and percentage of patients with hemoglobin abnormalities  [classified as in 
Section 11.2.4] up to 30 days after study drug discontinuation will be tabulated. 
[IP_ADDRESS] Vital signs and body weight  
Vital signs parameters blood pressure (i.e., diastolic blood pressure and systolic blood 
pressure), HR, and body weight will be summarized at each study visit up to EOT using 
the usual location and scale summary statistics  for both absolute values and changes from 
baseline. Patients for whom no post -baseline value is available are excluded from the 
analysis of the changes from baseline in the SS.  
11.3.6 Analysis of other variables 
Analyses associated with the sub -studies will be described in the SAP. 
11.4 Interim analyses 
11.4.1 Rationale 
The determination of the sample size nec essary to conclude on RVSV at final analysis 
relied on assumptions derived from a single source [Section 11.5]. Therefore, a 
conservative approach was taken and led to a large sample size, i.e. , 100 patients, to 
increase the probability of this study being conclusive. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 100/[ADDRESS_1250496] 2014- 004066- 20 
Doc No. D-16.554  
 
Literature recently published [Hassoun 2015, Trip 2015, Brewis 2016]  [Table 2] is in line 
with the initial assumptions , and suggests that the treatment effect on RVSV migh t be 
demonstrated before reaching 100 patients. Therefore, an interim analysis will be 
performed to allow for an early completion  of the study for efficacy . 
Table 2 New data published in 2015/2016 
Reference Patients w ith 
follow -up data  Reported data  
[Hassoun 2015] 24 incident 
CTD-PAH patients 
treated with PDE-5 
inhibitor–ERA 
combination for 36 weeks Median (Q1 -Q3) Baseline RVEDV (mL): 151.2 (138.4 –177.4) 
Median (Q1 -Q3) Post-treatment RVEDV (mL): 146.4 (120.5–165.4)  
 Median (Q1 -Q3)  Baseline RVESV (mL): 82.1 (65.6– 97.7) 
Median (Q1 -Q3) Post-treatment RVESV (mL):  
55.8 (49.4– 79.2) 
 
[Brewis 2016 ] 42 incident PAH 
patients mainly 
treated with PDE-5 inhibitor and/or 
ERA for  
3–8 months Mean (SD) Baseline Stroke volume index (mL/min2): 27 (8)  
Mean (SD) Post -treatment Stroke volume index (m L/m2): 32 (9)  
 
[Trip 2015 ] 
 30 incident IPAH or HPAH patients treated with PAH 
therapi[INVESTIGATOR_53301]  
0.5–2.5 years Median (Q1 -Q3) Baseline RVEDV (mL): 140 (124 –161) 
Median (Q1 -Q3) Post-treatment RVEDV (mL): 137 (117 –163) 
 
Median (Q1 -Q3) Baseline RVESV (mL): 93 (72 –109) 
Median (Q1 -Q3) Post-treatment RVESV (mL): 73 (54 –91) 
 
CTD-PAH = Connective Tissue Disease - Pulmonary Arterial Hypertension ; HPAH = Heritable Pulmonary Arterial 
Hypertension; IPAH = I diopathic Pulmonary Arterial Hypertension; PAH = Pulmonary A rterial Hypertension; 
PDE-5 = Phosphodiesterase type 5; ERA = Endothelin Receptor Antagonist;  RVEDV = Right Ventricular End 
Diastolic Volume; RVESV = Right Ventricular End Systolic Volume. 
11.4.[ADDRESS_1250497] 42 evaluable patients (i.e., included 
in the Modified FAS) are available for primary efficacy analysis.  
The interim analysis will use a hierarchical testing approach to maintain the overall type I 
error. As a first step, change from baseline to Week [ADDRESS_1250498] is negative, i.e. , the pre-defined efficacy boundary (p- value) is not crossed, recruitment 
will continue until 100 patients are enrolled. If it is positive (pre -defined efficacy 
boundary crossed), then PVR (ratio of Week 26 to baseline) will be tested. 
RVSV is to be tested first, as the potential effects of PAH -specific therapy on this 
variable are not so well known. The effect  of such therapi[INVESTIGATOR_892715] 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 101/[ADDRESS_1250499] be met. This 
contrasts with the final analysis, where it is sufficient to meet one endpoint. The reason 
for this choice is to mitigate the risk of closing the study too early to observe the full 
potential of macitentan.  
11.4.3 Statistical analysis 
The interim analysis will be performe d on the Modified FAS. Efficacy boundaries are 
defined in Table 3 and Table 4, and are calculated with 90% power, 1- sided 0.[ADDRESS_1250500] and are based on assumptions des cribed 
in Section 11.5 (sample size). To accommodate the need for the same number of patients 
included in the interim analysis of each primary endpoint, the selected information 
fraction (around 50%) is slightly different for RVSV and PVR. 
11.5 Sample size  
For MRI-based RVSV, no individual patient data are available at Actelion. Individual 
RVSV was approximated in the hemodynamic sub- study of SERAPHIN (AC -055-302) 
combining the cardiac index  obtained from the RHC with BSA and HR from vital signs 
measurements. The change f rom baseline in approximate RVSV was around 9 mL, in 
line with lite rature suggesting that a difference of 8 –12 mL is clinically relevant  
[Van Wolferen 2011] . Assuming a standard deviation of 18–22 mL, also based on the 
hemodynamic sub -study of SERAPHIN, the  sample size for 90% power is 30–93 
evaluable patients for final analysis (α = 0.02, one -sided). The number of patients and 
efficacy boundaries for the interim analysis are described in Table 3. 
For PVR, an integrated analysis of two bosentan studies, BENEFIT (AC -052-366) and 
EARLY (AC -052-364), and the hemodynamic sub- study of SERAPHIN  suggested that 
the mean change from baseline is expected to be around −0.24 on log scale (95% CI:  
−0.29, −0.19) and that the within group standard deviation is around 0.41 on log scale 
(90% CI: 0.39, 0.43). Under these assumptions, 30–84 evaluable patients are needed for 
final analysis for 90% power (α  = 0.005, one -sided). The number of patients  and efficacy 
boundaries for the interim analysis are  described in Table 4. 
The scenario retained to compute number of patients and p- value boundaries for 
interim/final analyses is based on conservative assumptions (lowest change and highest variability) , and is described in Table 3 (RVSV) and  Table 4 (PVR) below.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 102/[ADDRESS_1250501] 2014- 004066- 20 
Doc No. D-16.554  
 
Table 3 Efficacy boundaries for RVSV endpoint at interim/final analyses 
Change from 
baseline SD Information fraction for interim 
analysis Number of 
patients needed at interim 
analysis Number of 
patients needed at 
final analys is Efficacy 
Boundary on p-value scale ( Lan 
DeMets Pocock) 
– Interim analysis  Efficacy Boundary on p-value scale 
(Lan DeMets  
Pocock) – 
Final analysis  
8 22 0.45 42 93 0.[ZIP_CODE] 0.[ZIP_CODE] 
RVSV = Right Ventricular Stroke Volume; SD = Standard Deviation.  
 
Table 4 Efficacy boundaries for PVR endpoint at interim/final analyses 
Change from 
baseline on 
log scale SD Information 
fraction for 
interim analysis  Number of 
patients 
needed at interim 
analysis Number of patients 
needed at final analysis  Efficacy 
Boundaries on 
p-value scale (LanDeMets 
Pocock) – Interim 
analysis
* Efficacy Boundaries on 
p-value scale (LanDeMets 
Pocock) – 
Final 
analysis
** 
−0.19 0.43 0.5 42 84 0.0031 0.[ZIP_CODE] 
* Test at interim only if RVSV crossed pre-defined efficacy boundary. The information fraction for PVR is higher than 
for RVSV to fit same number of patients at interim analysis for both endpoints.  
** Boundary is 0.005 if not tested at interim  
PVR = Pulmonary Vascular Resistance; RVSV = Right Ventricular Stroke Volume; SD = Standard D eviation. 
To account for patient dropout and non- evaluable images,  the sample size was set at 
100 patients  for the final analysis . 
12 DATA HANDLING 
12.1 Data collection 
The investigator /delegate is responsible for ensuring the accuracy, completeness, and 
timeliness of the data reported. All source documents must be completed in a neat, legible 
manner to ensure accurate interpretation of the data. Data reported in the electronic  CRF 
derived from source documents must be consistent with the source documents. 
CRF data will be captured via electronic data capture (using the Rave system provided by 
[CONTACT_70598], Inc., a web -based tool ). The investigator and site staff will be trained 
to enter and edit the data via a secure network, with secure access features (username, 
password, and identification – an electronic password system). A complete electronic 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 103/[ADDRESS_1250502] 2014- 004066- 20 
Doc No. D-16.554  
 
audit trail will be maintained. The investigator/delegate will approve the data 
(i.e., confirm the accuracy of the data recorded) using an e lectronic signature (ref. to 
21 CFR Part 11). 
Patient screening data will be completed for all patients (i.e., eligible and non- eligible) 
through the IRT system and CRF . 
For each patient screened, regardless of study treatment  initiation, a CRF must be 
completed and signed by [CONTACT_093]/delegate . This also applies to those patient s who 
fail to complete the study. If a patient withdraws from the study, the reason must be noted 
on the CRF .  
12.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality  is maintained. On CRFs or 
other documents submitted to Actelion, patients must be identified only by [CONTACT_6227], and 
never by [CONTACT_180530] , hospi[INVESTIGATOR_180460] . The 
investigator/delegate must keep a patient identification code list, at the  site, showing the 
screening  number, the patient’s name, date of birth and address or any other locally 
accepted identifiers. Documents identifying the patients (e.g., signed ICF s) must not be 
sent to Actelion, and must be kept in strict confidence by [CONTACT_093]/delegate . 
12.[ADDRESS_1250503] patient status at any time  point during the course of 
the study. 
While entering the data, the investigator/delegate will be instantly alerted to data queries  
by [CONTACT_42940]. Additional data review will be performed  by [CONTACT_721095]. If 
discrepant  data are detected, a query specifying the problem and requesting clarificati on 
will be issued and visible to the investigator/delegate  via the CRF. All electronic queries 
visible in the system either require a data correction (when applicable) and a response 
from the investigator/delegate to clarify the queried data  directly in  the CRF, or simply a 
data correction in the CRF. The investigator/delegate must, on request, supply Actelion 
with any required background data from the study documentation or clinical records. This 
is particularly important when errors in data transcription are suspected. In the case of 
Health Authority queries, it is also necessary to have access to the complete study 
records, provided that patient confidentiality is protected.  This process will continue until 
database closure.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 104/[ADDRESS_1250504] operating procedure  (SOP). After database closure, the investigator will receive 
the CRF of the patients of her/his site (including all data changes made) on electronic 
media or as a paper copy.  
13 PROCEDURES AND GOOD CLINICAL PRACTICE 
13.1 Ethics and Good Clinical Practice 
Actelion and the investigators will ensure that the study is conducted in full compliance 
with ICH-GCP Guidelines, the principles of the “Declaration of Helsinki ” and with the 
laws and regulations of the country in which the research is conducted. 
13.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document provided to the 
patient (such as Patient Information Leaflet used to obtain informed consent) to an 
IRB/IEC. Approval from the committee must be obtained before starting the study, and 
must be documented in a dated letter to the investigator, clearly identifying the study, the 
documents reviewed, and the date of approval.  
Modifications made to the protocol after receipt of the approval must also be submitte d as 
amendments by [CONTACT_85213]/IEC in accordance with local procedures and 
regulations [ see Section  13.6]. 
A list of members participating in the  IRB/IEC meetings must be provided, including the 
names, qualifications  and functions of these members. If that is not possible, the attempts 
made to obtain this information along with an explanation as to why it cannot be obtained 
or disclosed must be documented in the study documentation. If a study staff member 
was present during a meeting, it must be clear that this person did not vote. 
13.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according 
to ICH-GCP guidelines and local regulations from each individual participating in this 
study and/or legal representative. The investigator/delegate must explain to patients that 
they are completely free to refuse to enter the study, or to withdraw from it at any time for any reason.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 105/[ADDRESS_1250505] 2014- 004066- 20 
Doc No. D-16.554  
 
The ICF will be provided in the country local language(s). 
Site staff authorized to participate to the consent process and/or to obtain consent from 
the patient  and/or legal representative will be listed on the Delegation of Authority for m. 
A study physician must always be involved in the consent process.  
The patient  and/or legal representative must sign  and personally date and time (if 
appropriate) the ICF before any study -related procedures begin (i.e., any procedures 
required by [CONTACT_760]). The ICF must also be signed and personally dated and timed (if 
appropriate) by [CONTACT_892792]. A copy of the signed and dated ICF is given to the patient and/or legal representative; the 
original is filed in the site documentation.  
The informed consent process must be fully documented in the patient’s medical records , 
including study reference, patient number, date/time (if applicable) when the patient was 
first introduced to Actelion clinical study, date/time (if applicable) of consent, who 
participated in the consent discussion, who consented the patient and any additional 
person present during the consent process (e.g., patient family member) . A copy of the 
signed ICF must be given to the patient  and/or legal representative.  
In the case that the site would like to recruit a patient who would be considered as 
vulnerable (e.g. , patient cannot read  or write, does not speak or understand the ICF 
language), additional measures must be implemente d in order to ensure patient rights are 
respected and the consent obtained is legally valid. Actelion, the regulatory authorities (if 
applicable) and the IRB/IEC must be informed prior to the recruitment. The consent 
process (e.g. , involvement of an impart ial witness) must be fully described, submitted  to, 
and approved by [CONTACT_1201]/IEC, according to procedures  and before  such patients are 
recruited.  
13.4 Compensation to patient s and investigators 
Actelion provides insurance in order to indemnify (with both legal and financial 
coverage) the investigator/ site against claims arising from the study, except for claims 
that arise from malpractice and/or negligence.  
The compensation of the patient in the event of  study-related injuries will comply with 
applicable regulations. 
13.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the approved version of the 
protocol and must not implement any deviation/change from the protocol, ex cept when 
the change involves only logistical or administrative aspects (e.g., change in telephone 
number), or in case it would be necessary to eliminate an immediate hazard to the patient.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 106/[ADDRESS_1250506] 2014- 004066- 20 
Doc No. D-16.554  
 
If a protocol deviation occurs, the investigator/delegate will inform Actelion or its 
representative in a timely manner. The investigator/delegate must document and explain 
any deviation from the approved protocol. IRB/IEC and regulatory authorities must be 
informed, according to their requirements, but no later than [ADDRESS_1250507] be submitted to IRB/IEC, and regulatory authorities, according 
to their requirements.  
13.7 Essential document s and retention of documents 
The investigator/delegate must maintain adequate records necessary for the 
reconstruction and evaluation of the study. A number of attributes are considered of 
universal importance to source data and the records that hold those data. These include that the data and records are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, consistent, endur ing, and available when needed. 
These records are to be classified into two different categories  of documents:  
investigator ’s file and patient  clinical source documents.  
These records must be kept by [CONTACT_721097]’s requirements (e.g. , as specified in the clinical study agreement), and  national 
and/or international regulations , whichever would be the longest period. If the 
investigator cannot guarantee this archiving requirement at the investigational site for any or all of the documents, special arrangements, respecting the data confid entiality, must be 
made between the investigator and Actelion to store these documents outside the site, so 
that they can be retrieved in case of a regulatory inspection. No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion must be notified in advance.  
If the site is using an electronic/computerized system to store patient medical records, it 
can be used for t he purpose of the clinical study if it is validated (as per [ADDRESS_1250508]) and if the monitor has been provided personal and restricted 
access to study patients only, to verify consistency between electronic source data and the 
CRF during monitoring visits.  
If the site is using an electronic/computerized system to store patient medical records but 
it could not be confirmed that the system is validated or if the monitor could not be 
provided access to the system, the site is requested  to print the complete set of source 
data needed for verification by [CONTACT_2037]. The print -outs must be numbered, stapled 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 107/[ADDRESS_1250509] 2014- 004066- 20 
Doc No. D-16.554  
 
together with a coversheet, signed and dated by [CONTACT_093] /delegate to confirm that 
these certified copi[INVESTIGATOR_892716]’s data. The printouts will be considered as the official clinical study records.  
In order to verify that the process the site uses to prepare certified copi[INVESTIGATOR_42874], the 
monitor must be able to observe this process and confirm that the comparison of the source documents and the certified copy did not reveal inconsistencies. The monitor does not need to verify this process for all data of all patients but at least for some of them 
(e.g., first patient; regular check during the study of critical data like inclusion/exclusion 
criteria, endpoints for some patients) as per Actelion ’s instructions. If it were not possible 
for the monitor to observe this process, it would not be possible to rely on the site ’s 
certified copi[INVESTIGATOR_180462]. The 
printouts must be filed either with the patient medical records or with the patient ’s CRF. 
13.8 Monitoring 
Prior to study start, a Site Initiation Visit ( SIV) will be performed after the required 
essential study documents are approved by [CONTACT_180494]. The study treatment  will be shipped 
to the site upon approval of the required essential documents.  
The principal investigator  [INVESTIGATOR_892717]. Site Information Technology 
support should also be available during the initiation visit.  
The SIV must be completed  before the site can start the screening of study patients. 
Following the SIV, a copy of the completed initiation visit  report and follow -up letter 
will be provided to the principal investigator  [INVESTIGATOR_892718] ( ISF). 
During the study, the monitor will contact [CONTACT_180534], and 
on request must be permitted to have access to trial facilities and all source documents 
needed to verify adherence to the protocol and the completeness, consistency and 
accuracy of the data being entered in the CRFs and other protocol -related documents. 
Actelion monitoring standards require full verification that informed  consent has been 
provided, and verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety and tolerability endpoints. Additional checks of the consistency of the source data with the CRFs will be performed 
according to the study -specific monitoring plan.  The frequency of the monitoring visits 
will be based on patient  recruitment rate and critical data collection times . 
The principal i nvestigator must ensure that the CRF is completed after a patient’s visit to 
the site, and that all requested patient files (e.g., ICFs, medical notes/charts, other 
documentation verifying the activities conducted for the study) are available for review by [CONTACT_2037]. The required site personnel must be available during monitoring visits 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 108/[ADDRESS_1250510] 2014- 004066- 20 
Doc No. D-16.554  
 
and allow adequate time to meet with the monitor to discuss study related issues. The 
investigator agrees to cooperate with the monitor(s) to ensure that any issues detected in the course of these monitoring visits are resolved. If the patient is hospi[INVESTIGATOR_42878] a 
hospi[INVESTIGATOR_42869], the investigator is responsible for contact[CONTACT_892793][INVESTIGATOR_215185] , in accordance with local regulations . 
A close-out visit will be performed for any initiated site and when there are no more 
active patient s and after all study data have been accepted by [CONTACT_892794]-up issues have been resolved. In case a site d oes not enroll any patients, the 
close-out visit may  be performed prior to study database closure  at the discretion of 
Actelion. 
13.[ADDRESS_1250511] be kept by [CONTACT_208289], ICH GCP as well as instructions from Actelion.  If the site needs to transfer 
the ISF to another location and/or if site facility c an no longer store the ISF, the principal 
investigato r must inform Actelion immediately.   
If the principal inv estigator will change , or if the site will relocate, the monitor must be 
notified as soon as possible.  
13.10  Audit  
Actelion’s Global Quality Management representative s may audit the investigator site 
during the study or after its completion. The purpose of this visit will be to determine the investigator ’s adherence to ICH -GCP, the protocol and applicable regulations ; adherence 
to Actelion’s requirements (e.g. , SOPs) will also be verified . Prior to initiating this audit, 
the investigator will be contact[CONTACT_180536] a time for the audit.  
The investigator and staff must cooperate with the auditor(s) and allow access t o all study 
documentation (e.g., patient  records) and facilities.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 109/[ADDRESS_1250512] 2014- 004066- 20 
Doc No. D-16.554  
 
13.11  Inspections 
Health Authorities and/or IRB/IEC may also wish to conduct an inspection of Actelion’ s 
clinical study during the study or after its completion.  
Should an inspection be requested by a Health Authority and/or IRB/IEC, the investigator 
must inform Actelion immediately, (usually via the monitor), that such a request has been 
made.  
The investigator and staff must cooperate with inspector(s) and allow access to all study documentation (e.g. patient records) and study facilities.  
13.[ADDRESS_1250513] results from its clinical studies on Actelion ’s Clinical Trial Register 
(SMADAR), and on external/national registries, as required by [CONTACT_2371]. 
Actelion’s Policy on Disclosure of Clinical Research Information can be found at:  
http://www.actelion.com/documents/corporate/policies_charters/policy_clinical- research-
information.pdf 
In accordance with the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a peer -reviewed jou rnal. Study results can be 
submitted for presentation at a congress before publication in a peer -reviewed journal. 
Authorship will be determined in accordance with the International Committee of Journal Editors (ICMJE) criteria , and be based on: 
• Substantial contributions to: the conception or design of the study, or the acquisition, 
analysis or interpretation of data; and  
• Drafting of the publication or critical review for important intellectual content; and  
• Providing final approval of the version to be published; and  
• Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 110/[ADDRESS_1250514] alterations and/or 
deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period. 
Actelion’s Policy on Scientific Publications can be found at: 
http://www.actelion.com/documents/corporate/policies_charters/policy_scientific -
publications.pdf 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 111/[ADDRESS_1250515] 2014- 004066- 20 
Doc No. D-16.554  
 
14 REFERENCES 
[Abman 2009] Abman SH. Role of endothelin recepto r antagonists in the treatment of 
pulmonary arterial hypertension. Annu Rev Med. 2009;60:13-23. 
[Addetia 2014] Addetia K, Bhave MN, Tabit CE, Gomberg -Maitland M, Freed BH, Dill 
KE. Sample size and cost analysis for pulmonary arterial hypertension drug tria ls 
using various imaging modalities to assess right ventricular size and function end 
points. Circ Cardiovasc Imaging. 2014;7:115-124. 
[Archer 2013] Archer SL, Fang YH, Ryan JJ, Pi[INVESTIGATOR_6683] L. Metabolism and bioenergetics in 
the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ. 2013 Jan;3(1):144-52. 
[ATS Statement 2002] Guidelines for the Six -Minute Walk Test. Am J Respir Crit Care 
Med 2002;166:111-7. 
[Benigni 1995] Benigni A. Defining the role of endothelins  in renal pathophysiology on 
the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens 1995;4:349-53. 
[Benza 2010] Benza RL, Miller DP, Gomberg- Maitland M, Frantz RP, Foreman AJ, 
Coffey CS. Predicting survival in pulmonary arterial hypertension insights from the registry to evaluate early and long -term pulmonary arterial hypertension disease 
management (REVEAL). Circulation. 2010;122:164-172. 
[Blalock 2010] Blalock SE, Matulevicius S, Mitchell LC, Reimold D, Warner J, Peshock 
R. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial 
hypertension. J Cardiac Fail 2010;16:121-127. 
[Bokhari 2011] Bokhari S, Raina A, Rosenweig EB, Schulze PC, Bokhari J, Einstein AJ. 
PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2011 Nov;4(6):641-7. 
[Bradlow 2010] Bradlow WM, Hughes ML, Keenan NG, Bucciarelli -Ducci C, Assomull 
R, Gibbs JS . Measuring the heart in pulmonary arterial hypertension (PAH): 
implications for trial study size. J Magn Reson Imaging. 2010 Jan;31(1):117-24. 
[Brewis 2016] Brewis MJ, Bellofiore A, Vanderpool RR, Chesler NC, Johnson MK, 
Naeije R . Imaging right ventricular function to predict outcome in pulmonary 
arterial hypertension. Int J Cardiol. 2016 Sep 1; 218:206-11 
[Brimioulle  2003] Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, 
Kerbaul F. Single -beat estimation of right ventricular end -systolic pressure -volume 
relationship. Am J Physiol Heart Circ Physiol. 2003 May;284(5):  
H1625-30. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 112/[ADDRESS_1250516] 2014- 004066- 20 
Doc No. D-16.554  
 
[Chua 1992] Chua B, Krebs CT, Chua CC, et al. Endothelin stimulates protein synthesis 
in smooth muscle cells. Am J Physiol 1992;262:E412-6. 
[Clarke 1989] Clarke J, Benjamin N, Larkin W, et al. Endothelin is a potent long lasting 
vasoconstrictor in men. Am J Physiol 1989;257:H2033-5. 
[Davie 2002] Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the 
proliferation of human pulmonary a rtery smooth muscle cells. Am J Respir Crit 
Care Med 2002;165:398-405. 
[de Nucci 1988] de Nucci G, Thomas R, D Orleans -Juste P, et al. Pressor effects of 
circulating endothelin are limited by [CONTACT_892795] -derived relaxing factor. Proc Natl Acad Sci [LOCATION_003] 
1988;85:9797-800. 
[Fisher 2006] Fisher MR, Mathai SC, Champi[INVESTIGATOR_174001], Girgis RE, Housten- Harris T, 
Hummers L. Clinical differences between idiopathic and scleroderma- related 
pulmonary hypertension. Arthritis Rheum. 2006 Sep;54(9):3043-50. 
[Foëx 1994] Foëx P, Leone BJ. Pressure-volume loops: a dynamic approach to the 
assessment of ventricular function. J Cardiothorac Vasc Anesth. 1994 F eb;8(1): 
84-96. 
[Franco 2012] Franco V. Right Ventricular Remodeling in Pulmonary Hypertension. 
Heart Failure Clin 8 (2012):403-412. 
[Galiè 2003] Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T. 
Effects of the oral endothelin -receptor antagonist bosentan on echocardiographic 
and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16;41(8):1380-6. 
[Galiè 2004] Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial 
hypertension. Cardiovasc Res 2004;61:227-37. 
[Galiè 2013] Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC. Updated 
Treatment Algorithm of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2013;62:D60-72. 
[Galiè 2014] Galie N, Albert Barbera J, Frost A, Ardeschir Ghofrani H, Hoeper M, 
Mclaughlin V  et al. AMBITION: A randomised, multicenter study of first- line 
ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). Eur Respir J. 2014;Suppl 58:44. 
[Giaid 1993]. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin- 1 in 
the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:  
1732–9. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 113/[ADDRESS_1250517] 2014- 004066- 20 
Doc No. D-16.554  
 
[Grothues 2003] Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. 
Interstudy reproducibility of right ventricular volumes, function, and mass with 
cardiovascular magnetic resonance. Am Heart J. 2004 Feb;147(2):218-23. 
[Hassoun 2009] Hassoun PM. Therapi[INVESTIGATOR_892719] -related pulmonary arterial 
hypertension. Expert Rev Respir Med. 2009;3(2):187-196. 
[Hassoun 2015] Hassoun PM, Zamanian, RT, Damico R, et al. Ambrisentan and tadalafil 
upfront combination therapy in scleroderma -associated PAH. AJRCCM. 
2015;192(9):1102-1110. 
[Hinderliter 1997] Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ , Badesch DB, 
Groves BM. Effects of long -term infusion of prostacyclin (epoprostenol) on 
echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997 Mar 18;95(6):1479-86. 
[Hirata 1993] Hirata Y, Emori T, Eguchi S. Endothelin receptor subtype B mediates 
synthesis of nitric oxide by [CONTACT_180540]. J Clin Invest 1993;91:1367-73. 
[Hoeper 2006] Hoeper MM, Lee SH, Voswinckel R, Palazzini  M, Jais X, Marinelli A, et 
al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19;48(12):2546-52. 
[Hoeper 2013] Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M. 
Definitions and Diagnosis of Pulmonary Hypertension. J Am Coll Cardiol 2013;62:D42-50. 
[Humbert 2004] Humbert M, Morell NW, Archer SL, et al. Cellular and Molecular 
Pathobiology of pulmonary Arterial Hypertension. J Am Coll Cardiol 2004;43: 
13S-24S. 
[Kasimir 2004] Kasimir MT, Seebacher G, Jaksch P, Winkler G, Schmid K, Marta GM. 
Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur J Cardiothorac Surg. [ADDRESS_1250518];26(4):776-81. 
[Kuehne 2004] Kuehne T, Yilmaz S, Steendijk P, Moore P, Groenink M, Saaed M. 
Magnetic resonance imaging analysis of right ventricular pressure- volume loops: in 
vivo validation and clinical application in patients with pulmonary hypertension. Circulatio n. [ADDRESS_1250519] 5;110(14):2010-6. 
[Kylhammar 2014] Kylhammar D, Persson L, Hesselstrand R, Rådegran G. Prognosis 
and response to first -line single - and combination therapy in pulmonary arterial 
hypertension. Scand Cardiovasc J. 2014 Jun 10:1-23. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 114/[ADDRESS_1250520] 2014- 004066- 20 
Doc No. D-16.554  
 
[Macitentan  IB] Investigator ’s Brochure. Macitentan ACT -064992. Endothelin receptor 
antagonist, Version 11. Actelion Pharmaceuticals Ltd, November 2013. 
[Massaki 1998] Massaki T. The discovery of endothelins. Cardiovasc Res 1998;39:  
530-3. 
[O’Callaghan 2011] O’Callaghan  DS, Savale L, Montani D, et al. Treatment of 
pulmonary arterial hypertension with targeted therapi[INVESTIGATOR_014]. Nat Rev Cardiol. 
2011;8(9):526-38. 
[Oudiz 2013] Oudiz RJ. Death in Pulmonary Arterial Hypertension. Am J Respir Crit 
Care Med. 2013 Aug 1;188(3):269-70.  
[Overbeek 2008] Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, 
Bronzwaer JGF. Right ventricular contractility in systemic sclerosis -associated and 
idiopathic pulmonary arterial hypertension. Eur Respir J 2008;31:1161-1166. 
[Peacock 2014] Peacock A, Crawley S, McLure L, Blyth K, Vizza CD, Poscia R. 
Changes in right ventricular function measured by [CONTACT_892796] -targeted therapy The 
EURO-MR study. Circ Cardiovasc. Imaging. 2014;7:107-114. 
[Pulido 2013] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani A. 
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013;369:809-18. 
[Raghu 2013] Raghu G, Million- Rousseau R, Morga nti A, Perchenet L, Behr J. 
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC Trial. Eur Respir J. 2013 Dec;42(6):1622-32. 
[Raymond 2002] Raymond RJ, Hinderliter  AL, Willis PW, Ralph D, Caldwell EJ, 
Williams W. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002 Apr 3;39(7):1214-9. 
[Rich 1992] Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium -channel 
blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327(2):76-81. 
[Rich 2012] Rich S. Right Ventricular Adaptation and Maladaptation in Chronic 
Pulmonary Arterial Hypertension. Cardiol Clin. 2012 May;30(2):257-69. 
[Roeleveld  2004] Roeleveld RJ, Vonk- Noordegraaf A, Marcus JT, Bronzwaer JG, 
Marques KM, Postmus PE. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest. 2004 Feb;125(2):572-9. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 115/[ADDRESS_1250521] 2014- 004066- 20 
Doc No. D-16.554  
 
[Simonneau 2013] Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, 
Ghofrani A. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll 
Cardiol 2013;62:D34-41. 
[Sitbon 2005] Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium 
channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 
111:3105-11. 
[Stewart 1991] Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin -1 in 
pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9. 
[Sugawara 1996] Sugawara F, Ninomiya H, Okamoto Y, et al. Endothelin-1-
inducedmitogenic responses of Chinese hamster ovary expressing human endothelin A: the role of a wortmannin- sensitive signalling pathway. Molec 
Pharmacol 1996;49:447-57. 
[Sunagawa 1980] Sunagawa K, Yamada A, Senda Y, Kikuchi Y, Nakamura M, 
Shibahara T. Estimation of the hydromotive source pressure from ejecting beats of the left ventricle. IEEE Trans Biomed Eng. 1980 Jun;27(6):299-305. 
[Swift 2014] Swift AJ, Rajaram S, Campbell MJ, Hurdman J, Thomas S, Capener D. 
Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2014 Jan;7(1):100-6. 
[Takeuchi 1991] Takeuchi M, Igarashi Y, Tomimoto S, Odake M, Hayashi T, Tsukamoto 
T. Single-beat estimation of the slope of the end -systolic pressure -volume relation 
in the human left ventricle. Circulation. 1991 Jan;83(1):202-12. 
[Tedford 2013] Tedford RJ, Mudd JO, Girgis RE, Mathai SC, Zaiman AL, Housten -
Harris T. Right ventricular dysfunction in systemic sclerosis -associated pulmonary 
arterial hypertension. Circ Heart Fail. 2013 Sep 1;6(5):953-63. 
[Trip 2013] Trip P, Kind T, van de Veerdonk MC, Marcus JT, de Man FS, Westerhof N. 
Accurate assessment of load -independent right ventricular systolic function in 
patients with pulmonary hypertension. J Heart Lung Transplant. 2013 Jan;32(1):  
50-5. 
[Trip 2015] Trip P, Rain S, Handoko ML, van der Bruggen C, Bogaard HJ, Marcus JT, 
Boonstra A. Clinical relevance of right  ventricular diastolic stiffness in pulmonary 
hypertension. Eur Respir J. 2015 Jun; 45(6):1603-12 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 116/[ADDRESS_1250522] 2014- 004066- 20 
Doc No. D-16.554  
 
[Van de Veerdonk 2011] van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, 
Heymans MW, Bogaard HJ, Boonstra A. Progressive right ventricular dysfunction 
in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9. 
[Van Wolferen 2006] van Wolferen SA, Boonstra A, Marcus JT, Marques KM, 
Bronzwaer JG, Postmus PE. Right ventricular reverse remodelling after sil denafil 
in pulmonary arterial hypertension. Heart. 2006 Dec;92(12):1860-1. 
[Van Wolferen 2011] van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, 
Marcus JT, Marques KM. Clinically significant change in stroke volume in pulmonary hypertension. Chest. 2011 May;139(5):1003-9. 
[Van Wolferen  2007] van Wolferen SA, Marcus JT, Boonstra A, Marques KM, 
Bronzwaer JG, Spreeuwenberg MD. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007 May;28(10):1250- 7. 
[Vonk-Noordegraaf 2011] Vonk- Noordegraaf A, Galiè N. The role of the right ventricle 
in pulmonary arterial hypertension. Eur Respir Rev. 2011;20(122):243-253. 
[Wilkins 2005] Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin- Sing W, Banya WA. 
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7. 
[Yamada 2012] Yamada Y, Okuda S, Kataoka M, Tanimoto A, Tamura Y, Abe T. 
Prognostic value of cardiac  magnetic resonance imaging for idiopathic pulmonary 
arterial hypertension before initiating intravenous prostacyclin therapy. Circ J. 2012;76(7):1737-43. 
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 117/[ADDRESS_1250523] as the baseline 
RHC to ensure data consistency.   
1 Material and methods  
• Patients will undergo right heart catheterization (RHC) at the study site or other 
institution in  case no suitable lab oratory is available at the study site in an appropriate 
care setting (e.g., cardiac catheterization laboratory, medical procedures unit, 
intensive care unit). Left heart  catheterization, if needed, must be carried out in the 
cardiac catheterization laboratory.  
• Hemodynamic evaluations will be carried out with the patient in the supi[INVESTIGATOR_2547]. 
Patients will breathe room air. If the patient requires supplemental oxygen during 
catheterization,  oxygen must be given during both baseline and the follow -up 
assessments (if applicable).  Electrocardiogram for the assessment of the heart rate 
(HR) will be monitored continuously. Systolic and diastolic systemic arterial 
pressures (s SAP, dSAP) will be measured by [CONTACT_892797]. 
• RHC will be perfo rmed according to laboratory’s standard procedures through  the 
internal jugular, subclavian, or femoral vein by a balloon catheter placed into either the right or left pulmonary artery. A triple -lumen, balloon- tipped thermodilution 
catheter will be  used for measurement of selected intracardiac pressures (at end -
expi[INVESTIGATOR_1516]) and cardiac  output (CO). A four -lumen, balloon- tipped thermodilution 
catheter can be used, if obtaining accurate pulmonary capi[INVESTIGATOR_47469]  
(PCWP) or pulmonary arterial pressure ( PAP) is problematic.  
• CO will be measured by [CONTACT_70964] . 
• For those patients on background medication that includes anticoagulants 
(e.g., warfarin), the  usual safety measures, as routinely used by [CONTACT_892798], must be taken.  
2 Assessments  
2.1 Hemodynamic parameters measured during RHC: 
• HR 
• CO 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 118/[ADDRESS_1250524] 2014- 004066- 20 
Doc No. D-16.554  
 
• Pulmonary artery pressure (systolic, diastolic, electronic mean: sPAP, dPAP, mPAP) 
• Mean right atrial pressure (mRAP)  
• PCWP or left atrial end diastolic  pressure (LVEDP). See Section  2.3. 
• Noninvasive sSAP and dSAP)  
2.2 Measurement and selection of hemodynamic parameters:  
• Hemodynamic pressures ( mPAP, mRAP, and PCWP , or LVEDP) will be measured in  
duplicate (10 minutes apart), or until 2 consecutive values do not differ >  10%: the 
last value will be recorded in the R HC page of the Case Report Form (CRF ). 
• For the measure of PCWP, the same method must be used consistently throughout the 
study. 
• HR and systemic arterial pressure: will be measured in duplicate (10 minutes apart), 
or until 2 consecutive values do not differ >  10%: the last value will be recorded in 
the RHC page of the CRF. 
• CO will be measured in tr iplicate, or until 3 consecutive values do not differ >  10%: 
the mean value will be recorded in the RHC  page of the CRF. 
• All measured hemodynamic values, including those not reported in the R HC page of 
the CRF, and the time when the measurements were taken  must be included in the 
catheterization report or recorded in a source document. 
2.3 Calculated hemodynamic parameters: 
• Pulmonary vascular resistance (dyn.sec.cm-5): 𝑃𝑉𝑅 =�𝑚𝑃𝐴𝑃−𝑃𝐶𝑊𝑃
𝐶𝑂�∗80 
• Total pulmonary vascular resistance (dyn.sec.cm-5): 𝑇𝑃𝑅 =𝑚𝑃𝐴𝑃
𝐶𝑂*80 
• Cardiac index  (l.min-1.m-2): 𝐶𝐼=𝐶𝑂
𝐵𝑆𝐴 
• Body surface area (m2): 𝐵𝑆𝐴 = 0. 007184∗(𝑤𝑒𝑖𝑔ℎ𝑡0.425)∗(ℎ𝑒𝑖𝑔ℎ𝑡0.725) 
with weight expressed in kg and height in cm. 
2.4 Data transmission for central assessment: 
Right ventricle  and pulmonary artery pressure signals over at least [ADDRESS_1250525] be provided. Pressure curves will be uploaded in a 
specially designed web site and will be centrally assessed.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 119/[ADDRESS_1250526] 2014- 004066- 20 
Doc No. D-16.554  
 
Appendix 2 Actelion guidelines for 6MWT  
The American Thoracic Society (ATS) published an official statement on the 6-minute 
walk test ( 6MWT) in 2002 [ATS Statement 2002]. Only a brief summary of these 
guidelines is included here. 
• The 6MWT must be performed indoors, along a long, flat, straight, enclosed corridor 
with a hard surface that is seldom traveled. The use of treadmill is forbidden. 
• The walking distance used for the test must be 30 meters (100 feet) in length. This 
distance should be marked every 3 meters (10 feet). The turnaround point should be 
marked with a cone. A starting line, which marks the beginning and the end of each 60-meter lap, should be marked on the floor using brightly colored tape. Any 
deviation from this must be approved in written form by [CONTACT_892799].  
• The study staff member administering the 6MWT will stand near the starting line 
during the test and must not walk with the patient! Intermittent rest periods are allowed if the patient can no longer continue. If the patient needs to rest, he/she may pause, lean against the wall or sit and should continue walking whenever he/she feels 
able. The timer must continue to run. The test can be stopped at any moment in case the patient complains of having chest pain, intolerable dyspnea, leg cramps, or has a pale or ashen appearance.  
• The 6MWT is a non- encouraged test. No instructions or encouragement will be given 
during the test. Eye contact [CONTACT_180545]. 
• For an individual patient, repeat testing must always be conducted, if possible, by [CONTACT_892800], at the same location, and preferably at about the same time of the day to minimize variability.  
Required equipment:  
• Countdown timer (or stop watch) 
• Mechanical lap counter 
• Two small cones for the turnaround points 
• A chair that can be easily moved along the walking course  
• Worksheets on a clipboard 
• Sphygmomanometer 
• Automated electronic defibrillator  
• Source of oxygen 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 120/[ADDRESS_1250527] 2014- 004066- 20 
Doc No. D-16.554  
 
Patient preparation  
• The patient should wear comfortable clothing and appropriate walking shoes. 
• The meals preceding the test should be light, and the patient should not have 
exercised vigorously within [ADDRESS_1250528]. 
• The patient should sit at rest for at least [ADDRESS_1250529] starts. 
• Patients must receive their usual medication on the day of the test. If the patient is 
used to taking bronchodilators before a walk, he/she should take them 5– [ADDRESS_1250530].  
• For patients receiving continuous 24- hour oxygen therapy, it is recommended that the 
flow rate remains constant for the duration of the study. However, from one hour 
prior to and until the completion of the 6MWT, the flow rate must remain constant. 
Measurement of the 6MWD/6MWT – Instructions to the patient  
The person administering the test will use the following exact dialogue with the patient: 
“The object of this test is to walk as far as possible for [ADDRESS_1250531] without hesitation. Now I ’m going to show you. Please watch the way I turn without 
hesitation ”. 
(The tester demonstrates the walking and pi[INVESTIGATOR_180470] a cone briskly).  
“Are you ready to do that? I am going to use this counter to keep track of the number of 
laps you complete. I will click it each time you turn around at this starting line. Remember the object is to walk AS FAR AS POSSIBLE for 6 minutes, but don’ t run or 
jog. I will tell you when [ADDRESS_1250532] elapsed. Keep walking when I talk.” After these instructions are given to the patient, the person administering the test will then ask: 
“Do you have any questions about the test?” 
“Please explain what you are going to do.” 
“Are you ready? ” 
“Start now, or whenever you are ready.” 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 121/[ADDRESS_1250533] 2014- 004066- 20 
Doc No. D-16.554  
 
As soon as the patient starts to walk, the tester will start the timer and write down  start 
time. 
The tester will tell the patient the time elapsed by [CONTACT_3041]:  
“You have 4 minutes to go.” 
“You have 2 minutes to go.” When the timer is 15 seconds from completion, the tester says: “In a moment I ’m going to tell you to stop. When I do, just stop right where you are and I 
will come to you .” 
When the timer alarm rings the tester says:  
“Stop!” The tester walks over to the patient, marks the spot where the patient stopped, records the  
total distance walked in the worksheet, and congratulates the patient on good effort.  
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 122/[ADDRESS_1250534] 2014- 004066- 20 
Doc No. D-16.554  
 
Appendix 3 Borg  dyspnea index  
Borg rating  Perceived exertion  
0 
0.5 
1 2 3 4 5 
6 
7 8 9 10 Nothing at all  
Very, very slight (just noticeable)  
Very slight  
Slight (light)  
Moderate  
Somewhat severe  
Severe (heavy)  
 Very severe  
  Very, very severe (maximal)  
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 123/[ADDRESS_1250535] signs of right 
heart failure. Dyspnea and/or fatigue may even be present at rest. 
Discomfort is increased by [CONTACT_180547].  
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 124/[ADDRESS_1250536] be stored below 30 °C and must be protected from moisture. Unopened, sealed study medication bottles may be stored in refrigerators (between the temperature range of +2 °C to 30 °C). If the temperature at a patient’s home exceeds 
30 °C, the patient must be instructed to store the unopened bottles of the study drug in 
his/her refrigerator. Frozen storage (below +2 °C) is not permitted. Unsealed bottles  must 
not be stored in the refrigerator.  
At the site, a temperature log must be maintained, and temperature control should occur 
at least on a weekly basis.  
Actelion will provide a temperature log if not available on site, however, the use of the log is not mandatory if the site has an acceptable means of recording the temperature. Any temperature- recording system routinely used at the site is acceptable, as long as all 
required information is included and certification of calibration is provided. If the temperature is captured electronically, a printout must be made available to the monitor 
during each on- site visit. 
In case a deviation from the defined temperature range is identified by [CONTACT_779], the deviation is to be reported to the monitor, preferably in writing and with supportive documentation (e.g., a copy of the temperature log showing data for all excursion days). The monitor must immediately notify Actelion for further advice. The study drug 
affected by a deviation will not be used (e.g., segregated physically at the investigational site) until confirmation by [CONTACT_892801]. In case the temperature deviation is defined as acceptable, a corresponding message is returned to the site via the monitor. 
In case the temperature deviation is defined as not acceptable and the quality of the study 
drug might be affected, the study drug is kept segregated at the investigational site and 
returned to Actelion following internal drug return processes. New study drug supplies will be provided to the site. 
Site temperature deviations correspondence must be kept in the Investigator Site File. 
The study centers will be supplied with the study drug according to the centers ’ needs, 
depending on the rate of patient enrollment. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 125/[ADDRESS_1250537] 2014- 004066- 20 
Doc No. D-16.554  
 
Appendix 6 Central laboratory 
In case of laboratory abnormalities  at any visit corresponding to the thresholds below, the 
central laboratory will alert Actelion and the concerned site. Alert flags will trigger these 
notifications . 
Analyte  Threshold  
ALT ≥ 3 × ULN 
AST ≥ 3 × ULN 
Hemoglobin  < 80 g/L, or 
Decrease by > 20g/L from last value before 
study drug initiation  
Beta-human chorionic gonadotropin  > 5 mIU/ml  
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit 
of the normal range. 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 126/[ADDRESS_1250538] 2014- 004066- 20 
Doc No. D-16.554  
 
Appendix 7 Eligibility questionnaire  
Site Identification  
Principal Investigator  _____________________________ 
 Patient Identification  
Patient number  └─┴─┴─┴─┴─┴─┴─┘ 
Age  └─┴─┘ 
Please complete the questionnaire below to document which tests/procedures have been performed in 
order to exclude other causes of pulmonary hypertension for the patien t indicated above.  
This questionnaire  must be completed prior to treatment initiation for all patients : 
a) with 30 < BMI <  35 kg/m2, and/or  
b) with 65 ≤ Age < 75 years 
1. Patient characteristics  
Body mass index └─┴─┘.└─┘ kg/m2 
Gender   □Male  □ Female 
PAH etiology   □ Idiopathic PAH 
    □ Heritable PAH  
    □ Drug- and toxin-induced PAH 
    □ PAH associated with connective tissue disease  
    □ PAH associated with congenital heart diseases, only simple  
    congenital systemic to pulmonary shunts at least [ADDRESS_1250539] recent Right Heart Catheterization date:  └─┴─┘└─┴─┴─┘└─┴─┘   
   dd         mmm yy 
mPAP: 
PVR: 
PCWP: 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 127/[ADDRESS_1250540] 2014- 004066- 20 
Doc No. D-16.554  
 
LVEDP: 
If RHC curves are available, please provide them.  
 Ongoing Not 
ongoing 
Relevant medical history: ---------------------------------------------------------------
---------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
   
 Yes No 
2. Was an echocardiography performed?  -----------------------------------------------------------------------------------------  
a. If yes, date of the most recent echocardiography:  
 └─┴─┘└─┴─┴─┘└─┴─┘   
   dd         mmm yy 
b. If yes, did it show  
i. left ventricular systolic dysfunction? -----------------------------------------------------------  
ii. left ventricular diastolic dysfunction? ----------------------------------------------------------  
iii. enlarged left ventricle ? ---------------------------------------------------------------------------------------  
iv. enlarged left atrium?  ----------------------------------------------------------------------------------------------  
v. left-sided valvular heart disease?  -------------------------------------------------------------------  
If you have answered “ Yes” to one or more of the questions above, how did you 
exclude this/these finding(s) as the main reason for pulmonary hypertension? 
-------------------------------- --------------------------------------------------------------------------------- 
 
  
 
 
 
 
  
   
 
 
 
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 128/[ADDRESS_1250541] 2014- 004066- 20 
Doc No. D-16.554  
 
-----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
 Yes No 
2. Was a ventilation/perfusion lung scan performed? ------------------------------------------------  
a. If yes, date of the most recent scan:   
Ventilation Scan └─┴─┘└─┴─┴─┘└─┴─┘  
   dd         mmm yy 
        Perfusion Scan  └─┴─┘└─┴─┴─┘└─┴─┘  
   dd         mmm yy 
 
b. If yes, did it show significant perfusion defects? --------------------------------------------------  
If you have answered “ Yes” to the question above, how did you exclude 
pulmonary thromboembolism as the main reason for pulmonary hypertension? 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------
  
 
 
 
  
 
  
 
 
 
  
 
 
 
  
 
3. Were lung function tests performed? --------------------------------------------------------------------------------------------  
a. If yes, date of the most recent  lung function tests:   
Spi[INVESTIGATOR_038]  └─┴─┘└─┴─┴─┘└─┴─┘     
                                                                              dd         mmm yy 
Body Plethysmography └─┴─┘└─┴─┴─┘└─┴─┘  
     dd         mmm yy 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 129/[ADDRESS_1250542] 2014- 004066- 20 
Doc No. D-16.554  
 
b. If yes, did it show  
i. FEV1/FVC < 70%? ------------------------------------------------------------------------------------------------  
ii. FEV1 < 65% of predicted value? --------------------------------------------------------------------  
iii. Total Lung Capacity < 60% of predicted value?  ------------------- 
If you have answered “ Yes” to one or more of the questions above, how did you 
exclude moderate to severe obstructive lung disease or moderate to severe 
restrictive lung disease as the main reason for pulmonary hypertension? 
-----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------
  
 
 
 
  
 
 
 
 
 Yes No 
1. Were any other relevant tests (e.g. , contrast-enhanced computed tomography, 
spi[INVESTIGATOR_85004], high resolution computed tomography, magnetic 
resonance imaging) performed to exclude other etiology than PAH?  -----------------  
2. If yes, which type of test(s) and when (indicate most recen t)? 
i. ----------------------------------------  └─┴─┘└─┴─┴─┘└─┴─┘  
      dd         mmm yy 
ii. ----------------------------------------  └─┴─┘└─┴─┴─┘└─┴─┘  
      dd         mmm yy 
iii. ----------------------------------------  └─┴─┘└─┴─┴─┘└─┴─┘  
   dd         mmm yy 
Please briefly describe the results of this/these procedures(s)  
3. ------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------- ---------------------------------------------- 
 
 
   
 
 
[STUDY_ID_REMOVED]
Macitentan / ACT -064992  
Pulmonary arterial hypertension  
Protocol AC -055-403, REPAIR  
Version 6 
8 November 2016,  page 130/[ADDRESS_1250543] 2014- 004066- 20 
Doc No. D-16.554  
 
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------
 
Investigator name:    
  
[CONTACT_1782] (DDMMMYYYY) : Investigator signature:  
[CONTACT_892807], signature [CONTACT_892808]:  
 
[STUDY_ID_REMOVED]